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Chapter 1
Subfertility is a major health problem worldwide, affecting at least one in six couples.1 
Treatments for subfertility are never far from the public eye, often inciting controversy and 
demands for greater transparency and accountability.2 The desire of the public to be better 
informed about the quality of subfertility care forces health care professionals to respond 
and disclose performance data. Intrauterine insemination (IUI) is a widely used method 
to treat subfertility.3 However, assessment of the quality of IUI care, which goes further 
than just assessing the obvious outcome measures clinical pregnancy and live birth rate, is 
not common. Therefore, the aim of this thesis is to study the quality of IUI care, focusing 
particularly on the extent, consequences and causes of variation in adherence to guidelines 
in IUI care and the implications for quality improvement.
This introductory chapter will start with a general description of the prevalence and causes 
of subfertility and the options available to treat subfertility. Second, current concepts of 
IUI will be addressed. Third, the relevance of clinical practice guidelines and performance 
indicators for quality improvement will be discussed. Fourth, motives to improve guideline 
adherence and determinants of guideline adherence will be considered. Finally, the chapter 
will end with the aim, research questions and outline of the thesis.
Subfertility
Subfertility is defined as failure to conceive within 1 year of regular unprotected sexual 
intercourse. Subfertility can be primary, in couples who have never conceived, or secondary, 
in couples who have conceived previously. It is estimated that 72.4 million couples around 
the world are currently subfertile.4 The prevalence of subfertility is remarkably similar 
between more and less developed countries.4
Several changes in the way of life of the population over the last decades have adversely 
affected fertility. First, the tendency to postpone childbearing has increased the incidence 
of subfertility due to age-related factors. In Western countries, the mean age of women at 
first childbearing is now around 29.5 years, as opposed to 25 two decades ago.5 Natural 
female fertility declines with age. For women up to 25, the cumulative conception rate 
is 85% at a year, but conception rates are more than halved by 35 or over.2 Second, a 
decline in fertility has also been attributed to lifestyle factors. For example, smoking, the 
use of prescribed, over-the-counter and recreational drugs, exposure to occupational and 
environmental hazards and obesity interfere with male and female fertility.6 Third, sexually 
transmitted infections such as chlamydia and gonorrhoea are highly prevalent and a major 
cause of pelvic inflammatory disease and tubal factor subfertility, particularly in developing 
countries.7,8 
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However, convincing data show that also in most Western countries rates of sexually 
transmitted infections are rising every year and seriously threaten the reproductive 
capacity.7,9-11 Fourth, an increase in male subfertility has been reported in several countries, 
possibly as a result of environmental pollution.12-15
A cause of subfertility can not be identified in 8-28% of couples.16 In approximately 27% 
of couples subfertility is attributed to ovulatory disorders and in 14% to tubal damage.17 
In a smaller proportion, the cause of subfertility is cervical mucus hostility, which stands for 
poor-quality or insufficient mucus of the cervical canal of the uterus, or endometriosis.18,19 
It is estimated that a low sperm count or quality is the cause of subfertility in 30% of 
couples.20 The presence of disorders in both the female and male partner has been reported 
to occur in about 39% of cases.6
Subfertility is an upsetting and difficult life experience. The unfulfilled desire to have a 
child has a huge impact on couples’ personal well-being.21-23 It is also not uncommon for 
the fertility problem to put a strain on the relationship and many couples experience a 
deterioration in their sexual relationship.1 Subfertility is often highly stigmatizing and can 
have profound social consequences for the men and women involved.24 Roughly half of the 
subfertile couples seek medical treatment for their fertility problems.4
Treatment of subfertility
For a long time, the treatment options that could be offered to couples with fertility problems 
to increase their chances of conception were limited. However, advances in the past decades 
have considerably expanded the possibilities to treat subfertility. Currently, there are three 
main types of fertility treatment: medical treatment, such as the use of drugs for ovulation 
induction for ovulatory disorders; surgical treatment, for example, tubal reconstructive 
surgery for mild tubal disease; and assisted reproduction. Assisted reproduction relates to 
all treatments designed to lead to conception by means other than sexual intercourse and 
include intrauterine insemination (IUI), donor insemination, in vitro fertilisation (IVF) and 
intracytoplasmic sperm injection (ICSI).
Assisted reproduction techniques have revolutionized the management of subfertility. 
The first paper about IUI was published in 1962.25 IVF was introduced in 1978 and ICSI 
in 1991.26,27 The assisted reproduction techniques have evolved extensively since their 
introduction through innovations and are currently widely used throughout the world. 
European data on assisted reproduction techniques show that in 2005 a total of 128 908 
IUI cycles were performed in 21 countries.28 By comparison, these countries reported 
a total of 69 082 IVF cycles and 134 684 ICSI cycles in 2005.28 The ratio of registered IUI 
cycles to the total of registered IVF and ICSI cycles in these countries collectively is 0.63. 
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However, in several individual countries this ratio is much higher, which means that in these 
countries the extent of IUI utilization equals or may even be greater than the IVF and ICSI 
utilization. In the Netherlands, for example, the estimated number of IUI cycles performed 
in 2003 was 28 500, compared to 15 769 IVF and ICSI cycles.29,30
The utilization of assisted reproduction techniques is a complex product of political, 
economic, social and cultural factors that determine the allocation of resources for fertility 
treatment.24 Overall, wide disparities exist with regard to access to fertility treatment.24 
Even in wealthy countries, access to fertility treatment at affordable levels may be limited. 
In most countries, though, IUI care is quite accessible. In the Netherlands, for instance, 
IUI is performed at 91 of the 101 public hospitals, including eight university hospitals, 35 
non-university teaching hospitals and 48 non-teaching hospitals.29 IVF and ICSI treatment, 
however, is usually limited to licensed clinics with accredited fertility laboratories. In the 
Netherlands, 12 public hospitals and one private clinic are certified to provide an entire 
IVF or ICSI treatment.30 Depending on a country’s national health policy, the cost of fertility 
treatment to the consumer can vary from nil to 100% of the total cost.24 In the Netherlands, 
provisions have been made within the national health policy to cover fertility assessment 
and treatment to a certain extent.
Intrauterine insemination
Intrauterine insemination (IUI) is widely used to manage male factor fertility problems, 
unexplained fertility problems and subfertility caused by cervical mucus hostility or minimal 
to mild endometriosis. It involves artificial insemination of prepared sperm directly into the 
uterus at the expected time of ovulation. The rationale of the procedure is to bring selected 
motile spermatozoa closer to the released oocyt. IUI can be done in natural cycles, called 
unstimulated IUI, or after ovarian stimulation with fertility drugs to increase the number of 
available oocytes and further enhance the probability of conception, called stimulated IUI.
Despite its popularity and the extensive literature on the subject, controversy regarding IUI 
remains. Above all, the overall success rate of IUI is controversial. Although IUI proved to 
be more effective than timed intercourse in subfertile couples, reported clinical pregnancy 
rates are, on average, only 5-13% per IUI cycle.3,16,18-20,28,31-34 Before deciding on IUI treatment, 
it is therefore important to consider the likelihood of pregnancy without IUI treatment, 
which is usually underestimated.1,3
Whether or not IUI should be combined with ovarian stimulation is often debated as 
well, particularly in terms of clinical effectiveness, safety and cost-effectiveness.35,36 In 
unexplained fertility problems and subfertility caused by minimal to mild endometriosis, 
stimulated IUI is associated with higher pregnancy rates than unstimulated IUI.16,18,33 
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However, compared to unstimulated IUI, stimulated IUI is only modestly better in subfertility 
due to cervical mucus hostility and not more effective in male factor fertility problems.19,20,34 
Even though stimulated IUI may increase the overall chance of conception compared to 
unstimulated IUI, the added value is limited and complications occur more frequently.3
The main concern about IUI in combination with ovarian stimulation is the increase in multiple 
pregnancies which, in turn, increases maternal and perinatal morbidity and mortality.37,38 
Multiple pregnancy rates up to 25% after stimulated IUI have been reported.33,38 Recently, 
more and more evidence shows that mild ovarian stimulation with strict cancellation criteria 
minimizes the risk of multiple pregnancy to approximately 10%, without compromising 
pregnancy rates.39 Other drawbacks of stimulated IUI are the considerable physical and 
psychosocial implications for couples and the higher costs.21-24,31,32 To put it briefly, treatment 
decisions in case of unexplained fertility problems and subfertility caused by minimal to 
mild endometriosis or cervical mucus hostility hinge on whether the increased chance of 
pregnancy after IUI in combination with ovarian stimulation justifies the risk of multiple 
pregnancy, patient discomfort and the costs of medication and the need for monitoring.3
Furthermore, the clinical effectiveness, safety and cost-effectiveness of IUI in relation to 
IVF have not been clarified completely. Consequently, it remains a matter of debate which 
subfertile couples are eligible for IUI, when to start IUI treatment, how many IUI cycles 
should be offered and when couples should be advised to shift to more sophisticated IVF 
treatment. Clearly, randomized controlled trials are needed to address these questions.
Relevance of clinical practice guidelines for quality improvement
It is widely recognized that the quality of health care is often inadequate.40-42 Published 
literature suggests that, in general, 30-40% of patients do not receive care according to 
the best scientific evidence available and 20-25% of the care provided is unnecessary or 
potentially harmful.43,44 As subfertility is a major health issue worldwide and its management 
is associated with health risks and high costs, the impact of substandard subfertility care on 
health and health care resources is considerable.2,45
Concerns about the consequences of substandard subfertility care prompted numerous 
initiatives to improve the uptake of research findings into daily practice. Many approaches 
have focused on better availability and presentation of evidence by identifying, evaluating 
and propagating evidence to health care professionals in accessible formats, such as clinical 
practice guidelines.40 Essentially, guidelines bridge the gap between evidence and practice.46 
Clinical practice guidelines are thus useful tools to help health care professionals and 
patients to make better decisions about clinically effective, safe and cost-effective care and 
reduce inappropriate practice variation.
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In the past years, both professional societies in the fields of obstetrics and gynaecology, and 
reproductive medicine as well as governmental agencies have put much effort and resources 
in the development and dissemination of clinical practice guidelines for subfertility care. 
These include the American Society for Reproductive Medicine (ASRM), the European 
Society of Human Reproduction and Embryology (ESHRE), the Nordic Federation of Societies 
of Obstetrics and Gynaecology (NFOG) and the National Institute for Health and Clinical 
Excellence (NICE). In the Netherlands, the Dutch Society of Obstetrics and Gynaecology 
(NVOG) has issued nine subfertility guidelines, including a guideline on IUI, as part of their 
extensive guideline programme (www.nvog.nl). Whether or not IUI guidelines are available 
in other countries is not exactly known.
High-quality guidelines can improve care, but low-quality guidelines may harm patients.47 
Therefore, clinical practice guidelines should meet specific quality criteria.48,49 The Appraisal 
of Guidelines for Research and Evaluation (AGREE) Collaboration, an international 
consortium of researchers from several countries with extensive knowledge and experience 
regarding clinical practice guidelines, developed and validated a generic instrument to 
assess the methodological quality of clinical practice guidelines on 23 key items, categorized 
in six domains: scope and purpose, stakeholder involvement, rigour of development, clarity 
and presentation, applicability, and editorial independence.50 Assessment of numerous 
guidelines with the AGREE Instrument revealed that the methodological quality varies 
substantially.51-56 The quality of IUI guidelines has not been systematically assessed yet.
Relevance of performance indicators for quality improvement
Health care delivery according to clinical practice guidelines is thought to be crucial in 
achieving optimal outcomes. However, studies suggest that development and dissemination 
of guidelines does not guarantee their implementation in daily practice.57-59 Prior research in 
various health care settings demonstrated wide variation in adherence to guidelines.44,60,61 
Therefore, reliable assessment of the extent to which practice performance in health care 
is consistent with guideline recommendations is imperative and requires a set of valid 
guideline-based performance indicators.40,62
Performance indicators can refer to process and structure aspects of care.63,64 Process indicators 
focus on the actual care delivered to patients. Structure indicators focus on organizational 
aspects of care. Preferably, performance indicators should be directly based on scientific 
evidence. The better the evidence, the stronger the benefits of applying the indicators in terms 
of improved outcomes.65 Therefore, clinical practice guidelines based on the best scientific 
evidence available are a good departure point for the development of performance indicators. 
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When scientific evidence for certain aspects of care is conflicting, methodologically weak 
or absent, performance indicators should be developed by an expert panel of health care 
professionals in a systematic consensus procedure that combines available evidence and 
expert opinion.66
Performance indicators can be used to compare actual care delivered to patients with 
recommended care in guidelines, make comparisons over time and between places, 
make judgements and set priorities, enhance quality improvement activities, support 
accountability, regulation and accreditation, and promote patient choice of providers.64 Even 
though the potential benefits of performance indicators are acknowledged internationally, 
only a few indicators have been suggested for subfertility care.62,67 A systematically developed 
set of valid guideline-based performance indicators for IUI care is not yet available. As a 
result, measuring practice performance in IUI care and comparing how it matches to the 
care proposed in guidelines has not been done so far.
Motives to improve guideline adherence
As mentioned before, most clinical practice guidelines do not get easily adopted into daily 
practice.57-59 In general, a new guideline will only be implemented if guideline adherence 
seems to offer advantages over the existing situation.47 For the majority of health care 
professionals, the most important motive to adhere to guidelines is that it helps to achieve 
better clinical outcomes of care for their patients, such as improved clinical effectiveness 
and safety. However, other motives, including financial benefits, may also promote guideline 
adherence. Such advantages are weighed against possible disadvantages, such as extra time 
commitment or costs. As the balance between the advantages and disadvantages becomes 
more favourable, guideline implementation is more likely to be successful.47 
In subfertility care, clinical pregnancy and live birth rate have been the undisputed outcome 
measures for years.68-70 High clinical pregnancy rates are considered to reflect outstanding 
practice performance and achieving the highest clinical pregnancy rates is usually top 
priority for fertility centres. Consequently, most recommendations in subfertility guidelines 
are probably based on evidence about the effect of practice performance on one or both of 
these primary outcomes. However, besides clinically effective, recommended care should 
also be safe, accessible, timely, efficient and patient-centred.71
The inclusion of economic evidence in clinical practice guidelines is a fairly recent 
phenomenon. The purpose of including economic evidence in guidelines is to allow 
recommendations not to be made just on the clinical effectiveness of different forms of 
care, but also on their cost-effectiveness. The aim is to produce guidelines that promote the 
efficient use of the scarce health care resources.
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Patient-centredness is another dimension of quality of care that gained particular importance 
over the past few years. Key elements of patient-centred care include information and 
education, respect for patients’ preferences, emotional support, physical comfort, 
coordination of care, involvement of family and friends, and continuity and transition.72 
Incorporating patients’ perspectives of care in clinical practice guidelines may contribute 
to the delivery of more patient-centred care that meets the true needs and expectations 
of patients. At present, it is generally acknowledged that information about patients’ needs 
and expectations of care should direct guideline development.50 There are various methods 
for ensuring that patients’ perspectives of care steer guideline development. For example, 
the guideline development group could involve patients’ representatives, consider literature 
reviews of patients’ evaluations of care or obtain such information by means of patient 
interviews and surveys. Nonetheless, integrating patients’ perspectives of care in clinical 
practice guidelines has just recently become more common.
Convincing the target group that guideline adherence leads to desired goals, such as better 
clinical effectiveness, safety, cost-effectiveness and patient-centredness, can improve 
guideline adherence.47 However, data about associations between guideline adherence and 
outcomes of IUI care are not yet available.
Determinants of guideline adherence
Previous research in other fields of medicine showed that a wide range of factors can 
influence guideline adherence and explain inappropriate practice variation.40,73,74 First, 
patients’ characteristics, including their demographic profile, behaviour, preferences, 
needs and expectations, are relevant to clinical decision-making and can inhibit or enhance 
adherence to guidelines.47 Second, several specific organizational characteristics, such 
as the availability of necessary materials, facilities, staff, and financial resources, and the 
reimbursement system, have been shown to influence guideline adherence.47 Third, 
characteristics of individual physicians have also been identified as potential barriers or 
facilitators for adherence to guidelines, mainly physicians’ knowledge, skills, attitudes and 
personal features.73,75
A good understanding of determinants of guideline adherence at the level of the patient, 
organization and individual physician is important in every approach to improve adherence 
to guidelines, because improvement strategies are more likely to be effective if they focus 
directly on barriers.40,57 Currently, little is known about the extent of variation in adherence 
to IUI guidelines and the potential barriers and facilitators involved.
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Aim and research questions of the thesis
This thesis aims to study the quality of IUI care, focusing particularly on the extent, 
consequences and causes of variation in adherence to guidelines in IUI care and the 
implications for quality improvement.
The research questions of the thesis are as follows:
• What is the availability and quality of IUI guidelines in Europe? (chapter 2)
• What is the quality of IUI care? Is guideline adherence in IUI care clinically effective? 
Which improvements are needed in IUI care? (chapter 3)
• What are the economic consequences of guideline adherence in IUI care? (chapter 4)
• What are patients’ perspectives of IUI care? (chapter 5)
• What are the determinants of guideline adherence in IUI care? (chapter 6 and 7)
Outline of the thesis
In this thesis, the quality of IUI care will be studied by means of a stepwise approach, which 
is displayed in diagrammatic form in Figure 1. The first step is to identify potential problems 
regarding guideline availability, quality and adherence in IUI care. Chapter 2 and 3 will reflect 
on potential problems. The second step is to consider the motives to improve guideline 
adherence in IUI care, including established motives, such as improved clinical effectiveness 
and safety, as well as commonly neglected motives, for example, increased cost-effectiveness 
and patient-centredness. Chapter 3, 4 and 5 will address the motives to improve guideline 
adherence. The third step is to investigate the determinants of guideline adherence in IUI 
care at the level of the patient, hospital and individual physician. Chapter 6 and 7 will focus 
on the determinants of guideline adherence. The final step is to review possible solutions to 
overcome problems regarding guideline availability, quality and adherence in IUI care, which 
include strategies targeted at guideline development and strategies directed at guideline 
implementation. In the general discussion in chapter 8, possible solutions, based on the 
main findings of the studies described in the thesis, will be presented. In addition, the most 
relevant methodological issues of the studies will also be discussed in this chapter.
General introduction
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Abstract
Background: International collaboration could facilitate systematic development of 
guidelines to regulate and improve clinical practice. To promote European collaboration in 
guideline development in reproductive medicine, insight in existing subfertility guidelines in 
Europe is essential. The study aim was to explore the number and quality of clinical practice 
guidelines on homologous intrauterine insemination (IUI) in Europe.
Methods: To identify IUI guidelines in Europe, electronic databases and the Internet 
were systematically searched, and key experts on assisted reproduction in 25 European 
countries were questioned. The quality of IUI guidelines was systematically assessed with 
the internationally validated Appraisal of Guidelines for Research and Evaluation (AGREE) 
Instrument. Qualitative methods were used to appraise IUI guideline recommendations and 
references.
Results: National guidelines on IUI are available in four out of 25 European countries. The 
quality of IUI guidelines in Europe is moderate to high, but recommendations and references 
differ considerably.
Conclusions: The number of IUI guidelines in Europe is surprisingly small and differences in 
their recommendations and references are considerable. To overcome these deficiencies in 
clinical guidance on IUI care in Europe, a central body with expertise in up-to-date guideline 
development methodology and sufficient resources could be established in Europe for central 
selection and international exchange of evidence to support guideline recommendations.
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Introduction
Assisted reproduction raises complex ethical, legal and social dilemmas. Controversial issues 
in reproductive medicine concern the restriction of assisted reproduction techniques (ARTs) 
based on age or sexual orientation, the impact of multiple births on health and health care 
resources, the donation of gametes or embryos, the cryopreservation of gametes, embryos 
or gonadal tissues and the preimplantation genetic screening of embryos.1 Criticism of 
assisted reproduction arises in the context of a broad spectrum of cultural, religious and 
social attitudes in societies towards technical intervention in human reproduction.2
Although the necessity of some form of regulation in reproductive medicine is obvious, there 
has been an ongoing debate in society regarding the best approach to regulate assisted 
reproduction.3 Many countries have opted for national legislation on assisted reproduction.4 
The recent legislative interventions of the Italian government to regulate reproductive 
medicine, restricting and banning several common procedures to assist human reproduction, 
are well-known.5,6 Although restrictive reproductive laws can impose strict limitations on 
the practice of assisted reproduction, it is argued that legislation is inappropriate to deal 
adequately with the continuing rapid technological advances in reproductive medicine.3
Development of clinical practice guidelines may be a more effective approach to regulate 
assisted reproduction. On the one hand, subfertility guidelines can be regarded as a means 
to external control of ethical, legal and social issues in reproductive medicine.7 On the 
other hand, subfertility guidelines can assist health care professionals and patients in the 
decision-making process regarding appropriate, safe and cost-effective care and improve 
the quality of subfertility care.8,9 Therefore, both authorities and health care professionals 
are interested in clinical practice guidelines and increasingly support the development of 
guidelines for reproductive medicine.
Given the potential detrimental consequences of low-quality guidelines for reproductive 
medicine, such guidelines should meet basic quality criteria.10 However, the development of 
high-quality guidelines requires specific expertise and considerable resources.7 International 
collaboration offers opportunities for sharing some elements of the expensive and time-
consuming process of guideline development.11,12 To promote European collaboration in 
guideline development activities in reproductive medicine, insight in existing subfertility 
guidelines in different European countries is essential. 
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However, little is known about subfertility guidelines in Europe. Therefore, we explored 
in which European countries subfertility guidelines are available and evaluated the 
methodological quality, recommendations and references of the identified subfertility 
guidelines. In this study, we focused on clinical practice guidelines regarding homologous 
intrauterine insemination (IUI), because of the expected high availability of clinical guidance 
in Europe on this frequently used technique to assist human reproduction.
Materials and methods
Selection of guidelines
To identify IUI guidelines in Europe, three systematic search methods were used. First, 
we searched Medline and PubMed up to May 2005 for IUI guidelines using the keywords 
‘fertility’, ‘fertility problems’, ‘infertility’, ‘subfertility’ and ‘intrauterine insemination’, 
combined with ‘guidelines’, ‘clinical practice guidelines’ or ‘recommendations’.
Second, we performed an Internet search in May 2005 to obtain IUI guidelines, using the 
previously mentioned keywords, in the search engines Google, Altavista and Yahoo. We also 
searched for IUI guidelines on the websites of (inter)national professional societies in the 
fields of obstetrics and gynaecology and reproductive medicine, for example, www.figo.
org, www.nfog.org, www.iffs-reproduction.org, www.eshre.com and www.nordicfs.org, 
and on websites of (inter)national institutes involved in guideline development, suchs as 
www.g-i-n.net, www.guideline.gov and www.cbo.nl. Searches were extended using links 
when available. Organizations were contacted by e-mail to retrieve possible IUI guidelines 
not published on the Internet.
Last, one author (JK) asked all 24 fellow members of the European IVF Monitoring (EIM) 
Consortium by e-mail for IUI guidelines. The European Society for Human Reproduction 
and Embryology (ESHRE) established the EIM Consortium in 1999 to start a collaborative 
data-collection programme for IVF in Europe. Members play a leading role or have lengthy 
experience in IVF programmes in their respective country and presumably in other aspects 
of assisted reproduction as well. Two and 4 weeks after the initial mailing, reminders were 
sent to non-respondents. During the annual meeting of the EIM Consortium in June 2005, 
non-respondents were asked once more to participate. If EIM members failed to respond, 
other key experts on assisted reproduction in these European countries were contacted. 
The online search utility to find members in the ESHRE membership file was used to obtain 
their contact details.
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We used the following criteria to select guidelines for appraisal:
•	 National guidelines from European countries.
•	 Clinical practice guidelines or separate sections of clinical practice guidelines, containing 
specific recommendations to assist clinical decision-making on homologous IUI care in 
secondary or tertiary health care settings, thus excluding systematic reviews and legal 
documents.
•	 Information available in the guideline or in a separate document about the guideline 
development process.
Selected IUI guidelines not published in Dutch or English were translated into Dutch.
Appraisal of methodological quality of guidelines
To evaluate the methodological quality of the selected IUI guidelines, we used the Appraisal 
of Guidelines for Research and Evaluation (AGREE) Instrument. The AGREE Instrument is 
an internationally validated, generic tool to assess the methodological quality of clinical 
practice guidelines on 23 key items, categorised in six domains: scope and purpose (three 
items), stakeholder involvement (four items), rigour of development (seven items), clarity 
and presentation (four items), applicability (three items) and editorial independence (two 
items).10 Detailed information about the AGREE Instrument is available on the website of 
the AGREE Collaboration (www.agreecollaboration.org). Four investigators appraised the 
selected IUI guidelines independently by scoring each item of the AGREE Instrument on 
a four-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree and 4 = strongly 
agree). Differences in ratings of more than one point per item were discussed to achieve 
consensus. We calculated six domain scores for each guideline by adding up the scores of 
the individual items in a domain given by the four appraisers and standardising the total 
as a percentage of the maximum possible score for that domain (range 0-100%). The final 
step in guideline appraisal with the AGREE Instrument involved an overall judgement about 
the usefulness of each guideline, based on the ratings of individual items and the balance 
between the domains. The overall assessment was scored on a four-point categorical scale 
(strongly recommended, recommended (with provisos or alterations), not recommended 
and unsure).
Appraisal of guideline recommendations
To appraise the recommendations of the included IUI guidelines, four authors extracted 
independently the key recommendations of each guideline. Discrepancies in recommendation 
extraction were discussed to reach agreement. Subsequently, we investigated whether 
systems to grade the quality of evidence and the strength of recommendations were used 
in the guideline development process. We also explored the scope of each IUI guideline, and 
we compared recommendations to assess the extent of variation between the selected IUI 
guidelines.
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Appraisal of guideline references
To evaluate the references on which the key recommendations of the IUI guidelines are 
based, we assessed the publication dates and origin of the references and the number of 
references shared with the other selected IUI guidelines.
Results
Selection of guidelines
After our search for IUI guidelines in Europe, we included four IUI guidelines, one each from 
Denmark, England and Wales, France and the Netherlands (Table 1). We verified that in 21 
other European countries, IUI guidelines were not available (Table 2).
The IUI guidelines from England and Wales, France and the Netherlands are peer-reviewed 
publications and in their respective language available on the Internet (Table 1). The Danish 
IUI guideline is a first draft of the update of a previous IUI guideline from 1997 and not yet 
published. Governmental agencies produced the IUI guidelines from England and Wales and 
France, whereas the Danish and Dutch IUI guidelines are developed by national professional 
organizations.
Country
Organization 
responsible for guideline 
development
Title Year of 
publication
Website
Denmark Danish Society 
of Obstetrics and 
Gynaecology (DSOG) and 
Danish Fertility Society 
(DFS)
Homologous 
intrauterine 
insemination a
Version 
2004
Not yet online
England
and
Wales
National Collaborating 
Centre for Women’s 
and Children’s Health, 
commissioned by the 
National Institute for 
Health and Clinical 
Excellence (NICE)
Fertility: assessment 
and treatment for 
people with fertility 
problems
Chapter 10: 
Intrauterine 
insemination
2004 www.ncc-wch.org.uk
www.nice.org.uk
www.rcog.org.uk
France National Agency for 
Accreditation and 
Evaluation in Health care 
(ANAES)
Subfertility of a couple 1996 www.anaes.fr
Netherlands Dutch Society of Obstetrics 
and Gynaecology (NVOG)
Intrauterine 
insemination
2000 www.nvog.nl
a First draft of the update of a previous IUI guideline from 1997.
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Eight of the 21 informants from European countries without IUI guidelines reported that 
national laws regulate assisted reproduction (Table 2). Nine informants mentioned the 
existence of other documents regulating reproductive medicine. Informants from Belgium, 
Latvia and Spain reported that a professional society in their country is currently developing 
subfertility guidelines. Informants from Italy and Poland mentioned plans for development 
of IUI guidelines in the near future.
Appraisal of methodological quality of guidelines 
The results of appraisal of the methodological quality of the selected IUI guidelines with the 
AGREE Instrument are summarized in Table 3. The IUI guideline from England and Wales 
rated high on the majority of AGREE criteria, and the domain scores varied between 58 
and 96%, which indicates a high overall guideline quality. According to the results of AGREE 
appraisal, this IUI guideline is strongly recommended for use in daily health care practice. 
The French and Dutch IUI guidelines scored high as well as low on a similar number of 
AGREE criteria, and most domain scores were between 30 and 60%, which indicates a 
moderate overall guideline quality. We were not able to appraise the Danish IUI guideline on 
two domains of the AGREE Instrument, which were stakeholder involvement and editorial 
independence, owing to the draft status of this guideline. Assessment of the Danish IUI 
guideline on four other domains showed a moderate overall guideline quality.
Appraisal with the AGREE Instrument revealed several flaws in the methodological quality 
of the Danish, French and Dutch IUI guidelines. It was unclear in the French and Dutch 
IUI guidelines whether patients participated in guideline development, causing low domain 
scores for stakeholder involvement. Neither the criteria for selecting evidence nor the 
methods used to formulate recommendations were explicitly described in the Danish and 
Dutch IUI guidelines, lowering domain scores for the rigour of development. None of the 
IUI guidelines from Denmark, France and the Netherlands considered cost implications of 
applying the recommendations, resulting in low domain scores for applicability. Finally, the 
French and Dutch IUI guidelines failed to mention whether the funding body influenced 
guideline development, and whether members of the guideline development group had 
conflicts of interest, causing poor domain scores for editorial independence. Overall, the IUI 
guidelines from Denmark, France and the Netherlands could be recommended for use in 
practice if alterations are made to overcome these particular flaws.
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Country Additional comments
Response: “No IUI guidelines”
Belgium
“Current development of subfertility guidelines by Flemish Society of Obstetrics and 
Gynaecology”
“Other documents about subfertility available” a
Czech 
Republic
“No guideline development activities due to lack of collaboration between professional 
societies, the government and insurance companies”
Finland
“No legislation on assisted reproduction available”
“Other documents about subfertility available” b
Germany
“No national guidelines, because Germany is divided in different states, each with different 
regulations”
“Other documents about subfertility available” c
Greece
“No guideline development activities due to lack of a guideline development programme 
of the Greek Infertility Society, and, up to recently, lack of a central health body”
Iceland
“No national guidelines, because there is only one fertility clinic in Iceland”
“Other documents about subfertility available” b
Ireland “Other documents about subfertility available” d
Italy
“Development of IUI guidelines is planned in the near future, as part of national legislation 
on assisted reproduction”
Poland “Development of IUI guidelines is considered by Polish Fertility and Sterility Society”
Portugal -
Slovakia “Other documents about subfertility available” e
Spain “Current development of subfertility guidelines by Spanish Fertility Society”
Switzerland -
Response: “No IUI guidelines; legislation on assisted reproduction available”
Austria “Other documents about subfertility available” f
Hungary -
Latvia
“Current development of subfertility guidelines by Latvian Association of Gynaecologists 
and Obstetricians”
Norway “Other documents about subfertility available” b
Russia -
Slovenia -
Sweden “Local guidelines on assisted reproduction available”
Ukraine -
233
Chapter 2
a ‘Perspective on ovulation induction’ and ‘Perspective on ovarian hyperstimulation syndrome’, published by the Flemish 
   Society of Obstetrics and Gynaecology (VVOG) (www.vvog.be).
b ‘Clinical and laboratory guidelines for ART in the Nordic countries’, published by the Nordic Federation of Societies of 
   Obstetrics and Gynaecology (NFOG) (www.nfog.org).
c ‘Guideline for psychosomatic oriented assessment and treatment for fertility problems’, ‘Recommendation for 
   assessment of infections and infection prophylaxis in ART’, ‘Perspective on ART: ovarian hyperstimulation treatment 
   with gonadotrophins or anti-oestrogens and risk for ovarian cancer’, and ‘Perspective on the comparison of 
   recombinant FSH and urinary-derived FSH’, published by the German Society of Gynaecology and Obstetrics (DGGG) 
   (www.dggg.de).
d ‘Report on possible approaches to the regulation of all aspects of assisted human reproduction and the social, ethical 
   and legal factors involved in determining public policy’, published by the Commission on Assisted Human Reproduction 
   (www.dodc.ie).
e ‘Guideline for subfertility management’, including a specific part about medical management of subfertility.
f ‘Guideline for assessment of subfertility with opportunities and limitations for treatment in gynaecology departments 
   without IVF’, published by the Austrian Society of Gynaecology and Obstetrics (OEGGG) (www.oeggg.at).
AGREE Instrument domains Denmark England and Wales France Netherlands
Scope and purpose (%) 50 67 63 53
Stakeholder involvement (%) No score a 79 35 33
Rigour of development (%) 51 96 73 52
Clarity and presentation (%) 77 83 52 63
Applicability (%) 31 58 17 31
Editorial independence (%) No score a 67 13 8
Overall assessment Recommend b
Strongly 
recommend c
Recommend b Recommend b
Standardized domain scores are calculated by adding up item scores in a domain and standardizing the total as a 
percentage of the maximum possible domain score (range 0-100%).
a Not possible to score the items in this domain in the first draft of the update of the Danish IUI guideline from 1997.
b Recommended with provisos or alterations to overcome insufficient or lacking information on the guideline.
c Strongly recommended without provisos or alterations.
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Appraisal of guideline recommendations
Systems to grade the quality of evidence and the strength of recommendations were used 
to develop the IUI guidelines from Denmark and England and Wales. Each recommendation 
in these guidelines was based on the best evidence available, graded according to the 
strength of the underlying evidence and explicitly linked to the supporting evidence. 
Recommendations in the French and Dutch IUI guidelines were not graded according 
to the strength of the underlying evidence, and the link between the recommendations 
and the supporting evidence was less clear. Therefore, it was not apparent whether the 
recommendations in the French and Dutch IUI guidelines were based on the best evidence 
available or on weak research data, personal opinions or common practice. 
The IUI guidelines differed in the number of key recommendations and in their coverage. 
The IUI guidelines from Denmark and England and Wales comprised of a limited set of 
evidence-based recommendations, whereas the French and Dutch IUI guidelines included 
considerably more recommendations. These differences were particularly apparent for 
the IUI guideline from England and Wales, consisting of eight key recommendations, and 
the Dutch IUI guideline, consisting of 31 key recommendations and covering topics that 
were outside the scope of the IUI guideline from England and Wales, mainly management 
and organizational aspects of IUI care. For example, four key recommendations of the 
Dutch IUI guideline covered timing in IUI treatment (‘IUI should be performed 20-30 
hours after detection of spontaneous luteinizing hormone surge’) and four other Dutch 
key recommendations were related to practice facilities for IUI care (‘IUI treatment results 
should be evaluated yearly’).
For detailed exploration of similarities and discrepancies between guideline 
recommendations, we compared the key recommendations of the IUI guideline with 
the best methodological quality, that is the IUI guideline from England and Wales, 
with recommendations of the other IUI guidelines (Table 4). The content of the key 
recommendations of the IUI guidelines differed considerably. For example, the IUI guidelines 
were not consistent in their recommendations to offer ovarian stimulation in IUI treatment. 
The IUI guideline from England and Wales explicitly stated that ovarian stimulation should 
not be offered to couples with mild male factor and unexplained subfertility, whereas 
others recommended stimulated IUI to manage these fertility problems. Furthermore, 
consensus was lacking for the suggested total number of IUI cycles. The IUI guideline from 
England and Wales and the Netherlands recommended up to six IUI cycles for couples with 
unexplained subfertility, whereas the Danish IUI guideline suggested three to six IUI cycles 
and the French IUI guideline at least six IUI cycles.
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Appraisal of guideline references
The total number of references in the selected IUI guidelines ranged between 11 and 38 
(Table 5). The majority of first authors of studies cited in the Dutch IUI guideline (73%) 
originated from the Netherlands. The French IUI guideline also cited a high proportion of 
studies from authors of their own country (33%). References in the IUI guidelines from 
Denmark and England and Wales were predominantly from the USA, the Netherlands and 
Canada. No references were shared by all four IUI guidelines, and only three references 
were present in three guidelines. The IUI guidelines from Denmark and England and Wales 
had the most references in common (n = 11), whereas the French IUI guideline shared just 
one reference with the Danish IUI guideline.
Discussion
This is the first study to provide insight into the number and quality of subfertility guidelines 
in Europe. National clinical practice guidelines on homologous IUI are currently only available 
in four out of 25 European countries. The methodological quality of the IUI guidelines in 
Europe is moderate to high, but the recommendations and references of these guidelines 
differ considerably.
The strong point of our study is the systematic and rigorous approach to identify IUI 
guidelines in Europe. Furthermore, the 100% response rate in our survey among key experts 
on assisted reproduction guarantees the scientific validity of our results on the availability, 
or otherwise, of IUI guidelines in 25 European countries. Another strength of our study 
is the systematic appraisal of the methodological quality of the IUI guidelines with the 
internationally validated AGREE Instrument.
Our study also has some limitations. First, in contrast with the systematic appraisal of 
the methodological quality of the IUI guidelines, we were not able to use a framework 
to evaluate the quality of individual guideline recommendations. Currently, no validated 
appraisal instruments for individual guideline recommendations are available. Second, our 
appraisal of the references of the IUI guidelines may seem limited, because we did not 
examine the quality of the cited studies nor the consistency between study conclusions 
and guideline recommendations. In other areas of medicine, numerous investigators 
showed deficiencies in methods used to search and select evidence and formulate guideline 
recommendations.13,14 As a result, clinical practice guidelines are not always based on 
a systematic review of literature, discrepancies exist between evidence and guideline 
recommendations, and few references are shared among guidelines on the same topic.15-17 
However, it is beyond the scope of our study to test the generality of these previous findings 
for reproductive medicine.
36
Subfertility guidelines in Europe: the quantity and quality of intrauterine insemination guidelines
Re
co
m
m
en
da
ti
on
 t
op
ic
s
De
nm
ar
k
En
gl
an
d 
an
d 
W
al
es
Fr
an
ce
N
et
he
rla
nd
s
In
di
ca
ti
on
s 
fo
r 
IU
I a
   
  M
al
e 
fa
ct
or
 s
ub
fe
rti
lit
y
Sti
m
ul
at
ed
 IU
I
U
ns
ti
m
ul
at
ed
 IU
I
Sti
m
ul
at
ed
 IU
I
Sti
m
ul
at
ed
 IU
I i
n 
m
ild
 
m
al
e 
fa
ct
or
 s
ub
fe
rti
lit
y 
b
U
ns
ti
m
ul
at
ed
 IU
I i
n 
se
ve
re
 
m
al
e 
fa
ct
or
 s
ub
fe
rti
lit
y 
c
   
  U
ne
xp
la
in
ed
 s
ub
fe
rti
lit
y
Sti
m
ul
at
ed
 IU
I
U
ns
ti
m
ul
at
ed
 IU
I
Sti
m
ul
at
ed
 IU
I
Sti
m
ul
at
ed
 IU
I
   
  M
in
im
al
 t
o 
m
ild
 e
nd
om
et
ri
os
is
Sti
m
ul
at
ed
 IU
I
U
ns
ti
m
ul
at
ed
 a
nd
 s
ti
m
ul
at
ed
 IU
I
Sti
m
ul
at
ed
 IU
I
N
ot
 m
en
ti
on
ed
In
di
ca
ti
on
 fo
r 
IU
I o
r 
FS
P 
d
FS
P 
in
 u
ne
xp
la
in
ed
 s
ub
fe
rti
lit
y
FS
P 
in
 u
ne
xp
la
in
ed
 s
ub
fe
rti
lit
y
N
ot
 m
en
ti
on
ed
N
ot
 m
en
ti
on
ed
Si
ng
le
 v
er
su
s 
do
ub
le
 IU
I
Si
ng
le
 IU
I p
er
 c
yc
le
Si
ng
le
 IU
I p
er
 c
yc
le
N
ot
 m
en
ti
on
ed
N
ot
 m
en
ti
on
ed
To
ta
l n
um
be
r 
of
 IU
I c
yc
le
s
   
  M
al
e 
fa
ct
or
 s
ub
fe
rti
lit
y
U
p 
to
 3
 t
o 
6 
IU
I c
yc
le
s
U
p 
to
 6
 IU
I c
yc
le
s
U
p 
to
 6
 IU
I c
yc
le
s
U
p 
to
 6
 IU
I c
yc
le
s
   
  U
ne
xp
la
in
ed
 s
ub
fe
rti
lit
y
U
p 
to
 3
 t
o 
6 
IU
I c
yc
le
s
U
p 
to
 6
 IU
I c
yc
le
s
A
t 
le
as
t 
6 
IU
I c
yc
le
s
U
p 
to
 6
 IU
I c
yc
le
s
   
  M
in
im
al
 t
o 
m
ild
 e
nd
om
et
ri
os
is
U
p 
to
 3
 t
o 
6 
IU
I c
yc
le
s
U
p 
to
 6
 IU
I c
yc
le
s
N
ot
 m
en
ti
on
ed
N
ot
 m
en
ti
on
ed
a  I
U
I, 
in
tr
au
te
ri
ne
 in
se
m
in
ati
on
. S
ti
m
ul
at
ed
 IU
I, 
IU
I a
ft
er
 o
va
ri
an
 s
ti
m
ul
ati
on
 u
si
ng
 g
on
ad
ot
ro
ph
in
s 
or
 o
ra
l a
nti
-o
es
tr
og
en
s.
 U
ns
ti
m
ul
at
ed
 IU
I, 
IU
I i
n 
na
tu
ra
l c
yc
le
s.
b  M
or
e 
th
an
 1
0 
m
ill
io
n 
m
oti
le
 s
pe
rm
at
oz
oa
 a
va
ila
bl
e 
aft
er
 s
pe
rm
 p
re
pa
ra
ti
on
.
c  B
et
w
ee
n 
1-
10
 m
ill
io
n 
m
oti
le
 s
pe
rm
at
oz
oa
 a
va
ila
bl
e 
aft
er
 s
pe
rm
 p
re
pa
ra
ti
on
.
d  F
SP
, f
al
lo
pi
an
 s
pe
rm
 p
er
fu
si
on
.
237
Chapter 2
Gu
id
el
in
e 
re
fe
re
nc
es
De
nm
ar
k
En
gl
an
d 
an
d 
W
al
es
Fr
an
ce
N
et
he
rla
nd
s
To
ta
l n
um
be
r 
of
 r
ef
er
en
ce
s
38
27
30
11
N
um
be
r 
of
 r
ef
er
en
ce
s 
pu
bl
is
he
d 
aft
er
 2
00
0 
(%
)
10
 (2
6)
5 
(1
9)
-
-
O
ri
gi
n 
of
 r
ef
er
en
ce
s 
a
   
  R
ef
er
en
ce
s 
fr
om
 o
w
n 
co
un
tr
y 
(%
)
2 
(5
)
4 
(1
5)
10
 (3
3)
8 
(7
3)
   
  T
op
 t
hr
ee
 r
ef
er
en
ce
s 
fr
om
 o
th
er
 c
ou
nt
ri
es
 (%
)
11
 (2
9)
 U
SA
8 
(3
0)
 U
SA
7 
(2
3)
 U
K
1 
(9
) U
SA
6 
(1
6)
 N
et
he
rl
an
ds
3 
(1
1)
 N
et
he
rl
an
ds
6 
(2
0)
 U
SA
1 
(9
) C
an
ad
a
4 
(1
1)
 C
an
ad
a
3 
(1
1)
 C
an
ad
a
2 
(7
) A
us
tr
al
ia
 /
 It
al
y
1 
(9
) I
nt
er
na
ti
on
al
N
um
be
r 
of
 r
ef
er
en
ce
s 
sh
ar
ed
 w
it
h 
ot
he
r 
gu
id
el
in
es
   
  D
en
m
ar
k
-
11
1
4
   
  E
ng
la
nd
 a
nd
 W
al
es
11
-
0
3
   
  F
ra
nc
e
1
0
-
0
   
  N
et
he
rl
an
ds
4
3
0
-
a  O
ri
gi
n 
of
 fi
rs
t 
au
th
or
 o
f c
it
ed
 s
tu
dy
.
38
Subfertility guidelines in Europe: the quantity and quality of intrauterine insemination guidelines
The small number of IUI guidelines in Europe is surprising. For years, IUI has been a 
frequently used therapeutic modality in reproductive medicine across Europe.18 In contrast 
with other ARTs, homologous IUI is not prohibited by legislation throughout Europe.19,20 
Thus, prohibitive laws do not account for the lack of IUI guidelines in the majority of 
European countries. Although some European countries have set down a legal framework 
within which homologous IUI treatment may take place, these laws do not support clinical 
decision-making in day-to-day subfertility care and cannot substitute clinical practice 
guidelines. Furthermore, the small number of IUI guidelines in Europe contrasts with the 
large number of guidelines on other medical issues, such as breast cancer or diabetes 
mellitus.12,21,22 Clearly, further research is necessary to elucidate underlying reasons for the 
lack of IUI guidelines in most European countries.
Despite the overall moderate-to-high methodological quality of IUI guidelines in Europe, 
some striking flaws in their methodological quality were identified with the AGREE 
Instrument. When interpreting these flaws, we must keep in mind that perspectives on 
optimal methods for guideline development changed over time.7 In fact, internationally 
recognized standards for development and reporting of clinical practice guidelines were just 
recently established by the AGREE Collaboration.10 Therefore, flaws in the methodological 
quality of the IUI guidelines may result from the use of different methods for guideline 
development at different moments in time. This supports our observation that the most 
recently published IUI guideline from England and Wales used more advanced methods 
for guideline development and scored highest on AGREE appraisal. Moreover, flaws in the 
methodological quality of the more dated IUI guidelines from France and the Netherlands 
mainly concern aspects of guideline quality that gained importance over the past few years, 
such as integrating patient preferences and opinions, economic evidence and statements 
regarding editorial independence in clinical practice guidelines.
Flaws in the methodological quality of the IUI guidelines may also be attributable to 
differences in resources. Professional societies generally have smaller budgets for guideline 
development than governmental agencies, which could explain the lower scores for the 
rigour of development on AGREE appraisal of the IUI guidelines produced by the Danish and 
Dutch professional organizations.23
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Both the number and content of the key recommendations of the IUI guidelines in Europe 
differed considerably. Differences in recommendations of guidelines on the same topic are 
common and mainly attributable to selection of different evidence to support guideline 
recommendations.14,21 This corresponds with the minimal overlap in references of the IUI 
guidelines. Some variation in references can be explained by the different publication dates 
of the IUI guidelines. However, previous studies reported that political and cultural factors, 
socioeconomic aspects and characteristics of health care systems are more important 
influences on the choice of evidence for guideline development.16,21 It is not imaginary 
that such factors also compromise the selection of evidence for guideline development in 
reproductive medicine.
In conclusion, this study revealed that the number of IUI guidelines in Europe is surprisingly 
small and that differences in the recommendations and references of these guidelines are 
considerable. How can we overcome these deficiencies in clinical guidance on IUI care in 
Europe? We suggest the establishment of a central body in Europe with expertise in 
up-to-date guideline development methodology and sufficient resources to select the best 
evidence available to support guideline recommendations. Subsequently, the evidence 
selected on a central level could be shared internationally in the form of evidence tables, 
summarizing the content of the selected studies and indicating the level of evidence 
according to validated evidence-level structures. In the context of reproductive medicine 
in Europe, this strategy for central selection and international exchange of evidence to 
support guideline recommendations may very well increase the number of subfertility 
guidelines in Europe, improve their scientific validity, promote international consensus on 
their clinical content and reduce duplication of effort and inefficient use of resources.11,23 
Interestingly, ESHRE recently applied this approach to select evidence on a European level 
for development of recommendations on the diagnosis and treatment of endometriosis.24 
The issue of whether or not ESHRE will continue to act as a central body to select evidence 
for development of guidelines on other clinical subjects in reproductive medicine should be 
discussed internationally. Proposals regarding other eligible European organizations to select 
and share evidence for guideline development in Europe should also be brought forward in 
an international debate. Clearly, establishment of a central body will be an important first 
step to facilitate systematic guideline development to promote best practice in reproductive 
medicine as well as in other health care settings.
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Abstract
Background: Health care delivery according to clinical practice guidelines is thought to 
be critical in achieving optimal outcomes. This study aimed to assess the extent to which 
practice performance in intrauterine insemination (IUI) care is consistent with guideline 
recommendations and to evaluate the association between guideline adherence and 
outcome of IUI care. 
Methods: In a retrospective cohort study, 1100 subfertile couples from 10 Dutch hospitals 
were asked to grant access to their medical record if they had undergone IUI treatment 
for assessment of guideline adherence using 25 systematically developed guideline-based 
performance indicators. 
Results: A total of 558 couples who started 2334 IUI cycles participated. Guideline adherence 
regarding 20 process and 5 structure aspects of IUI care was often substandard and varied 
considerably between hospitals. Out of 10 possible associations investigated, guideline 
adherence regarding sperm quality and guideline adherence regarding the total number of 
IUI cycles were associated with improved ongoing pregnancy rates after IUI. 
Conclusions: Guideline adherence in IUI care is far from optimal and varies substantially 
between hospitals. As associations between guideline adherence and ongoing pregnancy 
after IUI were mainly nonsignificant, further research is needed to evaluate associations 
between guideline adherence and other outcomes of IUI care besides ongoing pregnancy, 
such as patient safety and cost-effectiveness.
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Introduction
Subfertility is common. As one in six couples fails to conceive within 1 year of regular 
unprotected sexual intercourse, approximately 72.4 million couples around the world are 
currently subfertile.1,2 Roughly half of these couples seek medical care for their fertility 
problems.2,3 The clinical investigation and treatment of subfertility has considerable physical 
and psychosocial implications for couples.4-7 In addition, fertility treatment often carries a 
risk of multiple pregnancy which is associated with substantially higher rates of maternal 
and perinatal morbidity and mortality compared with singletons.8,9 The assessment and 
treatment of subfertility is also expensive and the increased rates of adverse pregnancy 
outcomes add further to the resources used in health care.10,11
It is widely recognized that the quality of health care is often inadequate.12-15 As subfertility 
is a major health issue worldwide and its management is associated with health risks 
and high costs, there is great concern about the impact of substandard subfertility care 
on health and health care resources.16,17 This prompted several professional societies in 
the fields of obstetrics, gynaecology and reproductive medicine as well as governmental 
agencies to develop clinical practice guidelines for subfertility care. These guidelines are 
tools to help physicians and patients to make better decisions about clinically effective, 
safe and cost-effective care and reduce inappropriate practice variation in subfertility care. 
Essentially, these guidelines describe ‘the best thing to do’ and aim to improve the outcome 
of subfertility care.
One of the most commonly used fertility treatments is homologous intrauterine insemination 
(IUI).18 The overall success rate of IUI remains controversial. On average, reported clinical 
pregnancy rates are only 5-13% per IUI cycle.10,18-24 Poor guideline adherence and a high 
degree of inappropriate practice variation in IUI care may be responsible for these low 
pregnancy rates. However, up until now, there has been limited published evidence about 
guideline adherence in IUI care and the link between guideline adherence and outcome of 
IUI care. Therefore, the objective of this study was to assess the extent to which practice 
performance in IUI care is consistent with guideline recommendations and to evaluate the 
association between guideline adherence and outcome of IUI care.
Variation in guideline adherence in intrauterine insemination care
46
Materials and methods
Study design and population
This retrospective cohort study at 10 Dutch hospitals was conducted using medical record 
and questionnaire data. The group of participating hospitals was made up of one large 
academic hospital providing tertiary care and nine medium-sized public hospitals providing 
secondary care. Five clinics were also teaching hospitals. Patients eligible to participate in 
the study were defined as subfertile couples who underwent IUI treatment at these 10 
hospitals during an inclusion period of 28 months, from April 2000 to August 2002. Subfertile 
couples who had undergone ovulation induction therapy for ovulatory disorders or IUI 
treatment with donated spermatozoa were not eligible to participate. Once the relevant 
institutional review boards gave their approval, the databases of the fertility laboratories 
of the participating hospitals were used to make a list of eligible couples per hospital. 
From each list, a random sample of couples in proportion to the size of the hospital’s IUI 
programme (50-150 couples per hospital) was selected by computer for participation in the 
study. The total sample consisted of 1100 subfertile couples. Each couple was requested 
in an informative letter to sign and return a consent form to grant access to their medical 
record. Non-respondents were sent a reminder after 4 weeks.
Indicator development
Reliable assessment of the extent to which practice performance in health care is consistent 
with guideline recommendations requires a set of valid guideline-based performance 
indicators.25,26 Therefore, a set of guideline-based performance indicators for IUI care was 
systematically developed for use in three steps: (I) preselection of recommendations; 
(II) expert consensus procedure; and (III) transcription and classification of final set of 
indicators.27-30
First, three authors independently preselected all recommendations from the four existing 
IUI guidelines in Europe.31-34 These IUI guidelines from Denmark, England and Wales, France 
and the Netherlands are evidence-based and of moderate to high methodological quality 
according to appraisal with the internationally validated AGREE Instrument.35 Discrepancies 
in the recommendations of the four IUI guidelines were assessed against the best available 
evidence to ensure selection of recommendations supported by the highest level of 
evidence. This resulted in a list of 33 recommendations on IUI care.
Second, an expert consensus procedure according to the RAND-modified Delphi method 
was conducted to explore consensus among a group of opinion leaders about the relevance 
of the preselected recommendations.27,28,36,37 In the two-round consensus procedure, a 
panel of 13 experts in the field of IUI and quality-of-care research rated the relevance of 
the 33 preselected recommendations to patients’ health benefit and cost-effectiveness on a 
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five-point Likert scale (1 = strongly disagree; 5 = strongly agree). Moreover, the experts were 
asked to provide a top-five ranking of recommendations they considered most important. 
The experts also had the opportunity to comment on each proposed recommendation and 
suggest additional recommendations for evaluation. In the first round, 10 recommendations 
with at least 75% of the ratings on both criteria in the categories ‘agree’ and ‘strongly 
agree’ and a top-five ranking were selected. In the second round, the experts re-evaluated 
the remaining 23 recommendations and eight newly suggested recommendations. This 
re-evaluation resulted in the selection of another 15 recommendations with at least 75% of 
the ratings on one criterion in the categories ‘agree’ and ‘strongly agree’.
Third, the new selection of 25 key recommendations on IUI care was transcribed 
into indicators. This resulted in the final set of 25 guideline-based performance 
indicators for IUI care. Of these, 20 indicators were related to process aspects of 
IUI care, subdivided into 10 main categories: screening for tubal occlusion (n = 1), 
sperm quality (n = 1), indications for IUI (n = 3), total number of IUI cycles (n = 2), 
monitoring in IUI (n = 3), timing in IUI (n = 2), dose of gonadotrophins in stimulated IUI
(n = 3), timing of human chorionic gonadotrophin (hCG) administration in stimulated IUI 
(n = 2), dose of hCG in stimulated IUI (n = 1), and cancellation criteria in stimulated IUI (n = 2) 
(Table 1). The other five indicators referred to structure aspects of IUI care: practice facilities 
for IUI (n = 5) (Table 2).
Data collection
Data about process aspects of IUI care (20 process indicators described in Table 1), clinical 
outcomes, and patient characteristics such as female age, type and duration of subfertility 
and diagnosis, were abstracted from medical records by two trained research assistants 
using standardized audit forms. To assess the reliability of data collection, both research 
assistants independently re-abstracted a randomly selected sample of 24 medical records 
from two different hospitals. The extent of agreement regarding the collected data, corrected 
for chance, was calculated using the kappa statistic. The average reliability of data collection 
was very good (κ = 0.96; range 0.83-1.0).
Data about structure aspects of IUI care (five structure indicators described in Table 2) 
were collected by means of a short questionnaire distributed to one gynaecologist in each 
participating hospital.
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Process indicator
No. of 
subfertile 
couples to 
whom indicator 
applies a
Performance 
score 
(%) b
Range 
across 10 
hospitals 
(%)
Screening for tubal occlusion
Before starting IUI, screening for tubal occlusion 
should be performed
558 75 66-93
Sperm quality
More than one million motile spermatozoa should be 
available for IUI after sperm preparation
553 74 0-88
Indications for IUI
Couples with male factor fertility problems should be 
offered unstimulated IUI
40 59 0-100
Couples with unexplained fertility problems should 
be offered stimulated IUI
208 94 70-100
Couples with cervical mucus hostility should be 
offered unstimulated IUI
51 38 0-100
Total number of IUI cycles
Couples with male factor fertility problems should be 
offered up to six IUI cycles
78 26 0-43
Couples with unexplained fertility problems should 
be offered up to six IUI cycles
79 46 0-73
Monitoring in IUI
Patients undergoing stimulated IUI should be 
monitored by transvaginal ultrasonography
450 98 87-100
Patients undergoing unstimulated IUI should be 
monitored by LH measurements
173 53 0-100
LH measurements should be performed twice daily 110 25 0-66
Timing in IUI
IUI should be performed 38-42 hours after 
administration of hCG
429 19 3-68
IUI should be performed 20-30 hours after detection 
of spontaneous LH surge
241 9 0-42
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Dose of gonadotrophins in stimulated IUI
The dose of gonadotrophins in the first cycle of 
stimulated IUI should be 75 IU per day
254 30 0-63
The dose of gonadotrophins should be adapted if 
ovarian stimulation does not result in 2 or 3 follicles 
> 16 mm
277 33 13-47
If the dose of gonadotrophins is raised to achieve 
multifollicular growth, this should be done with 37.5 
IU per day per cycle
23 20 0-79
Timing of hCG administration in stimulated IUI
Patients undergoing stimulated IUI with 
gonadotrophins should be administered hCG when 
dominant follicular diameter reaches 18 mm
247 47 26-73
Patients undergoing stimulated IUI with oral anti-
oestrogens should be administered hCG when 
dominant follicle diameter reaches 20 mm
200 48 0-75
Dose of hCG in stimulated IUI
hCG should be administered at a dose of 5000 IU 403 21 0-100
Cancellation criteria in stimulated IUI
An IUI cycle should be cancelled if ovarian ultrasound 
reveals five or more follicles > 12 mm or three or 
more follicles > 16 mm
42 71 0-100
Advice to withhold from unprotected sexual 
intercourse should be given if ovarian ultrasound 
reveals five or more follicles > 12 mm or three or 
more follicles > 16 mm
30 53 0-100
hCG, human chorionic gonadotrophin. IUI, intrauterine insemination. Stimulated IUI, IUI after ovarian stimulation using 
gonadotrophins or oral anti-oestrogens. Unstimulated IUI, IUI in natural cycles. LH, luteinizing hormone.
a The maximum number of subfertile couples to whom a process indicator can apply is 558.
b Each performance score was calculated in two steps: (I) the number of IUI cycles of a couple in which practice 
   performance was consistent with a guideline recommendation was divided by the total number of IUI cycles of the 
   couple to which the recommendation applied; (II) the proportions of individual subfertile couples were added together 
   and divided by the number of subfertile couples to whom the guideline recommendation applied.
Variation in guideline adherence in intrauterine insemination care
50
Statistical analysis
To assess the extent to which practice performance in IUI care is consistent with guideline 
recommendations, the performance scores of the 25 indicators for IUI care were calculated. The 
performance score of each process indicator was calculated in two steps. First, the number of IUI 
cycles of a couple in which practice performance was consistent with a guideline recommendation 
was divided by the total number of IUI cycles of the couple to which the recommendation applied. 
Second, these proportions of individual subfertile couples were added together and divided by the 
number of subfertile couples to whom the guideline recommendation applied. If IUI treatment 
resulted in a pregnancy, only IUI cycles prior to this pregnancy were used for analysis, excluding 
possible consecutive IUI cycles within the study period. The performance score of each structure 
indicator was calculated by dividing the number of hospitals in which practice performance 
was consistent with a guideline recommendation by the number of hospitals to which the 
recommendation applied. Performance scores ranged from 0 to 100%.
To evaluate the association between guideline adherence and outcome of IUI care, survival 
analysis based on the Cox proportional hazards model was used. The Cox proportional hazards 
model makes it possible to estimate the effect of explanatory variables on time to events, taking 
incomplete follow-up into account. Ongoing pregnancy, defined as a clinical pregnancy confirmed 
by the presence of fetal heart rate beyond 16 weeks’ gestation, was considered the main outcome 
and selected as dichotomous censoring variable (ongoing pregnancy or no ongoing pregnancy). 
The 20 process indicators for IUI care were eligible explanatory variables. However, the indicators 
within each of the 10 main categories of process indicators were aggregated to reduce the number 
of explanatory variables from 20 to 10. Accordingly, 10 aggregated process indicators (Table 1) were 
Structure indicator Performance score (%) a
Practice facilities for IUI
Semen volume for IUI should be 0.2-0.5 ml after sperm preparation 90
IUI laboratory should be accredited 60
Ovarian ultrasound monitoring to measure follicular size and number should be 
possible every day
90
IUI should be possible at least five days per week 100
IUI treatment results should be evaluated yearly 50
a The number of hospitals to which the indicator applies is 10.
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selected as dichotomous explanatory variables (performance score < 90% or ≥ 90%). Four patient 
and four hospital characteristics were taken into account as cofactors: female age (years), type of 
subfertility (primary or secondary), duration of subfertility (months), diagnosis (male factor fertility 
problems, unexplained fertility problems or cervical mucus hostility), hospital size (< 700 or ≥ 700 
beds), teaching hospital (teaching or non-teaching), IVF facilities (IVF or no IVF), and number of 
physicians involved in the IUI programme (≤ 10 or > 10).
Two separate survival models were designed. One model for the total cohort and a second model 
for a subgroup that underwent stimulated IUI treatment since several process indicators were 
solely related to stimulated IUI, as opposed to unstimulated IUI. P < 0.05 was considered statistically 
significant. Analyses were performed using SAS software (SAS 8.2 for Windows, SAS Institute, Cary, 
North Carolina, USA).
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Results
Study population
Figure 1 presents the recruitment of eligible subfertile couples for participation in the study. 
A total of 765 subfertile couples was willing to participate. We excluded 184 couples because 
they had undergone ovulation induction therapy for ovulatory disorders or IUI treatment
with donated spermatozoa. Another 23 couples were excluded because there was no access 
to their medical records. As a result, 558 subfertile couples who started a total of 2334 IUI 
cycles were eligible for study.
Table 3 shows the patient characteristics. Median female age at the first IUI cycle was 32 years 
(range 23-46). Most couples (49%) were diagnosed with unexplained subfertility. The median 
number of started IUI cycles was three (range 1-15). The patient characteristics female age, 
type of subfertility (primary or secondary), duration of subfertility and diagnosis (male factor 
fertility problems, unexplained fertility problems, or cervical mucus hostility) did not differ 
significantly between hospitals.
Follow-up until the pre-specified outcome, either pregnancy or discontinuation of unsuccessful 
IUI treatment, was complete for 415 couples who started a total of 1803 IUI cycles. A total of 
131 of these couples achieved an ongoing pregnancy after IUI treatment, giving an ongoing 
pregnancy rate per followed-up couple of 31.6% (range across 10 hospitals, 17-49%). Among 
the 131 IUI-related ongoing pregnancies were 13 multiples (9.9%; range across 10 hospitals, 
0-29%), including 12 twins and one triplet. All multiple pregnancies resulted from IUI combined 
with ovarian stimulation using gonadotrophins (77%) or oral anti-oestrogens (23%).
Guideline adherence regarding process aspects of IUI care
Guideline adherence regarding the 20 process aspects of IUI care varied substantially 
(Table 1). Adherence to recommended processes ranged from 9% for timing in unstimulated 
IUI to 98% for monitoring by transvaginal ultrasonography in stimulated IUI. Several process 
aspects, including the total number of IUI cycles, timing in IUI, the dose of gonadotrophins, 
timing of hCG administration and the dose of hCG in stimulated IUI, had low rates of adherence 
(performance scores 9-48%).
Adherence to recommended processes also differed considerably between the 10 participating 
hospitals. Differences between hospitals were particularly striking with regard to indications 
for IUI and cancellation criteria in stimulated IUI, with performance scores ranging from 0 to 
100%. Typical differences existed between hospitals in guideline adherence regarding the dose 
of hCG in stimulated IUI. While two hospitals always administered hCG at the recommended 
dose of 5000 IU (performance score 100%), the other eight hospitals always or predominantly 
administered hCG at a dose of 10 000 IU (performance score 0-25%).
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Guideline adherence regarding structure aspects of IUI care
Guideline adherence regarding the five structure aspects of IUI care varied as well (Table 2). 
Appropriate practice facilities for IUI provided subfertile couples in the majority of hospitals 
the opportunity to receive recommended care, including the most favourable semen 
volume for IUI (performance score 90%), ovarian ultrasound monitoring on every day of 
the week (performance score 90%) and IUI on at least 5 days per week (performance score 
100%). However, structure aspects such as the accreditation status of IUI laboratories and 
yearly evaluation of IUI treatment results had lower rates of adherence (performance scores 
respectively 60 and 50%).
Characteristic Value (range)
Median female age (years) 32 (23-46)
Type of subfertility (%) a
Primary 66
Secondary 34
Median duration of subfertility (months) b 26 (0.3-112)
Diagnosis (%)
Male factor fertility problems 42
Unexplained fertility problems 49
Cervical mucus hostility 9
Median number of started IUI cycles 3 (1-5)
Number of IUI-related ongoing pregnancies c
Singletons 118
Multiples 13
a Subfertility can be primary, in couples who have never conceived, or secondary, in couples who have 
  conceived previously.
b Duration of subfertility was defined as the period between the start of regular unprotected sexual 
   intercourse and the first IUI cycle.
c Ongoing pregnancy was defined as a clinical pregnancy of more than 16 weeks’ gestation.
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Guideline adherence and ongoing pregnancy after IUI
Survival analysis revealed three statistically significant associations between at least 90% 
guideline adherence and ongoing pregnancy after IUI, out of 10 possible associations 
investigated (Table 4 and 5). Guideline adherence regarding sperm quality had the strongest 
and most consistent association with improved ongoing pregnancy rates after IUI. Adherence 
to the recommendation that more than one million motile spermatozoa should be available 
for IUI after sperm preparation increased the chance of an ongoing pregnancy more than 
five to six times (hazard ratio 5.56 (3.74-8.25) in total cohort; hazard ratio 6.05 (3.69-9.93) in 
subgroup who underwent stimulated IUI, both P < 0.0001). Guideline adherence regarding 
the total number of IUI cycles was also associated with improved ongoing pregnancy rates 
after IUI. Indeed, adherence to the recommendation that couples should be offered up to 
six IUI cycles increased the chance of an ongoing pregnancy and the likelihood of an ongoing 
pregnancy was considerably reduced if subfertile couples continued IUI treatment beyond 
the recommended number of six cycles (hazard ratio 0.23 (0.11-0.46), P < 0.0001 in total 
cohort; hazard ratio 0.21 (0.10-0.47), P = 0.0001 in subgroup who underwent stimulated IUI). 
Determinant β P value Hazard ratio (95%-CI)
Predictors of ongoing 
pregnancy a
Process indicator
Sperm quality b 1.715 < 0.0001 5.56 (3.74-8.25)
More than one million motile 
spermatozoa
Total number of IUI cycles c -1.493 < 0.0001 0.23 (0.11-0.46) Not more than six IUI cycles
Patient characteristic
Type of subfertility d -0.386 0.0376 0.68 (0.47-0.98) Secondary subfertility
Duration of subfertility e -0.014 0.0381 0.98 (0.97-0.99) Shorter duration of subfertility
a Ongoing pregnancy was defined as a clinical pregnancy of more than 16 weeks’ gestation.
b Process indicator regarding sperm quality: ‘More than one million motile spermatozoa should be available for IUI after 
  sperm preparation’.
c Process indicator regarding the total number of IUI cycles: ‘Couples should be offered up to six IUI cycles’.
d Subfertility can be primary, in couples who have never conceived, or secondary, in couples who have conceived 
  previously.
e Duration of subfertility was defined as the period between the start of regular unprotected sexual intercourse and the 
  first IUI cycle.
355
Chapter 3
In contrast, adherence to the recommended dose of 5000 IU hCG in stimulated IUI decreased 
the chance of an ongoing pregnancy by half (hazard ratio 0.49 (0.25-0.97), P < 0.0441 in 
subgroup who underwent stimulated IUI).
Survival analysis also showed that two patient characteristics were significantly related 
to ongoing pregnancy after IUI (Table 4 and 5). The likelihood of an ongoing pregnancy 
was much lower if couples had never conceived (hazard ratio 0.68 (0.47-0.98), P = 0.0376 
in total cohort) or had a longer duration of subfertility (hazard ratio 0.98 (0.97-0.99), 
P = 0.0381 in total cohort; hazard ratio 0.97 (0.95-0.99), P = 0.0008 in subgroup who 
underwent stimulated IUI).
Determinant β P value Hazard ratio (95%-CI)
Predictors of ongoing 
pregnancy a
Process indicator
Sperm quality b  1.800 <0.0001 6.05 (3.69-9.93)
More than one million motile 
spermatozoa
Total number of IUI cycles c -1.546 0.0001 0.21 (0.10-0.47) Not more than six IUI cycles
Dose of hCG d -0.705 0.0411 0.49 (0.25-0.97) More than 5000 IU hCG
Patient characteristic
Duration of subfertility e -0.030 0.0008 0.97 (0.95-0.99) Shorter duration of subfertility
a Ongoing pregnancy was defined as a clinical pregnancy of more than 16 weeks’ gestation.
b Process indicator regarding sperm quality: ‘More than one million motile spermatozoa should be available for IUI after  
  sperm preparation’.
c Process indicator regarding the total number of IUI cycles: ‘Couples should be offered up to six IUI cycles’.
d Process indicator regarding the dose of hCG in stimulated IUI: ‘hCG should be administered at a dose of 5000 IU’.
e Duration of subfertility was defined as the period between the start of regular unprotected sexual intercourse and the 
   first IUI cycle.
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Discussion
Although guideline adherence appears adequate for some process and structure aspects of 
IUI care, on the whole, guideline adherence in IUI care is far from optimal. Also striking is the 
large variability in guideline adherence between different hospitals. Associations between at 
least 90% guideline adherence and ongoing pregnancy after IUI were mainly non-significant.
Strengths and limitations of the study
The strength of the study is the rigorous assessment of the extent to which practice 
performance in IUI care is consistent with guideline recommendations, using a systematically 
developed set of valid guideline-based performance indicators for IUI care. The large sample 
of 558 subfertile couples from 10 different hospitals who started a total of 2334 IUI cycles 
contributes to the validity of these research results.
The study also has some limitations. First, the influence of selection bias remains uncertain.38 
Twenty-five per cent of the selected couples refused to participate in the study. More than 
half of these couples reported the reason for refusal to participate, which was mainly a 
lack of time or interest. As the overall participation rate was adequate, it is suspected that 
selection bias did not significantly distort the results of the study.
Second, the study relied primarily on chart abstraction to collect data on practice performance 
in IUI care. This was an elaborate exercise and may also have introduced bias as previous 
research showed that chart abstraction somewhat underestimates the quality of actual 
practice performance.39 However, in the near future, the use of electronic medical records 
will increase, presenting an excellent opportunity to incorporate performance indicators in 
electronic medical records as mandatory items to fill out. This will almost certainly facilitate 
the assessment, registry, monitoring, and comparison of practice performance on local, 
national and international level.25,26
Third, incomplete follow-up could also be considered a limitation of the study. Ideally, 
all subfertile couples enrolled in the study are followed until the pre-specified outcome, 
either pregnancy or discontinuation of unsuccessful IUI treatment, is observed. However, 
some couples had not yet reached this outcome by the time the study ended. Therefore, 
survival analysis based on the Cox proportional hazards model, which takes this incomplete 
follow-up properly into account, was used.
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Fourth, to evaluate the association between guideline adherence and ongoing pregnancy 
after IUI, the study performed survival analysis in which optimal guideline adherence was 
defined as adherence to a guideline recommendation in at least 90% of IUI cycles per 
couple. This cut-off point of at least 90% may seem arbitrary. However, as survival analysis 
was performed using other cut-off points, such as 75%, 80% and 85%, the survival model did 
not change, just the estimates of the effect to a limited extent.
Meaning of the study
Published literature is full of examples of patients receiving inappropriate care according 
to current scientific evidence and professional insight laid down in guidance.12-15 This study 
established that practice performance in IUI care is for the most part not consistent with 
guideline recommendations. There is also a wide variation in guideline adherence between 
different hospitals. Clearly, the consequences of substandard IUI care are considerable. 
Therefore, interventions that address the identified deficits in IUI care are warranted.
As time and resources for initiatives to change practice performance in health care are 
generally limited, targeted interventions to specifically improve aspects of care that 
are associated with better clinical outcomes are probably most effective and efficient.12 
However, up until now, data regarding the association between guideline adherence and 
outcome of subfertility care were limited. This study revealed two statistically significant 
associations between guideline adherence and improved ongoing pregnancy rates after IUI 
which can direct future quality improvement activities. In other words, efforts should be 
made to specifically promote implementation of the guideline recommendations on sperm 
quality and the total number of IUI cycles.
Remarkably, adherence to the recommendation that hCG should be administered at a dose 
of 5000 IU in stimulated IUI was negatively associated with ongoing pregnancy after IUI. 
The lack of, published evidence to support or oppose this association is surprising. The 
underlying reasons of this finding can be speculated upon. However, to judge this finding 
by its true merits, the causal relationship between the dose of hCG used in stimulated IUI 
and the ongoing pregnancy rate should be investigated in a randomized controlled trial first.
A statistically significant association between at least 90% guideline adherence and ongoing 
pregnancy after IUI could not be established for seven out of the 10 possible associations 
investigated. Similarly, the few studies previously performed found only small statistically 
significant or non-significant associations between guideline adherence and patient 
mortality rates for acute myocardial infarction, heart failure and pneumonia, despite large 
sample sizes.40-42 This raises a fundamental question: Why can’t adherence to guideline 
recommendations that are mostly based on solid research evidence be successfully linked 
to better patient outcomes in actual practice?
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There are probably several explanations. An explanation might be that guideline 
recommendations are not always based on top-level evidence.27-30 In the present study, 60% 
of the process indicators was supported by top-level evidence. Therefore, more well-designed 
studies, preferably randomized controlled trials, are needed to improve the strength of the 
supporting evidence of guideline recommendations. It is also possible that the findings about 
practice performance and clinical outcomes from homogeneous study samples that are 
used to form and support guideline recommendations may not be applicable to all patients 
in actual practice.40 Another, highly plausible explanation might be that we only investigated 
the association between guideline adherence and ongoing pregnancy and not all guideline 
recommendations are necessarily associated with improved ongoing pregnancy rates. For 
example, recommendations regarding the dose of gonadotrophins and cancellation criteria 
in stimulated IUI are associated with patient safety.
Although this study found mainly non-significant associations between guideline adherence 
and ongoing pregnancy after IUI, it can not be necessarily said that guideline adherence is 
rather useless. Instead, attention should be focused on evaluating associations between 
guideline adherence and other outcomes of IUI care besides ongoing pregnancy, such as 
patient safety and cost-effectiveness.
General considerations
Health care delivery according to clinical practice guidelines is thought to be critical 
in achieving optimal outcomes. Reliable assessment of the extent to which practice 
performance in health care is consistent with guideline recommendations is therefore a 
key step in the dynamic process of quality assessment and improvement. This requires a 
set of valid guideline-based performance indicators. Tailored interventions to address 
shortcomings in practice performance come next. Preferably, the focus should be on care 
aspects strongly associated with improved outcomes. More research to establish such 
associations between guideline adherence and outcomes is necessary. To be sure that 
interventions to improve practice performance have the desired effect, ongoing assessment 
of practice performance in routine health care is warranted. To succeed, each quality control 
system will need adequate support and appropriate levels of funding. As all countries 
face common challenges to deliver appropriate, high-quality care to patients, there is an 
argument for more international collaboration in the development and research regarding 
clinical practice guidelines, performance indicators and implementation strategies to 
improve health care. 
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Abstract
Background: Fertility guidelines are tools to help health care professionals and patients to 
make better decisions about clinically effective, safe as well as cost-effective care. This study 
aimed to assess the cost-effectiveness of optimal versus suboptimal guideline adherence in 
intrauterine insemination (IUI) care from a societal perspective.
Methods: In a retrospective cohort study involving medical record analysis and a patient 
survey in which 415 subfertile couples from 10 Dutch hospitals participated, interviews with 
staff members and a review of hospitals’ financial department reports and literature, data 
were obtained about patient characteristics, process aspects and clinical outcomes of IUI 
care, and resources consumed. In the cost-effectiveness analyses, restricted to four relevant 
IUI guideline recommendations, the ongoing pregnancy rate per couple (effectiveness), the 
average medical and non-medical costs of IUI care, possible additional in vitro fertilisation 
(IVF) treatment, pregnancy, delivery and period from birth up to 6 weeks after birth for both 
mother and offspring per couple (costs), and the incremental net monetary benefits (INB) 
were calculated.
Results: Optimal adherence to the guideline recommendations about sperm quality, the 
total number of IUI cycles and dose of human chorionic gonadotrophin (hCG) was cost-
effective with an incremental net monetary benefit between € 645 and over € 7500 per 
couple, depending on the recommendation and assuming a willingness to pay of € 20 000 
for a live birth.
Conclusions: Optimal guideline adherence in IUI care has substantial economic benefits 
compared to suboptimal guideline adherence. These results provide an excellent opportunity 
to increase awareness among health care professionals, patients and authorities about the 
importance of guideline development and implementation.
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Introduction
Health care expenditures have increased enormously in the last decades.1 Therefore, high-
quality care consists nowadays not only of choosing the most clinically effective and safe 
treatment pathway, but also considering the cost-effectiveness.2 In fertility care, perceived 
by many as elective, the delivery of cost-effective care is considered even more important. 
Expenditures for fertility care are high due to the increased use of advanced assisted 
reproduction techniques and because of complications, such as ovarian hyperstimulation 
syndrome, increased rates of adverse pregnancy outcomes, which are usually caused by 
multiple pregnancies, and productivity loss.3-5
Clinical practice guidelines can assist health care professionals and patients to make better 
decisions about clinically effective, safe and cost-effective care. In spite of this, little is 
known about the link between guideline adherence and cost-effectiveness in health care in 
general. Moreover, the association between guideline adherence and cost-effectiveness in 
fertility care has not been explored, even though approximately 80 million couples around 
the world are currently subfertile and over 700 000 fertility treatment cycles are initiated 
yearly.6-8 Therefore, the study aimed to investigate if optimal adherence to guideline 
recommendations in fertility care is cost-effective from a societal perspective compared 
to suboptimal adherence to guideline recommendations. The focus was on homologous 
intrauterine insemination (IUI), a frequently used fertility treatment associated with 
considerable expenditures and a high degree of practice variation with potential for cost 
saving.
Materials and methods
Study design
Cost-effectiveness analyses were performed to investigate if optimal adherence to four 
recommendations derived from a systematically developed set of 25 guideline-based 
performance indicators for IUI care9 was cost-effective compared to suboptimal adherence 
to these recommendations. Three of these recommendations proved in a prior study to be 
independently associated with clinical outcome of IUI care (recommendations 1-3)9 and one 
recommendation was expected to be an important cost driver in IUI care (recommendation 4), 
and, therefore, subject of the cost-effectiveness analyses:
1. ‘More than one million motile spermatozoa should be available for IUI after sperm 
preparation’.
2. ‘Couples with male factor or unexplained fertility problems should be offered up to six 
IUI cycles’.
3. ‘Human chorionic gonadotrophin (hCG) should be administered at a dose of 5000 IU 
(instead of 10 000 IU)’.
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4. ‘Couples with male factor fertility problems or cervical mucus hostility should be offered 
unstimulated IUI (IUI in natural cycles) and couples with unexplained fertility problems 
should be offered stimulated IUI (IUI after ovarian stimulation using gonadotrophins or 
oral anti-oestrogens)’. 
The cost-effectiveness analyses were conducted from a societal perspective.
Setting and study population
The cost-effectiveness analyses were performed as part of a retrospective cohort study to 
assess the extent of adherence to IUI guideline recommendations at 10 of the 91 Dutch 
hospitals providing IUI care.9 These 10 hospitals were selected to represent a variety of 
settings and included one large university hospital providing tertiary care and nine public 
hospitals providing secondary care, including four intermediate-sized, non-university 
teaching hospitals, two intermediate-sized, non-teaching hospitals, and three smaller, non-
teaching hospitals. Patients eligible to participate in this study were defined as subfertile 
couples who underwent IUI treatment at these 10 hospitals during an inclusion period of 28 
months, from April 2000 to August 2002. Couples were randomly selected by computer from 
the databases of the fertility laboratories of the 10 participating hospitals, in proportion to 
the size of each hospital’s IUI programme (50-150 couples per hospital). The total sample 
consisted of 1100 subfertile couples. Couples who had undergone ovulation induction therapy 
for ovulatory disorders or IUI treatment with donated spermatozoa and couples who had 
not reached the pre-specified outcome, either pregnancy or discontinuation of unsuccessful 
IUI treatment, in the given study period were excluded. The involved institutional review 
boards approved the study and participating couples signed an informed consent.
Data collection 
Effectiveness
The extent of adherence to IUI guideline recommendations was previously assessed with 
a systematically developed set of 25 guideline-based performance indicators for IUI care.9 
Relevant data about patient characteristics, process aspects and clinical outcomes of IUI 
care were abstracted from medical records by two trained researchers using standardised 
audit forms.
Costs
Both direct and indirect medical costs as well as direct and indirect non-medical 
costs of IUI care were taken into account. Medical costs included costs for staff, 
equipment, disposable materials, medication, sperm preparation, and workplace 
and overhead. All medical costs, except for sperm preparation, were variable costs. 
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Non-medical costs were patients’ travel expenses and productivity loss due to absence 
from work. The resources consumed were estimated by means of medical record analysis, 
a patient survey with written questionnaires, interviews with staff members involved in 
IUI care, such as gynaecologists, embryologists, laboratory staff, nurses, counter clerks, 
administrators, and interior decorators, and a review of hospitals’ financial department 
reports and literature. To quantify the actual resources consumed, true costs instead of 
charges were assessed, using an activity-based costing approach.
The societal costs of singleton or multiple pregnancy, delivery and period from birth up to 6 
weeks after birth  for both mother and offspring resulting from IUI treatment, and, in case 
no pregnancy was achieved with IUI treatment, of possible additional in vitro fertilisation 
(IVF) treatment and singleton or multiple pregnancy, delivery and period from birth up to 6 
weeks after birth for both mother and offspring resulting from IVF treatment were derived 
from a previously performed Dutch study.10
All costs were expressed in year 2009 euro (€) by means of the consumer price index (CPI) 
for health care costs in the Netherlands (statline.cbs.nl).
Statistical analysis
Demographic data of the participating couples were presented as median values with ranges 
or as percentages in case of absolute numbers. Group comparisons for differences in patient 
characteristics were performed by Mann-Whitney U and Chi-square tests.
Effectiveness was defined as an ongoing pregnancy, that is, a clinical pregnancy of more 
than 16 weeks’ gestation. A secondary outcome measure was ongoing multiple pregnancy. 
Effectiveness data were given as point estimates with 95%-confidence intervals (95%-CI).
The average medical and non-medical costs of IUI care were calculated in two steps. First, 
the resources consumed by each couple, expressed in units, were multiplied by its unit 
prices. Second, the costs of IUI care of individual couples were added together and divided 
by the total number of couples involved. Because of the skewed distribution of the cost 
parameters used as input for these cost calculations, the raw data were log transformed 
after which statistical inferences could be drawn using parametric statistical tests (ANOVA 
and T-tests).
To assess the cost-effectiveness of optimal versus suboptimal adherence to the four IUI 
guideline recommendations, the ongoing pregnancy rate per couple, the average costs 
of IUI care per couple and the incremental net monetary benefits (INB) were calculated. 
Guideline adherence was considered optimal if a couple was treated in at least 90% of the 
IUI cycles according to a guideline recommendation. If a couple was treated in less than 
90% of the IUI cycles according to a guideline recommendation, guideline adherence 
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was considered suboptimal. The INB places a monetary value on a clinical improvement 
by assigning a monetary value to the incremental benefit achieved and subtracting the 
incremental costs of achieving this benefit. The INB assessment is particularly useful in 
dominant scenarios, which means health gain in combination with a reduction in costs 
or, vice versa, health reduction despite higher costs. INB is defined as: Kμ
Δe 
 - μ
Δc 
, where 
K equals the maximum amount that society would be willing to pay for the incremental 
improvement in outcome, for instance, an ongoing pregnancy or live birth, μ
Δe 
 represents 
the incremental benefit and μ
Δc
 the incremental costs. A positive INB implies that the costs 
of an intervention are less than the value of the additional benefit achieved. A negative 
INB implies that an intervention should be rejected, as its costs are higher than the value 
of the benefit achieved. The baseline willingness to pay for a live birth was estimated at 
€ 20 000 according to Granberg.11 To calculate confidence intervals belonging to the INB, 
Fieller’s theorem was applied.12 To incorporate deterministic uncertainty surrounding the 
point estimates of INB, the willingness to pay for a live birth was varied from € 0 to € 20 000, 
thus taking a conservative position regarding K.
In the same manner, additional scenarios were investigated to consider the societal costs 
of singleton or multiple pregnancy, delivery and period from birth up to 6 weeks after birth 
for both mother and offspring resulting from IUI treatment, and, in case no pregnancy was 
achieved with IUI treatment, of possible additional IVF treatment and singleton or multiple 
pregnancy, delivery and period from birth up to 6 weeks after birth for both mother and 
offspring resulting from IVF treatment. The proportion of couples that opted for IVF and 
its related technologies if IUI treatment had not resulted in a pregnancy was estimated at 
71% and they underwent on average 2.1 IVF treatment cycles. In 71% of these couples, IVF 
resulted in an ongoing pregnancy and 14% of these pregnancies were multiples. These data 
have not been published, but were derived from another Dutch cohort study among 470 
couples who had undergone IUI treatment during the same study period.13
The cost-effectiveness analyses were performed for each recommendation independently, 
assuming ceteris paribus, that is, ‘all other things were held constant’. P < 0.05 was 
considered statistically significant. Analyses were performed with the Statistical Programme 
for the Social Sciences (SPSS 16.0 for Windows, SPSS Inc., Chicago, Illinois, USA).
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Results
Study population
Figure 1 shows the recruitment of eligible subfertile couples for participation in the study. 
A total of 765 subfertile couples was willing to participate, but 350 couples were excluded 
because study of their medical records revealed that they had undergone ovulation induction 
therapy for ovulatory disorders or IUI treatment with donated spermatozoa (n = 184) or they 
had not reached the pre-specified outcome, either ongoing pregnancy or discontinuation of 
unsuccessful IUI treatment, by the time the study ended (n = 143), or because there was 
no access to their medical records (n = 23). As a result, 415 subfertile couples who started a 
total of 1803 IUI cycles were eligible for the cost-effectiveness analyses.
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Effectiveness
Adherence to the four IUI guideline recommendations varied between 16 and 74%. A total 
of 171 out of 415 couples (41%) became pregnant during IUI treatment and 140 pregnancies 
(82%) were ongoing. Among the 13 ongoing multiple pregnancies (9.3%) were 12 twins and 
one triplet (Table 1).
Characteristic Value (range)
Median female age (years) 32 (23-46)
Type of subfertility (%) a
Primary 66
Secondary 34
Median duration of subfertility (months) b 27 (0.3-112)
Diagnosis (%)
Male factor fertility problems 43
Unexplained fertility problems 48
Cervical mucus hostility 9
Median number of started IUI cycles 4 (1-15)
Type of IUI treatment (%) c
Unstimulated 20
Stimulated 68
Both 12
Number of ongoing pregnancies d
Singletons 127
Multiples 13
a Subfertility can be primary, in couples who have never conceived, or secondary, in couples who conceived previously.
b Duration of subfertility was defined as the period between the start of regular unprotected sexual intercourse and the 
  first IUI cycle.
c IUI, intrauterine insemination. Stimulated IUI, IUI after ovarian stimulation using gonadotrophins or oral 
  anti-oestrogens. Unstimulated IUI, IUI in natural cycles.
d Ongoing pregnancy was defined as a clinical pregnancy of more than 16 weeks’ gestation.
The patient characteristics are listed in Table 1. For each guideline recommendation, the 
patient characteristics female age, type of subfertility (primary or secondary) and duration 
of subfertility did not differ significantly between the group in which guideline adherence 
was optimal and the group in which guideline adherence was suboptimal.
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Costs
Table 2 presents the cost parameters used as input for the cost calculations of IUI care and Table 
3 shows the calculated average medical and non-medical costs of IUI care. The total medical costs 
of one unstimulated IUI cycle were € 331 (95%-CI 311-351) and the total non-medical costs € 128 
(95%-CI 117-138). Altogether, the average total costs of one unstimulated IUI cycle were estimated 
at € 459 (95%-CI 432-486). The average total costs of one stimulated IUI cycle were significantly 
higher, that is, € 1248 (95%-CI 1212-1285) using gonadotrophins and € 762 (95%-CI 726-798) 
using oral anti-oestrogens. Accordingly, the average total costs of one stimulated IUI cycle, using 
either gonadotrophins or oral anti-oestrogens, were estimated at € 1038 (95%-CI 1009-1068).
Cost-effectiveness
Table 4 and 5 summarize the results of the assessment of the cost-effectiveness of optimal versus 
suboptimal guideline adherence in IUI care. Table 4 shows the results of the cost-effectiveness 
analyses concerning the costs of IUI care. With a willingness to pay of € 20 000 for a live birth, 
the INB was positive for three out of the four recommendations investigated, which were sperm 
quality, the total number of IUI cycles and indications for IUI. In other words, optimal adherence 
to these guideline recommendations was cost-effective and could save between € 235 and over 
€ 11 000 per couple. 
Table 5 presents the results of the cost-effectiveness analyses in which, besides the costs of IUI 
care, the costs of singleton or multiple pregnancy, delivery and period from birth up to 6 weeks 
after birth for both mother and offspring resulting from IUI treatment, and, in case no pregnancy 
was achieved with IUI treatment, of possible additional IVF treatment and singleton or multiple 
pregnancy, delivery and period from birth up to 6 weeks after birth  for both mother and offspring 
resulting from IVF treatment were also taken into account. With a willingness to pay of  € 20 000 
for a live birth, the INB was positive for three out of the four recommendations investigated, 
which were sperm quality, the total number of IUI cycles and dose of hCG. Optimal adherence to 
these guideline recommendations could save between € 645 and over € 7500 per couple. 
Comparing Table 4 and 5 revealed that optimal adherence to the guideline recommendations 
about sperm quality and the total number of IUI cycles became slightly less cost-effective when 
the effects and costs of possible additional IVF treatment and pregnancies and deliveries were 
considered, as opposed to IUI care alone. Furthermore, optimal adherence to the guideline 
recommendation about indications for IUI was no longer cost-effective when these additional 
effects and costs were included within the analyses. In contrast, optimal adherence to the 
guideline recommendation about the dose of hCG became cost-effective when these effects and 
costs were taken into account, probably because suboptimal adherence to this recommendation, 
thus the administration of hCG at a dose of 10 000 IU, resulted in slightly more pregnancies, albeit 
predominantly multiple pregnancies, that is, 12 out of the total of 13 multiple pregnancies.
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Discussion
Main findings
This study showed that optimal guideline adherence in IUI care was cost-effective for 
three out of the four recommendations investigated. The potential societal cost saving per 
couple starting with IUI treatment varied between € 645 and over € 7500, depending on 
the recommendation and assuming a willingness to pay of € 20 000 for a live birth. For 
Europe, where over 128 000 IUI cycles are initiated each year to treat approximately 32 000 
subfertile couples, this could mean a possible cost saving of at least 20 million euro yearly.14 
Strengths and limitations of the study
The study is unique by comparing optimal with suboptimal care and performing the cost-
effectiveness analyses from a societal perspective with empirical data. Even though the 
inclusion of future costs within economic evaluations of health care is recommended, this 
is rarely done.28,29 However, this study conducted cost-effectiveness analyses in which the 
costs of possible additional IVF treatment, pregnancy, delivery and period from birth up 
to 6 weeks after birth for both mother and offspring were considered as well. Remarkably, 
in these analyses, adherence to most of the guideline recommendations remained cost-
effective, but with lower incremental net monetary benefits than considering only the costs 
of IUI care. This could be explained by the fact that most other cost-effectiveness studies 
aimed to determine the benefit of reducing cost-driving medical care, complications or 
disease recurrence. The benefit of IUI treatment is the achievement of a pregnancy, a health 
status that consumes more costs than a non-pregnant health status. The societal costs of 
a singleton, and in particular, of a multiple pregnancy greatly exceed the costs of an IUI or 
IVF treatment cycle. Therefore, the inclusion of these future costs may have unfavourably 
influenced the results of the current analyses, but presents a more realistic and sustainable 
economic picture.
Despite of the innovative character and the use of empirical data from daily practice, some 
limitations of the study have to be addressed. First, since not all recommendations applied 
to all 415 included couples, smaller groups were left for some of the economic analyses. 
Nevertheless, the incremental net monetary benefit estimations might not have suffered 
too much, considering their relatively small 95%-confidence intervals.
Moreover, it can be questioned if the results can directly be translated to other countries 
as the investigations were performed in Dutch fertility practice. However, a previous study 
reported that most European countries do not have IUI guidelines.30 It can be assumed 
that in the absence of clinical practice guidelines, inappropriate practice variation is 
more extensive.31,32 Therefore, our results are especially interesting for countries without 
guidelines for IUI care, as potential cost saving could be even higher.
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Finally, the implications of the results for current IUI care can be questioned, since the results 
were based on data from the period April 2000 to August 2002. Given that the indications 
for IUI treatment, IUI procedures, as well as the number and content of IUI guidelines in 
Europe have not changed over the past few years and a more recent re-measurement with 
a subset of the original performance indicators for IUI care showed no improvement in 
guideline adherence in IUI care, it seems reasonable to assume that the presented data are 
not outdated.33,34
Comparison with other studies
There are only a few studies published about the cost-effectiveness of guideline adherence 
in health care in general. One of these studies was performed by Koskinen and co-authors 
who investigated the impact of an intervention to improve guideline adherence regarding 
the treatment of acute otitis media on clinical outcomes and costs.15 The cost-effectiveness 
was calculated for the total group of patients with a post-intervention guideline adherence 
rate of 78%. The incremental cost-effectiveness ratio in their study was € 205 per symptom-
free patient, which means that an investment of € 205 in health care was needed to gain an 
additional symptom-free patient. The difference with our study is that they did not perform 
a cost-effectiveness analysis comparing patients receiving optimal and suboptimal care 
according to guideline recommendations. 
In addition, Harmsen and colleagues investigated the cost-effectiveness of optimal care 
according to guideline recommendations for urinary tract infections in children compared 
with current care, that is, optimal and suboptimal care mixed.16 The incremental net 
monetary benefit of optimal care in this study ranged from € 20 to € 200, assuming a 
willingness to pay for a quality-adjusted life year (QALY) that ranged from € 0 to € 80 000. 
However, outcomes in this study were based on several assumptions about cost behaviour 
and effects. Therefore, the robustness of the conclusions drawn in this study was limited. 
A few other studies investigated the financial impact of guideline adherence from a 
health care point of view and concluded that treating patients according to guideline 
recommendations may reduce direct medical costs.15,17-26 However, the non-medical costs 
were not taken into account, even though non-medical costs can represent a considerable 
part of the total costs.27 In the present study, 16 to 28% of the costs per IUI cycle could be 
attributed to travel expenses and productivity loss, and the indirect costs of pain, suffering, 
discomfort, and so on, were not even included.
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Implications
In conclusion, optimal guideline adherence in IUI care has substantial economic benefits. 
Therefore, it is valuable to make an effort to improve guideline development and 
implementation. Moreover, the cost-effectiveness of guideline adherence should be more 
often subject of investigations to gain more insight into practice variation and potential cost 
saving in health care. 
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Subfertile couples’ negative experiences with intrauterine insemination care
Abstract
Objective: To identify subfertile couples’ experiences with specific aspects of intrauterine 
insemination (IUI) care and to determine which patient and hospital characteristics affect 
their experiences.
Design: Cross-sectional survey with written questionnaires.
Setting: One large tertiary hospital and nine medium-sized hospitals, including both teaching 
and nonteaching centres, in the southeast of the Netherlands.
Patients: 1100 subfertile couples who underwent IUI treatment between April 2000 and 
August 2002.
Results: The response rate was 71%. Many subfertile couples have had negative experiences 
with IUI care, particularly regarding the doctor’s attitude and coordination of care. Among 
several patient and hospital characteristics that significantly predicted these negative 
experiences, the main predictors were no ongoing pregnancy and high education level.
Conclusions: From the perspective of subfertile couples, several aspects of IUI care are 
in serious need of improvement, particularly care aspects regarding the doctor’s attitude 
and coordination of care. These findings are an important incentive for developing tailored 
interventions that address the reported deficits in IUI care in order to meet subfertile 
couples’ needs better.
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Introduction
The primary outcome of fertility treatment is live birth. However, positive patient evaluations 
of subfertility care are more and more considered an important treatment outcome as 
well.1 In addition, positive patient evaluations of subfertility care are increasingly seen as 
key indicators of good practice performance.2 Alternatively, negative patient evaluations of 
subfertility care can highlight shortcomings in practice performance and set priorities for 
quality improvement activities.3 In recent years, exploring patients’ evaluations of care to 
monitor and improve practice performance has become increasingly common in all sections 
of health care.4-6
Measuring patients’ evaluations of care seems simple, but the best approach is subject 
of debate.7 The main way in which patients’ evaluations of care have been sought is by 
measuring patient satisfaction.8 However, as satisfaction refers to an emotional response to 
the whole health care experience, some argue that satisfaction is insensitive to particular 
problems in practice performance.1,6,9 Measuring patients’ experiences with concrete 
aspects of care may be a more useful approach because the results are more factual and 
specific.4,10 Evidence now confirms that measuring patients’ experiences with concrete 
aspects of care provides a clear view of specific problems in practice performance and is 
therefore more meaningful than measuring satisfaction.9,11 Nevertheless, this approach has 
not yet been widely adopted.
Interpreting patients’ evaluations of care is not clear-cut either.12 Several background factors, 
mainly patient and hospital characteristics, can influence patients’ evaluations of care to 
some extent8, and understanding how these factors affect patients’ evaluations of care is 
therefore critical to interpreting the evaluations correctly.12 This is particularly important if 
patients’ evaluations of care are used to compare the performance of individual providers 
or different health care organizations.13-15 Most studies have investigated the extent to 
which background factors influence patients’ satisfaction with care.8 Clearly, there is a need 
for studies that explore which background factors have a significant effect on patients’ 
experiences with specific aspects of care.
Therefore, the primary aim of our study was to identify subfertile couples’ experiences 
with concrete aspects of subfertility care. For this purpose, we used a newly developed 
questionnaire that was based on the existing patient experience questionnaires of the 
Picker Institute (www.pickerinstitute.org), but has been tailored to the specific needs and 
concerns of subfertile couples. 
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The secondary aim was to determine which patient and hospital characteristics affect 
subfertile couples’ experiences with concrete aspects of subfertility care. In this study, we 
focused on subfertile couples’ experiences with homologous intrauterine insemination (IUI) 
care because IUI care concerns many subfertile couples and involves the full spectrum of 
health care delivery, including investigation, treatment and counseling and information 
giving, in an outpatient setting.
Materials and methods
Study design and population
A cross-sectional survey with written questionnaires was performed among 1100 subfertile 
couples who underwent IUI treatment between April 2000 and August 2002 as part of a 
retrospective audit of IUI practice performance at 10 Dutch hospitals. This group of hospitals 
was made up of one large tertiary centre and nine medium-sized centres, including both 
teaching and non-teaching hospitals, in the southeast of the Netherlands. Once the relevant 
institutional review boards gave their approval, we used the databases of the fertility 
laboratories of the participating hospitals to identify the subfertile couples for inclusion in 
the study. Subfertile couples who had undergone ovulation induction therapy for ovulatory 
disorders or IUI treatment with donated spermatozoa were excluded from the sample.
After the development of the questionnaire, we sent each subfertile couple a questionnaire 
and an informative letter between November 2002 and May 2003 and asked them to 
complete the questionnaire together. Two weeks after the initial mailing, we sent a reminder 
card to non-respondents. Subfertile couples received a second copy of the questionnaire if 
they did not return the first questionnaire within 4 weeks.
Questionnaire development
To develop the questionnaire for measuring subfertile couples’ experiences with IUI 
care, we built upon the existing patient experience questionnaires of the Picker Institute 
(www.pickerinstitute.org). These questionnaires cover seven dimensions of patient-centred 
care: information and education, respect for patients’ preferences, emotional support, 
physical comfort, coordination of care, involvement of family and friends and continuity and 
transition.10
Since items within each dimension required adaptation in order to refer to the specific 
needs and concerns of subfertile couples undergoing IUI treatment, we performed extensive 
qualitative research to determine their priorities. 
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First, we systematically reviewed the literature regarding patients’ evaluations of subfertility 
care to find out what aspects of care had previously been identified as important to 
subfertile couples.1,3,16-20 Next, we interviewed 10 subfertile couples undergoing IUI 
treatment in depth to confirm the priority of the aspects of care derived from the literature 
review and to check whether any important aspects of IUI care had not been taken into 
account. Each interview lasted approximately half an hour. The interviews were tape-
recorded and transcribed. Then two researchers (EH and WN) independently analyzed the 
content to identify the aspects of IUI care that are most important to subfertile couples.
Aspects of IUI care that were prioritized by subfertile couples were selected and put into 
questionnaire format. This resulted in a pilot version of the questionnaire that was tested in 
cognitive interviews with six subfertile couples undergoing IUI treatment and refined on the 
basis of their comments.
Questionnaire content
The 12-page questionnaire consisted of 58 questions. We asked subfertile couples to 
rate their experiences regarding 20 specific aspects of IUI care on a six-point Likert scale 
(1 = inadequate; 6 = excellent). These aspects of IUI care related to information and 
explanation, for example, ‘Were you given enough information about the possible side 
effects of IUI treatment?’, the doctor’s attitude, for instance, ‘Did the doctor make it easy 
for you to ask questions?’, coordination of care, for example, ‘Were you given a choice of 
appointment dates and times for outpatient consultations?’, and waiting times, for instance, 
‘How long were the waiting times in the waiting room for outpatient consultations?’ 
(Table 1). The questionnaire also included items about patient characteristics: age, ethnic 
background, education level, income, type and duration of subfertility, number of started 
and cancelled IUI cycles, type of IUI treatment, time spent on the hospital visit for an IUI 
procedure and ongoing pregnancy.
Statistical analysis
Data from the questionnaires were entered into a database and analyzed with the Statistical 
Programme of the Social Sciences (SPSS 12.0 for Windows, SPSS Inc., Chicago, Illinois, 
USA). Descriptive analyses were performed to describe the previously mentioned patient 
characteristics. Since subfertile couples’ negative experiences with IUI care are most 
helpful for signalling care aspects in need of improvement, we calculated the proportion 
of subfertile couples who used the most negative answering categories (1 = inadequate 
or 2 = doubtful) to rate their experiences regarding the 20 concrete aspects of IUI care. 
We used multivariate linear regression analysis to determine which patient and hospital 
characteristics affect subfertile couples’ experiences with IUI care. 
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Aspects of IUI care Experiences (% 
inadequate or doubtful) a
Information and explanation
Information about the alternatives to IUI treatment, e.g. adoption 27
Information about the possible side effects of IUI treatment 19
Information about the efforts for IUI treatment 17
Information about the time span of IUI treatment 13
Information about the success rates of IUI treatment 9
Doctor’s attitude
Informing you about organizations that provide emotional support 41
Caring about the impact of subfertility on the male partner 30
Allowing you to decide about your own IUI treatment 24
Taking enough time to talk with you 18
Showing interest in you as a person 18
Number of different doctors met 18
Cooperation with other doctors 14
Making it easy for you to ask questions 10
Treating you with respect and courtesy 9
Coordination of care
Appointment options for outpatient consultations 27
Continuity on weekends of scheduling short-term outpatient consultations 27
Continuity on weekends and holidays of outpatient consultations 21
Appointment options for semen analysis 13
Waiting times
Waiting times in the waiting room for outpatient consultations 24
Waiting time for the first outpatient consultation after being referred 15
a Percentages of subfertile couples who used the most negative answering categories (1 = inadequate or 2 = doubtful) to 
   rate their experiences regarding the specific aspects of IUI care.
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For regression analysis, subfertile couples’ experiences regarding the 20 specific aspects 
of IUI care were clustered by means of factor analysis to reduce the number of dependent 
variables. Four factors were identified: information and explanation (five items; Cronbach’s 
alpha 0.87), doctor’s attitude (nine items; Cronbach’s alpha 0.90), coordination of care 
(four items; Cronbach’s alpha 0.83) and waiting times (two items; Cronbach’s alpha 0.53). 
Subsequently, we calculated sum scores for each factor to obtain continuous dependent 
variables. Lower scores indicated more negative experiences of subfertile couples with IUI 
care.
Patient and hospital characteristics were selected as predictor variables on the basis of 
their potential relevance as determinants of subfertile couples’ experiences with IUI care, 
which was either hypothesized or established in previous studies.1,3,16-19 We selected 11 
patient characteristics as predictor variables: female age, male age, couple’s education level 
(low, intermediate or high), net monthly family income (four income categories), type of 
subfertility (primary or secondary), duration of subfertility, number of started IUI cycles, 
number of cancelled IUI cycles, type of IUI treatment (unstimulated, stimulated or both), 
time spent on the hospital visit for an IUI procedure and ongoing pregnancy (none, IUI 
related or other). Five hospital characteristics were selected as predictor variables: type of 
hospital (10 participating hospitals), hospital size (< 700 or ≥ 700 beds), teaching hospital 
(yes or no), IVF facilities (yes or no) and number of physicians involved in the IUI programme 
(≤ 10 or > 10).
We conducted a series of univariate analyses to investigate the associations of the various 
predictor variables with each of the four dependent variables. We set P < 0.20 as the criterion 
for acceptance in the regression model. The following predictors were not associated with 
any of the dependent variables and excluded from regression analysis: net monthly family 
income, time spent on the hospital visit for an IUI procedure and IVF facilities.
We also checked the collinearity between predictor variables using correlation analyses. 
We chose a conservative strategy, with r ≥ 0.6 in at least one correlation as the criterion for 
multicollinearity. As a result, male age was not selected for regression analysis owing to a 
high correlation with female age. Likewise, we excluded type of hospital from regression 
analysis because of high correlations with hospital size, teaching hospital and number of 
physicians involved in the IUI programme.
We used multivariate linear regression analysis with backward elimination procedures to 
determine which patient and hospital characteristics significantly influenced subfertile 
couples’ experiences with IUI care, using a separate model for each dependent variable. 
P < 0.05 was considered statistically significant.
Subfertile couples’ negative experiences with intrauterine insemination care
94
Results
Study population
Figure 1 presents the recruitment of eligible subfertile couples for participation in the study. 
A total of 956 of 1079 (89%) subfertile couples who underwent IUI treatment between April 
2000 and August 2002 responded. While 191 couples refused to take part in the study or 
considered themselves ineligible, 765 (71%) subfertile couples were willing to participate. Of 
these, we excluded 184 couples because they had undergone ovulation induction therapy 
for ovulatory disorders or IUI treatment with donated sperm. As a result, 581 subfertile 
couples were eligible to participate in the study.
595
Chapter 5
Table 2 presents the patient characteristics. Most subfertile couples had an intermediate 
(40%) or high (47%) education level. Subfertility was primary, rather than secondary, in 
most (74%) of the couples. The median number of started IUI cycles was five (range, 
1-19). Thirty-two per cent of the subfertile couples achieved an ongoing pregnancy with IUI 
treatment.
Subfertile couples’ negative experiences with IUI care
Subfertile couples’ negative experiences regarding 20 specific aspects of IUI care are 
presented in Table 1. Quite a few subfertile couples had negative experiences with the 
information and explanation given in IUI care. A significant proportion of the couples (27%) 
received insufficient information about the alternatives to IUI treatment, for example 
adoption. In addition, 19% received little or no information about the possible side effects 
of IUI treatment.
Regarding the doctor’s attitude, many subfertile couples reported negative experiences. The 
doctor gave 41% of the couples insufficient information about organizations that provide 
emotional support. Another 30% felt that the doctor did not care enough about the impact 
of subfertility on the male partner. Approximately one in four subfertile couples said that 
the doctor did not allow them to decide about their own IUI treatment.
Subfertile couples also had negative experiences with the coordination of IUI care. Nearly 
one-third of the couples mentioned that the options for choosing appointment dates and 
times for outpatient consultations were inadequate. Likewise, 27% had problems scheduling 
short-term outpatient consultations during weekends.
Several subfertile couples reported negative experiences with waiting times in IUI care, 
particularly in the waiting room for outpatient consultations (24%).
Determinants of subfertile couples’ negative experiences with IUI care
Multivariate linear regression analysis showed that several patient and hospital characteristics 
significantly predicted subfertile couples’ negative experiences with IUI care (Table 3). The 
regression models explained between 3.6% and 8.4% of the variance in subfertile couples’ 
negative experiences with IUI care.
No ongoing pregnancy and high education level had the strongest and most consistent 
associations with subfertile couples’ negative experiences with IUI care. No ongoing 
pregnancy predicted negative experiences with information and explanation, the doctor’s 
attitude and coordination of care. High education level was predictive of negative experiences 
with the doctor’s attitude, coordination of care and waiting times.
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Characteristic Value (range)
Median female age (years) 34 (24-49)
Median male age (years) 36 (18-57)
Ethnic background (%) a
Dutch 97
Non-Dutch 3
Education level (%) b
Low 13
Intermediate 40
High 47
Net monthly family income (euros) (%) c
< 1250 3
1250–1750 13
1750–2750 28
> 2750 56
Type of subfertility (%) d
Primary 74
Secondary 26
Median duration of subfertility (months) e 18 (0-240)
Median number of started IUI cycles 5 (1-19)
Median number of cancelled IUI cycles 1 (1-16)
Type of IUI treatment (%) f
Unstimulated 17
Stimulated 72
Both 11
Ongoing pregnancy (%) g
None 43
IUI-related 32
Other, for example, spontaneous or after consecutive fertility treatments 25
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More cancelled IUI cycles and undergoing both unstimulated and stimulated IUI treatment 
were also associated with subfertile couples’ negative experiences with IUI care. More 
cancelled IUI cycles predicted negative experiences with information and explanation and 
coordination of care. Undergoing both unstimulated and stimulated IUI treatment was a 
predictor of negative experiences with coordination of care and waiting times.
Among the hospital characteristics, only hospital size was significantly related to subfertile 
couples’ negative experiences with IUI care. A hospital size of less than 700 beds was 
predictive of negative experiences with coordination of care.
a Ethnic background of the couples was determined by the origin of both partners: Dutch, one or both partners are of 
   Dutch origin; non-Dutch, both partners are not of Dutch origin.
b Education level of the couples was determined by the highest education level of both partners: low, primary or lower 
   vocational education; intermediate, secondary or intermediate vocational education; high, higher professional 
   education or university.
c Net monthly family income of the couples was categorized according to the level of the Dutch modal income in euros: 
   < 1250, below Dutch modal income; 1250–1750, Dutch modal income; 1750–2750, modal to 1.5 times Dutch modal 
   income; > 2750, above 1.5 times Dutch modal income.
d Subfertility can be primary, in couples who have never conceived, or secondary, in couples who conceived previously.
e Duration of subfertility was defined as the period between the start of regular unprotected sexual intercourse and the 
   first outpatient consultation for subfertility.
f  IUI, intrauterine insemination. Stimulated IUI, IUI after ovarian stimulation using gonadotrophins or oral 
   anti-oestrogens. Unstimulated IUI, IUI in natural cycles.
g Ongoing pregnancy was defined as a clinical pregnancy of more than 16 weeks’ gestation.
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Experiences with 
IUI care Determinants В ρ R
2 a Predictors of negative experiences
Information and 
explanation
Number of cancelled 
IUI cycles
-0.285 .038
.059
More cancelled IUI cycles
Ongoing pregnancy b -2.754 .000 No ongoing pregnancy
Doctor’s attitude
Education level c 2.263 .050
.036
High education level
Ongoing pregnancy b -3.161 .000 No ongoing pregnancy
Coordination of 
care
Education level c 1.541 .015
.084
High education level
Number of cancelled 
IUI cycles
-0.348 .009 More cancelled IUI cycles
Type of IUI treatment d 1.660 .011
Both unstimulated and stimulated 
IUI
Ongoing pregnancy b -1.610 .001 No ongoing pregnancy
Hospital size e -1.513 .002 Hospital size of less than 700 beds
Waiting times
Education level c 0.569 .000
.049
High education level
Type of IUI treatment d 0.493 .023
Both unstimulated and stimulated 
IUI
a Explained variance in final regression model.
b Ongoing pregnancy was defined as a clinical pregnancy of more than 16 weeks’ gestation.
c Education level of the couples was determined by the highest education level of both partners: low, primary or lower 
   vocational education; intermediate, secondary or intermediate vocational education; high, higher professional 
   education or university.
d Type of IUI treatment was categorized by the use of ovarian stimulation: unstimulated IUI, IUI in natural cycles; 
   stimulated IUI, IUI following stimulation of the ovaries using gonadotrophins or oral anti-oestrogens.
e Hospital size was determined by the number of beds per hospital (< 700 or ≥ 700 beds)
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Discussion
Many subfertile couples have had negative experiences with IUI care, particularly regarding 
the doctor’s attitude and coordination of care. Among several patient and hospital 
characteristics that significantly predicted these negative experiences, the main predictors 
were no ongoing pregnancy and high education level.
The strength of the study is that we measured subfertile couples’ experiences with concrete 
aspects of IUI care rather than measuring satisfaction. Unlike the more subjective and 
nonspecific satisfaction ratings, our results are easily interpretable and can indicate specific 
aspects of care in need of change to guide quality improvement efforts. Another strong 
point of the study is that we focused the assessment of subfertile couples’ experiences with 
IUI care on aspects of care that proved to be important to them. To guarantee that the 
experiences were measured from the patient’s perspective, we used a questionnaire that 
was based on the conceptual framework of key dimensions of patient-centred care of the 
Picker Institute.10 Furthermore, subfertile couples undergoing IUI treatment played a crucial 
role in the process of tailoring the questionnaire to their specific needs and concerns.
When interpreting our results, limitations of the study must be taken into account. The 
influence of non-response bias remains uncertain.21 However, our response rate was 
greater than the mean response rate of approximately 67% for comparable questionnaire 
studies.22,23 In addition, prior research suggests that differences in patients’ evaluations of 
care between respondents and non-respondents may be relatively small.24 Therefore, we 
suspect that non-response had only a modest influence on the final conclusions of the study.
Given a study design that relies on subfertile couples’ memories of experiences with IUI 
care, there is a potential of recall bias.21 However, previous validation studies have shown 
that personal reproductive history can reliably be obtained retrospectively through 
questionnaires, even after periods of more than 14 years.25,26 Considering that the impact of 
IUI treatment on subfertile couples is high, it can be assumed that they can adequately recall 
their experiences at the time of treatment. Although we cannot disregard the possibility that 
recall bias could have affected the results found here, we believe that it does not represent 
a serious threat to the internal validity of the study.
Since seeking fertility treatment concerns both partners, we asked each subfertile couple to 
complete the questionnaire together. Whether or not each couple actually completed the 
questionnaire jointly is not exactly known. However, this issue was not further addressed 
because Sabourin and colleagues have shown that satisfaction ratings of subfertile women 
and men were strongly correlated.16
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Although patients with fertility problems generally report that they are satisfied with the care 
received2,3,16,17, many subfertile couples evaluated their care less positively when asked to 
report on their experiences with specific aspects of IUI care in detail. The evidence provided 
here is in agreement with recent findings in other areas of health care, where satisfaction 
ratings have presented a limited and overoptimistic picture of the quality of practice 
performance as well.6,9 Aspects of IUI care regarding the doctor’s attitude and coordination 
of care emerged as the highest priorities for improvement. Interestingly, patients with 
fertility problems ranked the doctor’s attitude most highly in terms of importance in a 
survey conducted by Souter and colleagues.3 Obviously, the need to improve care aspects 
that are highly valued by patients is greater than care aspects that patients consider less 
important.27 Activities to improve the quality of IUI care should therefore be primarily 
directed at care aspects relating to the doctor’s attitude. For example, doctors could bring 
about improvements by making an effort to consistently discuss organizations that provide 
emotional support with each subfertile couple seeking IUI treatment, as 41% of the couples 
had been inadequately informed about this matter.
Another important finding was that subfertile couples’ experiences with organizational 
aspects of IUI care were clustered into two dimensions by means of factor analysis: 
coordination of care and waiting times. This seems to suggest that subfertile couples see 
coordination of care and waiting times as two distinct concepts. Perhaps this is attributable 
to differences in how important subfertile couples consider both concepts in relation to 
quality of care. According to Souter and colleagues, most patients with fertility problems 
give a lower priority to waiting times than to other aspects of care.3 Likewise, a literature 
review of patients’ priorities regarding general practice care showed that care aspects 
regarding waiting times were far less important to patients than other care aspects.28 Even 
though many quality improvement activities tend to focus on waiting times, this does not 
reflect subfertile couples’ priorities.
Among several patient and hospital characteristics that significantly predicted subfertile 
couples’ negative experiences with IUI care, no ongoing pregnancy and high education level 
were identified as the main predictors. These results are in line with previous research on 
patient satisfaction with subfertility care where no treatment-related pregnancy or delivery 
and high education level have been cited as determinants of dissatisfaction.1,2,16,18 The 
evidence presented here suggests that important predictors such as ongoing pregnancy and 
education level should be taken into account in the interpretation of subfertile couples’ 
experiences with IUI care.
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Several hypotheses can be developed to explain the determinants of subfertile couples’ 
negative experiences with IUI care. For example, why is a high education level predictive 
of negative experiences with IUI care? It is possible that highly educated subfertile 
couples are more assertive consumers of infertility services.1 Subfertile couples with an 
assertive consumerist position in IUI treatment could be better informed and have higher 
expectations of infertility services, and they may be less reluctant to give critiques.2,8 
Regardless of explanations, findings about predictors of negative experiences with IUI care 
can be regarded as an incentive to further customize practice performance in IUI care in 
order to meet the needs of certain subgroups of subfertile couples more effectively. Thus, 
for instance, subfertile couples who undergo IUI treatment but are still unsuccessful in 
achieving an ongoing pregnancy require extra information and explanation. Similarly, 
subfertile couples who receive both unstimulated and stimulated IUI treatment particularly 
need improvements in the coordination of care and waiting times.
Whereas the amount of variance explained in the final regression model was rather small, 
there may be more relevant background factors that affect subfertile couples’ experiences 
with IUI care than those explored in this study, for example psychosocial factors.2,16,17 Clearly, 
additional research into other determinants of subfertile couples’ experiences with IUI care 
is imperative.
In conclusion, our study shows that many subfertile couples have had negative experiences 
with IUI care. Several aspects of IUI care are in serious need of improvement, particularly 
care aspects regarding the doctor’s attitude and coordination of care. These findings are a 
strong incentive for developing tailored interventions that address the reported deficits in 
IUI care in order to meet subfertile couples’ needs better.
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Patient and hospital characteristics associated with variation in guideline adherence in IUI care
Abstract
Objective: To assess the association of patient and hospital characteristics with adherence 
to guideline for intrauterine insemination (IUI) care.
Design: Retrospective cohort study using, multilevel regression analysis. Characteristics 
studied at the patient level were female age, type and duration of subfertility, diagnosis 
and number of started IUI cycles. At hospital level, the characteristics studied were hospital 
size, teaching hospital, in vitro fertilisation (IVF) licence and number of physicians involved 
in the IUI programme. Data were obtained from medical records and questionnaires for 
gynaecologists.
Setting and participants: Five hundred and fifty-eight subfertile couples who underwent IUI 
treatment at 10 Dutch hospitals. 
Main outcome measures: Adherence to systematically developed guideline-based 
performance indicators describing 20 processes of IUI care. 
Results: A total of 558 couples who started 2334 IUI cycles participated. Guideline adherence 
in IUI care was often substandard and varied considerably between hospitals. Variation in 
guideline adherence in IUI care was associated with the patient characteristics ’diagnosis’ 
and ‘female age’. Only adherence to the guideline recommendation regarding ‘screening 
for tubal occlusion’ was associated with hospital characteristics (‘hospital size’ and ‘IVF 
licence’). Large explained variances up to 39% were found for the different models.
Conclusions: A number of patient and hospital characteristics were associated with variation 
in guideline adherence in IUI care, particularly the patient characteristics ‘diagnosis’ and 
‘female age’. The identification of different subgroups in the patient population and diffent 
types of hospitals with regard to the extent of guideline adherence in IUI care is important 
for the tailoring of interventions to improve IUI care.
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Introduction
Subfertility is a major health problem, affecting millions of couples around the world.1 
Intrauterine insemination (IUI) is a widely used fertility treatment for male factor fertility 
problems, unexplained fertility problems and subfertility caused by cervical mucus hostility 
(poor-quality or insufficient mucus of the cervical canal of the uterus) or minimal to mild 
endometriosis. It involves insemination of prepared sperm directly into the uterus at the 
expected time of ovulation. The rationale of the procedure is to bring selected motile 
spermatozoa closer to the released oocyt.
IUI can be done in natural cycles, called unstimulated IUI, or after ovarian stimulation with 
fertility drugs to increase the number of available oocytes and further enhance the probability 
of conception, called stimulated IUI. Whether or not IUI should be combined with ovarian 
stimulation is often debated, particularly in terms of clinical effectiveness, safety and cost-
effectiveness. The main concern about IUI with ovarian stimulation is the increase in multiple 
pregnancies, which, in turn, increases maternal and perinatal morbidity and mortality.2
Wide disparities exist with regard to access to fertility treatment,3 though in most countries, 
IUI care is quite accessible. In the Netherlands, for instance, IUI care is delivered at 91 of the 
101 public hospitals, including eight university hospitals, 35 non-university teaching hospitals 
and 48 non-teaching hospitals, and provisions have been made within the national health 
policy to cover IUI care.4
As IUI treatment is associated with health risks and high costs, IUI should be used carefully and 
only for conditions where it has been proven useful for.5,6 To assist health care professionals 
in decision making about IUI, clinical practice guidelines for IUI care in which the best 
scientific evidence is summarized, combined with clinical experience, have been developed 
in European countries such as Denmark, England and Wales, France and the Netherland.7
However, usually, large gaps exist between the best scientific evidence described in 
guidelines and daily practice.8 In general, about 30-40% of patients do not receive care 
according to present scientific evidence and about 20-25% of the care provided is not 
needed or potentially harmful.9 To decrease inappropriate practice variation and improve 
the quality of care, measurement of actual practice performance is a key step.10 This requires 
performance indicators, which are defined as measurable elements of practice performance 
for which there is evidence or consensus that they can be used to assess the quality of care 
provided.11 In a prior study, a set of 25 guideline-based performance indicators for IUI care 
was systematically developed and used to assess the extent to which practice performance 
in IUI care is consistent with guideline recommendations.12 The overall poor guideline 
adherence in IUI care and large variability between different hospitals was striking.12
Patient and hospital characteristics associated with variation in guideline adherence in IUI care
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Previous research in other fields of medicine showed that a variety of factors at patient and 
hospital level can explain poor guideline adherence and inappropriate practice variation.13-17 
For IUI care, evidence is scarce about the influence of such factors. However, our hypothesis 
is that variation in guideline adherence in IUI care may also result from differences in patient 
or hospital characteristics. To test this hypothesis, this study assessed whether or not patient 
and hospital characteristics are associated with variation in guideline adherence in IUI care. 
Knowledge about the influence of such factors is important for the tailoring of interventions 
to improve IUI care.
Methods
Study design and population
The extent of variation in guideline adherence in IUI care was assessed in a previously 
performed retrospective cohort study at 10 of the 91 Dutch hospitals providing IUI care.12 
The 10 study hospitals were selected to represent a variety of settings and included one large 
university hospital providing tertiary care and nine public hospitals providing secondary 
care, including four intermediate-sized, non-university teaching hospitals, two intermediate-
sized, non-teaching hospitals, and three smaller, non-teaching hospitals. Patients eligible to 
participate in this study were defined as subfertile couples who underwent IUI treatment 
at these 10 hospitals during an inclusion period of 28 months. Subfertile couples who 
had undergone ovulation induction therapy for ovulatory disorders or IUI treatment with 
donated spermatozoa were not eligible to participate. Once the relevant institutional review 
boards gave their approval, the databases of the fertility laboratories of the participating 
hospitals were used to make a list of potentially eligible couples per hospital. As registration 
of IUI treatment is not obligatory in the Netherlands, identification of couples who had 
undergone homologous IUI was compromised in some of the participating hospitals. In 
hospitals with unsatisfactory registration of IUI, all couples listed in the database of the 
fertility laboratory were added to the list of potentially eligible couples. This means that this 
list was not restricted to couples who had undergone homologous IUI, but may also have 
included couples who had undergone ovulation induction therapy for ovulatory disorders 
or IUI treatment with donated spermatozoa. From each list, a random sample of couples 
in proportion to the size of the hospital’s IUI programme (50-150 couples per hospital) was 
selected by computer for participation in the study. The total sample consisted of 1100 
subfertile couples. Each couple was requested in an informative letter to sign and return a 
consent form to grant access to their medical record. Non-respondents received a reminder 
after 4 weeks.
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Data collection
Performance indicators for IUI care
The extent of variation in guideline adherence in IUI care was previously assessed with a 
systematically developed set of 25 guideline-based performance indicators for IUI care.12 
Of these, 20 indicators referred to a range of process aspects of IUI care. Data about these 
process aspects and clinical outcomes of IUI care were abstracted from medical records by 
two trained research assistants using standardized audit forms.
Patient and hospital characteristics
Patient and hospital characteristics were selected because of their potential association 
with guideline adherence in IUI care, which was hypothesized on the basis of prior research 
findings.13-18
Five patient characteristics were selected: female age (years), type of subfertility (primary 
or secondary), duration of subfertility (months), diagnosis (male factor fertility problems, 
unexplained fertility problems or cervical mucus hostility), and number of started IUI cycles 
(≤6 or >6 cycles). These five patient characteristics were reported by physicians in a prior 
study on barriers to adherence to an IUI guideline as specific characteristics that affect IUI 
guideline adherence.18 In other health care settings, age and diagnosis were often associated 
with guideline adherence.13-17 Data about these patient characteristics were abstracted from 
the medical records.
Four hospital characteristics were selected: hospital size (large or intermediate/small), 
teaching hospital (teaching or non-teaching), in vitro fertilisation (IVF) license (that is, 
legal permission to perform IVF, or no license), and number of physicians involved in the 
IUI programme (> 10 or ≤ 10). These four hospital characteristics were derived from the 
previous study on barriers to adherence to an IUI guideline in which hospital size, teaching 
hospital, facilities and number of staff were identified as specific characteristics that 
influence IUI guideline adherence.18 Data about these hospital characteristics were publicly 
available and confirmed by one gynaecologist in each participating hospital by means of a 
short questionnaire.
Patient and hospital characteristics associated with variation in guideline adherence in IUI care
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Statistical analysis
Descriptive analyses (frequencies and means) were performed to describe patient and 
hospital characteristics. Multilevel regression analysis according to Leyland19 was used to 
assess the extent to which variation in guideline adherence in IUI care, measured with 
performance indicators (dependent variables), was explained by patient and hospital 
characteristics (independent variables). The reason for using this analysis was the intrinsically 
hierarchical nature as IUI cycles (level 1) were nested in the sample of subfertile couples 
(level 2), who were nested in hospitals (level 3).
To increase the number of couples eligible for an indicator and reduce the number of 
dependent variables, the 20 process indicators were aggregated into the following nine 
categories: screening for tubal occlusion (n = 1), sperm quality (n = 1), indications for IUI
(n = 3), total number of IUI cycles (n = 2), monitoring in IUI (n = 3), timing in IUI (n = 2), 
dose of gonadotrophins in stimulated IUI (n = 3), timing and dose of human chorionic 
gonadotrophin (hCG) in stimulated IUI (n = 3), and cancellation criteria in stimulated IUI 
(n = 2) (Appendix 1).
Prior to multilevel regression analysis, correlation analysis was performed to evaluate 
collinearity between all possible characteristics (independent variables). Variables with 
high correlation coefficients (> 0.4) were excluded from multilevel regression analysis. The 
indicator ‘cancellation criteria in stimulated IUI’ was also excluded from multilevel regression 
analysis, because of the small number of eligible subfertile couples.
In multilevel regression analysis, P < 0.05 was considered statistically significant. To assess 
the extent to which variation in guideline adherence could be explained by patient and 
hospital characteristics in the multilevel model (fit of the models), the explained variance 
per model was calculated. Analyses were performed using SAS software (SAS 12.0 for 
Windows; SAS Institute, Cary, North Carolina, USA).
6111
Chapter 6
Process indicator
Screening for tubal occlusion
Before starting IUI, screening for tubal occlusion should be performed
Sperm quality
More than one million motile sperm should be available for IUI after sperm preparation
Indications for IUI
Couples with male factor fertility problems should be offered unstimulated IUI
Couples with unexplained fertility problems should be offered stimulated IUI
Couples with cervical mucus hostility should be offered unstimulated IUI
Total number of IUI cycles
Couples with male factor fertility problems should be offered up to six IUI cycles
Couples with unexplained fertility problems should be offered up to six IUI cycles
Monitoring in IUI
Patients undergoing stimulated IUI should be monitored by transvaginal ultrasonography
Patients undergoing unstimulated IUI should be monitored by LH measurements
LH measurements should be performed twice daily
Timing in IUI
IUI should be performed 38-42 hours after administration of hCG
IUI should be performed 20-30 hours after detection of spontaneous LH surge
Dose of gonadotrophins in stimulated IUI
The dose of gonadotrophins in the first cycle of stimulated IUI should be 75 IU per day
The dose of gonadotrophins should be adapted if ovarian stimulation does not result in two or three 
follicles larger than 16 mm
If the dose of gonadotrophins is raised to achieve multifollicular growth, this should be done with 37.5 
IU per day per cycle
Patient and hospital characteristics associated with variation in guideline adherence in IUI care
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Results
Study population
The recruitment of eligible subfertile couples for participation in the study is presented in 
Figure 1. A total of 956 out of 1079 (89%) subfertile couples responded. While 191 of these 
couples refused to participate or considered themselves ineligible, 765 (71%) subfertile 
couples were willing to participate and returned a signed consent form to grant access to 
their medical record. Of these couples, 207 were excluded, mostly because study of their 
medical records revealed that they had undergone ovulation induction therapy for ovulatory 
disorders or IUI treatment with donated spermatozoa (n = 184) or there was no access to 
their medical records (n = 23). Accordingly, 558 subfertile couples who started a total of 
2334 IUI cycles were eligible for study.
Patient and hospital characteristics
Patient characteristics are shown in Table 1. Hospital characteristics are presented in Table 2. 
The patient characteristics female age, type of subfertility (primary or secondary), duration 
of subfertility and diagnosis (male factor fertility problems, unexplained fertility problems 
or cervical mucus hostility) did not differ significantly between hospitals. One hundred 
thirty-one couples achieved an ongoing pregnancy after IUI treatment, giving an ongoing 
pregnancy rate per couple of 23% (range across 10 hospitals, 13-41%). Among the 131 IUI-
related ongoing pregnancies were 13 multiples (9.9%; range across 10 hospitals, 0-29%), 
including 12 twins and one triplet.
Timing of hCG administration in stimulated IUI
Patients undergoing stimulated IUI with gonadotrophins should be administrated hCG when dominant 
follicular diameter reaches 18 mm
Patients undergoing stimulated IUI with oral anti-oestrogens should be administrated hCG when 
dominant follicle diameter reaches 20 mm
hCG should be administered at a dose of 5000 IU
Cancellation criteria in stimulated IUI
An IUI cycle should be cancelled if ovarian ultrasound reveals five or more follicles > 12 mm or three or 
more follicles > 16 mm
Advice to withhold from unprotected sexual intercourse should be given if ovarian ultrasound reveals 
five or more follicles > 12 mm or three or more follicles > 16 mm
hCG, human chorionic gonadotrophin. IUI, intrauterine insemination. Stimulated IUI, IUI after ovarian stimulation using 
gonadotrophins or oral anti-oestrogens. Unstimulated IUI, IUI in natural cycles. LH, luteinizing hormone.
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Variation in guideline adherence in IUI care
The extent of variation in guideline adherence in IUI care, measured with nine aggregated 
indicators, is summarized in Table 3. Guideline adherence in IUI care was often substandard 
and differed considerably between the 10 participating hospitals.
Patient and hospital characteristics and variation in guideline adherence in IUI care
The associations between different patient and hospital characteristics and guideline 
adherence in IUI care are shown in Table 4.
In this study of 558 patients in 10 Dutch hospitals, the main patient characteristic 
associated with guideline adherence in IUI care was ‘diagnosis’. This characteristic was 
associated with guideline adherence in five out of nine possible associations investigated. 
Patient and hospital characteristics associated with variation in guideline adherence in IUI care
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Overall, couples with male factor or unexplained fertility problems were significantly less 
often treated according to guideline recommendations than couples with cervical mucus 
hostility. Likewise, ‘female age’ was associated with guideline adherence in two out of nine 
possible associations investigated. In particular, younger women were more often treated 
according to guideline recommendations regarding ‘indications for IUI’ and ‘monitoring in 
IUI’ than older women.
In this study of 10 Dutch hospitals, the hospital characteristics ‘hospital size’ and ‘IVF 
license’ were associated with guideline adherence regarding ‘screening for tubal occlusion’. 
Smaller hospital size and no IVF license doubled the chance of adherence to this guideline 
recommendation. Adherence to other guideline recommendations was not influenced by 
hospital characteristics. Variation in guideline adherence regarding ‘screening for tubal 
occlusion’, ‘indications for IUI’ and ‘monitoring in IUI’ could be explained for a substantial 
part by the measured patient and hospital characteristics, with explained variances of 17%, 
39% and 15%, respectively.
Characteristic Value (range)
Median female age (years) 32 (23-46)
Type of subfertility (%) a
Primary 66
Secondary 34
Median duration of subfertility (months) b 26 (0.3-112)
Diagnosis (%)
Male factor fertility problems 42
Unexplained fertility problems 49
Cervical mucus hostility 9
Median number of started IUI cycles 3 (1-5)
Number of IUI-related ongoing pregnancies c
Singletons 118
Multiples 13
a Subfertility can be primary, in couples who have never conceived, or secondary, in couples who have conceived previously.
b Duration of subfertility was defined as the period between the start of regular unprotected sexual intercourse and the 
   first IUI cycle.
c Ongoing pregnancy was defined as a clinical pregnancy of more than 16 weeks’ gestation.
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Discussion
A number of patient and hospital characteristics were associated with the extensive 
variation in guideline adherence in IUI care, especially the patient characteristics ’diagnosis’ 
and ‘female age’. Guideline adherence regarding ‘screening for tubal occlusion’, ‘indications 
for IUI’ and ‘monitoring in IUI’ showed relatively large explained variances, mostly by patient 
characteristics, of 17, 39 and 15%, respectively.
Meaning of the study
Literature shows that, in general, patients often receive inappropriate care according to 
current scientific evidence and professional insight laid down in clinical practice guidelines.9 
This is also true for IUI care. Our results suggest that much of IUI care in Dutch hospitals is not 
consistent with guideline recommendations.12 Clearly, the consequences of inappropriate 
IUI care are considerable. Therefore, it is important to gain more insight into factors that 
determine that these guidelines are not adhered to in daily practice. The identification of 
Characteristic Value 
Hospital sizea
Large 1
Intermediate 6
Small 3
Teaching hospital
Teaching 5
Non-teaching 5
IVF licenseb
License 2
No license 8
Number of physicians involved in the IUI programme
Over 10 3
5-10 3
Under 5 4
a Hospital size was determined by the number of beds: large, at least 700 beds; intermediate, 500-700 beds; small, under 
   500 beds.
b IVF licence, legal permission to perform in vitro fertilisation.
Patient and hospital characteristics associated with variation in guideline adherence in IUI care
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Process indicator
No. of subfertile 
couples to 
whom indicator 
applies a
Perfor-
mance 
score b
(%)
Range 
across 10 
hospitals
(%)
Screening for tubal occlusion
Before starting IUI, screening for tubal occlusion 
should be performed
550 75 66-93
Sperm quality
More than one million motile sperm should be 
available for IUI after sperm preparation
550 74 0-88
Indications for IUI
Couples with male factor fertility problems should be 
offered unstimulated IUI 
OR Couples with unexplained fertility problems should 
be offered stimulated IUI
289 74 55-85
Total number of IUI cycles
Couples with male factor fertility problems 
OR unexplained fertility problems should be offered 
up to six IUI cycles
148 36 9-53
Monitoring in IUI
Patients undergoing stimulated IUI should be 
monitored by transvaginal ultrasonography 
OR Patients undergoing unstimulated IUI should be 
monitored by LH measurements
550 71 50-96
Timing in IUI
IUI should be performed 38-42 hours after 
administration of hCG
OR IUI should be performed 20-30 hours after 
detection of spontaneous LH surge
520 13 2-60
Dose of gonadotrophins in stimulated IUI
The dose of gonadotrophins in the first cycle of 
stimulated IUI should be 75 IU per day
AND The dose of gonadotrophins should be adapted 
if ovarian stimulation does not result in two or three 
follicles larger than 16 mm
352 6 0-14
Timing and dose of hCG in stimulated IUI
Patients undergoing stimulated IUI with 
gonadotrophins should be administered hCG when 
dominant follicular diameter reaches 18 mm
OR Patients undergoing stimulated IUI with oral 
anti-oestrogens should be administered hCG when 
dominant follicular diameter reaches 20 mm
AND hCG should be administered at a dose of 5000 IU
400 4 0-23
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different subgroups in the patient population and different types of hospitals with regard to 
the extent of guideline adherence in IUI care is important for the tailoring of interventions 
to improve IUI care. For example, in our study, patients with male factor and unexplained 
fertility problems were less often treated according to guideline recommendations than 
patients with cervical mucus hostility. This finding should be taken into account in the 
development of an intervention programme to improve guideline adherence in IUI care. 
In other words, special attention should be paid to the patients with male factor and 
unexplained fertility problems. Such interventions can be provider or patient directed, for 
instance, educational programmes for professionals or information leaflets for patients.
So far, none but a few studies searched for characteristics at different levels influencing 
practice performance in hospital care. Some examples are studies regarding patients who 
suffered from stroke, community acquired pneumonia and cancer.15-17 With regard to stroke 
patients, Schmidt found that ‘stroke type’, ‘accompanying diagnosis’ and ‘treatment in 
specialized units’ significantly increased the probability of guideline adherence.15 Schouten et 
al found that the ‘severity of illness’ and ‘location of first treatment’ were positive predictors 
of guideline adherence.16 ‘Medical history’ and ‘presence of a specialized committee for 
antibiotic therapy’ were negatively associated with guideline adherence.16 These kinds of 
results have also been reported for cancer patients. Ouwens et al, for instance, found that 
guideline adherence was mostly influenced by the patient characteristics ‘stage of disease’, 
‘age’ and ‘presence of comorbidity’.17 In the present study, comparable results were found 
as ‘diagnosis’ and ‘female age’ were important characteristics associated with guideline 
adherence in IUI care.
Cancellation criteria in stimulated IUI
An IUI cycle should be cancelled 
AND Advise to withhold from unprotected sexual 
intercourse should be given if ovarian ultrasound 
reveals five or more follicles > 12 mm or three or 
more follicles > 16 mm
30 53 0-100
hCG, human chorionic gonadotrophin. IUI, intrauterine insemination. Stimulated IUI, IUI after ovarian stimulation using 
gonadotrophins or oral anti-oestrogens. Unstimulated IUI, IUI in natural cycles. LH, luteinizing hormone.
a The maximum number of subfertile couples to whom a process indicator can apply is 550. From the total cohort of 558 
   couples, eight had to be excluded from analysis because their follow-up time was unknown.
b Each performance score was calculated in two steps: (1) the number of IUI cycles of a couple in which practice 
   performance was consistent with a guideline recommendation was divided by the total number of IUI cycles of the 
   couple to which the recommendation applied and (2) the proportions of individual subfertile couples were added 
   together and divided by the number of subfertile couples to whom the guideline recommendation applied.
Patient and hospital characteristics associated with variation in guideline adherence in IUI care
118
Characteristics associated with guideline adherence per 
process indicator OR (95% CI) 
a P value R2 b
Screening for tubal occlusion
Longer duration of subfertility 1.02 (1.00 – 1.04) 0.037
0.17
Intermediate/small hospital size 1.96 (1.19 – 3.23) 0.008
IVF license c 0.56 (0.34 – 0.93) 0.024
Diagnosis:  male factor fertility problems vs. cervical mucus 
hostility
0.28 (0.17 – 0.47) < .0001
unexplained fertility problems vs. cervical mucus 
hostility
0.29 (0.13 – 0.64) 0.002
Sperm quality
Not more than six IUI cycles 1.52 (1.05 – 2.17) 0.026
0.03
Diagnosis:  male factor fertility problems vs. cervical mucus 
hostility
0.45 (0.34 – 0.61) < .0001
unexplained fertility problems vs. cervical mucus 
hostility
0.80 (0.48 – 1.36) 0.413
Indications for IUI
Younger female age 1.10 (1.01 – 1.20) 0.024
0.39
Diagnosis:  male factor fertility problems vs. cervical mucus 
hostility
0.05 (0.02 – 0.11) < .0001
unexplained fertility problems vs. cervical mucus 
hostility
0.05 (0.02 – 0.11) < .0001
Total number of IUI cycles
No associated characteristics - - -
Monitoring in IUI
Younger female age 1.06 (1.01 – 1.14) 0.041
0.15
Diagnosis:  male factor fertility problems vs. cervical mucus 
hostility
0.20 (0.12 – 0.34) < .0001
unexplained fertility problems vs. cervical mucus 
hostility
0.13 (0.06 – 0.28) < .0001
Timing in IUI
No associated characteristics - - -
Dose of gonadotrophins in stimulated IUI
Primary subfertility 1.46 (1.03 – 2.09) 0.035 0.01
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In subfertility care, ‘diagnosis’ and ‘female age’ are also known to influence the outcome 
‘ongoing pregnancy after fertility treatment’. Pregnancy rates vary by type of diagnosis and 
decline with increasing female age.20-22 It is possible that physicians, with the likelihood 
of a pregnancy in mind, deliberately decide to treat patients with particular diagnoses or 
of certain ages not according to guidelines. For example, physicians may decide to treat 
older couples with male factor fertility problems in an early stage with stimulated instead 
of unstimulated IUI, despite the increased risks of ovarian hyperstimulation syndrome and 
multiple pregnancy, because of the supposed increased pregnancy rates of stimulated IUI.
This is in line with the results of a previous study, in which professional barriers to adherence to 
an IUI guideline were identified.18 Although the majority of physicians mentioned agreement 
with the IUI guideline, disagreement with certain aspects of the guideline was also reported. 
One out of five physicians reported limitations with regard to their flexibility in considering 
patients’ requests and making personal considerations. Moreover, one out of six mentioned 
that the IUI guideline does not consider characteristics of individual patients adequately. 
Knowledge about patient and hospital characteristics associated with guideline adherence 
as well as barriers to guideline adherence should guide the development of tailored 
interventions to improve IUI care, such as adjustment of IUI guideline recommendations.
Timing and dose of hCG in stimulated IUI
Diagnosis:  male factor fertility problems vs. cervical mucus 
                    hostility
0.48 (0.31 – 0.76) 0.002
0.01
unexplained fertility problems vs. cervical mucus 
hostility
1.56 (0.80 – 3.01) 0.191
Cancellation criteria in stimulated IUI
No associated characteristics - - -
hCG, human chorionic gonadotrophin. IUI, intrauterine insemination. Stimulated IUI, IUI after ovarian stimulation using 
gonadotrophins or oral anti-oestrogens. Unstimulated IUI, IUI in natural cycles. LH, luteinizing hormone.
a OR > 1 means a positive association with the process indicator; OR < 1 means a negative association with the process 
   indicator.
b Explained variance for final regression model.
c IVF licence, legal permission to perform in vitro fertilisation
Patient and hospital characteristics associated with variation in guideline adherence in IUI care
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Another explanation for differences in guideline adherence with different diagnoses may 
be that the couples diagnosed with cervical mucus hostility are a rather uniform group 
with a straightforward diagnostic and treatment pathway, while couples diagnosed with 
male factor or unexplained fertility problems are more heterogeneous groups with wide-
ranging diagnostic paths and treatment possibilities. Furthermore, international consensus 
regarding the best care for couples with male factor or unexplained fertility problems has 
not yet been reached. For instance, there is a lively international discussion about the 
effectiveness of stimulated and unstimulated IUI in these couples.23
In this study, only two hospital characteristics were associated with guideline adherence in 
one of the nine possible associations investigated. ‘Larger hospital size’ and ‘IVF license’ were 
associated with suboptimal guideline adherence regarding ‘screening for tubal occlusion’. 
This finding may initially seem surprising, but a plausible explanation could be that small, 
non-IVF-licensed hospitals have to account to larger, IVF-licensed hospitals when couples 
are referred for tertiary care. So, smaller, non-IVF-licensed hospitals have an extra drive to 
treat their patients according to IUI guideline recommendations.
Strengths and limitations of the study
A strong point of the study is the rigorous assessment of variation in guideline adherence 
in IUI care, using a systematically developed set of valid guideline-based performance 
indicators for IUI care. The large sample of 558 subfertile couples from 10 different hospitals 
who started a total of 2334 IUI cycles contributes to the validity of the research results. 
Another strength of the study is that potential characteristics associated with variation in 
IUI care were analysed at different levels in one model using multilevel regression analysis.
However, the study also has its limitations. First, the influence of selection bias remains 
uncertain. Twenty-five per cent of the selected couples refused to participate in the study. 
More than half of these couples reported the reason for refusal to participate, which was 
mainly a lack of time or interest.
Second, the limited number of patient and hospital characteristics analysed could be 
considered a limitation of the study. The nine selected characteristics were derived from a 
previous study on barriers to adherence to an IUI guideline in which specific characteristics 
that influence IUI guideline adherence were identified as well as research findings from other 
fields of medicine. Clearly, other patient and hospital characteristics could be investigated 
and considered in future research.
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Third, another level which could explain variation in guideline adherence in IUI care is the 
level of the professional. Unfortunately, this level could not be taken into account in this 
study as most subfertile couples were treated by a team, as opposed to an individual care 
provider. It was therefore not possible to relate one professional to one couple.
Fourth, only two hospital characteristics determined the extent of guideline adherence in just 
one out of the nine possible associations investigated. For some characteristics at hospital 
level, variation between the different hospitals was too small to assess their influence on 
practice performance, perhaps as a result of the limited sample size of 10 hospitals. To gain 
more insight into potential relevant hospital characteristics, more than 10 hospitals would 
need to participate in future studies. Another possibility is to study hospital characteristics 
which are strongly related to the process of care, such as the presence of a fertility nurse.24
In conclusion, this study identified a number of patient and hospital characteristics that 
were associated with variation in guideline adherence in IUI care, in particular the patient 
characteristics ’diagnosis’ and ‘female age’. The identification of different subgroups in the 
patient population and different types of hospitals with regard to the extent of guideline 
adherence in IUI care is important for the tailoring of interventions to improve IUI care. 
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Abstract
Background: Guidelines aim to improve clinical practice, but are not self-implementing. 
Insight in barriers to physician guideline adherence is crucial for development of effective 
implementation strategies. The study aim was to identify barriers to physician adherence 
to an intrauterine insemination (IUI) guideline of the Dutch Society of Obstetrics and 
Gynaecology.
Methods: We conducted a cross-sectional survey among all Dutch gynaecologists, 
residents and fertility physicians (n = 860), using written questionnaires that were based 
on information obtained in focus group discussions. We investigated barriers related to 
physicians’ knowledge and attitudes, and external barriers.
Results: The response rate was 65%. We used 344 questionnaires for analysis. Physicians’ 
knowledge was adequate with a median unfamiliarity rate with each of the 31 key guideline 
recommendations of 12%. Physicians’ attitudes were generally positive, especially regarding 
guideline development and quality. Important attitude-related barriers included physicians’ 
lack of self-efficacy regarding physician-patient communication and poor outcome 
expectancy. External barriers were mostly related to specific patient characteristics and 
associated with higher age of physicians and less consultations for fertility problems per 
week.
Conclusions: Multiple barriers impede physician adherence to subfertility guidelines, mainly 
physicians’ lack of self-efficacy and low outcome expectancy. Both physicians and patients 
play an important role in future implementation interventions to optimize subfertility care.
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Introduction
In the field of reproductive medicine, the advanced diagnostic and treatment techniques 
are associated with a high physical and psychosocial impact on patients, risks of various 
complications, such as ovarian hyperstimulation syndrome and multiple pregnancies, 
ethical dilemmas and high costs.1,2 Subfertility guidelines, such as the fertility guideline of 
the National Institute for Clinical Excellence (NICE), aim to assist physicians and patients 
in the decision-making process regarding appropriate, safe and cost-effective care and to 
improve the quality of subfertility care.3,4
However, guidelines are not self-implementing.5 Guideline implementation may be best 
described as ‘a stepwise and planned introduction of a guideline, aiming to integrate its 
recommendations profoundly into the daily performance of health care professionals’.6 
Studies suggest that, besides publication and dissemination of guidelines, more intensive 
intervention strategies are necessary to promote guideline implementation and alter health 
care delivery.7-9 It is increasingly recognized that these intervention strategies should be 
based upon assessment of potential barriers to guideline adoption.5,10,11
A wide range of factors has been identified as possible barriers to the implementation of 
guidelines. A review showed that many investigators have focused on characteristics of 
individual physicians to explain failure of guideline implementation.12 Cabana and colleagues 
reviewed 76 studies on barriers to physician guideline adherence and identified seven 
general types of barriers.13 They developed a framework in which these barriers are classified 
into three main categories: barriers related to physicians’ knowledge (lack of awareness and 
lack of familiarity), barriers that affect physicians’ attitudes (lack of agreement, lack of self-
efficacy, lack of outcome expectancy and lack of motivation) and external barriers (patient-, 
guideline- and environment-related factors).
Since most subfertility guidelines have only been disseminated and have not been 
systematically implemented yet, physician adherence to subfertility guidelines is probably 
not ideal. However, little is known about the extent of physician adherence to subfertility 
guidelines and the potential barriers involved. For instance, we still lack this information for 
the nine subfertility guidelines produced as part of the guideline programme of the Dutch 
Society of Obstetrics and Gynaecology (NVOG). The NVOG has issued 55 clinical practice 
guidelines since 1996, using a systematic approach to prepare evidence-based guidelines 
of high quality. The Appraisal of Guidelines for Research and Evaluation (AGREE) instrument 
is used to support this developmental process.14 NVOG guidelines are disseminated among 
NVOG members by mail and internet (www.nvog.nl).
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In this study, we focused on the NVOG guideline regarding intrauterine insemination (IUI). 
This guideline includes 31 key recommendations about indications, management and 
organizational aspects of IUI care (Table 1). The main issues addressed in the IUI guideline 
are also within the scope of other subfertility guidelines, such as the NICE guideline. We 
aimed to identify barriers to physician adherence to this subfertility guideline and to classify 
the identified barriers according to the framework of Cabana and colleagues.13 Additionally, 
we explored characteristics of physicians and practice settings associated with barriers to 
adherence to this subfertility guideline.
Recommendation topics No. recommendations a Examples of recommendations
Conditions to start IUI 3
Before starting IUI, screening for tubal occlusion 
should be performed
Indications for IUI 5
Couples with severe male factor fertility problems 
should be offered unstimulated IUI
Total number of IUI 
cycles
2
Couples with unexplained fertility problems should 
be offered up to 6 IUI cycles
Monitoring in IUI 3
Patients undergoing stimulated IUI should be 
monitored with transvaginal ultrasonography
Timing in IUI 4
IUI should be performed 38-42 hours after 
administration of hCG
Medical management in 
stimulated IUI
6 hCG should be administered in a dosage of 5000 IE
Cancellation criteria in 
stimulated IUI
4
An IUI cycle should be cancelled if ovarian 
ultrasound reveals > 3 follicles > 16 mm
Practice facilities for IUI 4 IUI treatment results should be evaluated yearly
a Number of recommendations per topic.
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Materials and methods
Study design and population
We conducted a cross-sectional survey using written questionnaires among all 860 
physicians working in the field of obstetrics and gynaecology in the Netherlands, including 
698 gynaecologists, 82 residents and 80 fertility physicians (medical doctors specialized in 
assisted reproduction). Databases of the NVOG and the Dutch Society of Fertility Physicians 
(VVF) were used to obtain the contact details of the study population.
After the development and pilot testing of the questionnaire, we sent this questionnaire 
with an accompanying informative letter and a return envelope to all selected physicians. 
Two weeks after the initial mailing, we sent a reminder card to non-respondents requesting 
them to complete and return the questionnaire. Subjects received a second copy of the 
questionnaire if they did not return the first questionnaire within 4 weeks. 
Questionnaire development
A systematic review of literature revealed that little is known about barriers to physician 
adherence to subfertility guidelines. Therefore, we used qualitative research methods in 
the developmental process of the questionnaire to obtain information about potential 
barriers to physician adherence to the IUI guideline. We performed two semi-structured 
focus group discussions, one with 13 residents and fertility physicians and one with 11 
gynaecologists. These physicians were all commonly participating in IUI programmes. We 
selected participants of different age, sex, length of time in practice and practice setting in 
the south-east of the Netherlands. An independent gynaecologist used a topic guide with 
open-ended questions to moderate the focus group discussions. Questions were based on 
the barrier classification system described by Cabana and colleagues.13 Barriers to physician 
guideline adherence were discussed with regard to the 31 key recommendations of the IUI 
guideline. Each focus group discussion lasted for approximately 2.5 hours. Sessions were 
tape-recorded and fully transcribed. Two researchers (EH, WN) conducted independently 
a content analysis. Potential barriers to physician adherence to the IUI guideline were 
identified and classified into the three previously mentioned domains of the framework of 
Cabana and colleagues.13 Differences in interpretations were minimal and consensus was 
promptly achieved. For the development of our questionnaire, data from the focus group 
discussions were combined with an existing validated questionnaire designed to identify 
barriers to physician adherence to clinical practice guidelines.15
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Questionnaire content
The 19-page questionnaire consisted of 95 questions. To evaluate physicians’ 
knowledge, respondents were questioned about their familiarity with each of the 31 key 
recommendations of the IUI guideline by closed questions (yes/no). To assess physicians’ 
attitudes, we asked participants to respond to statements about agreement with each 
of the 31 key recommendations of the IUI guideline, agreement with the IUI guideline, 
self-efficacy (confidence in the ability to perform a behaviour), outcome expectancy 
and motivation to follow guideline recommendations. To identify external barriers, we 
questioned physicians about their opinions regarding patient-, guideline- and environment-
related factors affecting their behaviour to adhere to guideline recommendations. Opinions 
regarding attitude-related and external barriers were scored on a five-point Likert-scale 
(1 = strongly agree; 5 = strongly disagree). Suggestions for additional guideline 
recommendations and the prevalence of demographic characteristics were identified with 
closed questions with several answer possibilities.
Analysis
We entered data from collected questionnaires into a database. Data were cleaned and 
analyzed with the Statistical Program for the Social Sciences (SPSS 11.0 for Windows, SPSS 
Inc., Chicago, Illinois, USA). Frequencies were calculated to describe the main barriers to 
physician adherence to the IUI guideline.
We aimed to assess the independent effects of different determinants on barriers to 
physician guideline adherence, which were characteristics of physicians and practice 
settings, such as age, sex, education, specialty (gynaecologist, resident or fertility physician), 
type of gynaecologist (gynaecologist specialized or not in the field of subfertility care), 
average number of consultations for fertility problems per week, teaching hospital and IVF 
facilities, using multivariate linear regression analysis. First, we performed a factor analysis 
to cluster the different attitude-related and external barriers in order to reduce the number 
of dependent variables. Attitude-related barriers regarding agreement with each of the 31 
key recommendations of the IUI guideline were clustered into six factors: indications (two 
factors), medication, cancellation criteria, timing using LH measurements and organizational 
aspects. Other attitude-related barriers (listed in Table 2) were aggregated into three factors: 
agreement with the IUI guideline and outcome expectancy, self-efficacy and motivation. 
External barriers (presented in Table 3) were also clustered into three factors: patient-
related external barriers (two factors) and guideline-related and environment-related 
external barriers. Subsequently, we calculated sum scores for all 12 factors of the factor 
analysis to obtain continuous dependent variables. Finally, Spearman’s correlation analysis 
was carried out to evaluate collinearity between determinants. 
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All physician and practice setting characteristics mentioned above were selected for 
multivariate linear regression analysis with backward elimination procedures, except 
education and type of gynaecologist owing to high correlation with specialty. Statistical 
significance was set at P < 0.05.
Statements Agree (%) a
Agreement with the IUI guideline
Working according to IUI guideline requires financial compensation 57
IUI guideline limits flexibility to consider patients’ requests 19
IUI guideline could be abused easily in medical disciplinary law 18
IUI guideline does not consider characteristics of individual patients adequately 14
IUI guideline limits flexibility to make my own considerations 12
IUI guideline conflicts with current clinical practice norms and values 9
IUI guideline is not valuable for self education 5
IUI guideline does not contribute to uniformity in IUI care 3
IUI guideline is not based on sufficient evidence 3
IUI guideline is confusing and difficult to understand 2
IUI guideline is not developed rigorously 0.3
Self-efficacy
Convincing patients about low success rates of IUI treatment is difficult 24
Convincing patients about risks of multiple pregnancies is difficult 20
Denying patients’ requests is difficult 18
Outcome expectancy
Desired outcomes of working according to IUI guideline are not expected on short term 29
Motivation
Working according to IUI guideline is time-consuming 11
Changing my well-established routines is difficult 9
My willingness to take risks in IUI treatment is greater than of colleagues 7
My working method and IUI guideline do not match well 4
My religious background complicates IUI guideline adherence 3
Resistance to working according to guidelines in general 3
My lack of certain skills complicates IUI guideline adherence 2
a Physicians in agreement with a specific statement of all responding physicians.
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Statements Agree (%) a
Patient-related factors
Patients with elevated early follicular phase FSH levels complicate IUI guideline 
adherence
43
Patients > 35 years of age complicate IUI guideline adherence 33
Patients with unexplained subfertility complicate IUI guideline adherence 22
Patients undergoing their 5th or 6th IUI cycle complicate IUI guideline adherence 22
Patients with non-Dutch ethnic background complicate IUI guideline adherence 20
Patients < 25 years of age complicate IUI guideline adherence 18
Patients with secondary subfertility complicate IUI guideline adherence 13
Patients with low socioeconomic status complicate IUI guideline adherence 12
Guideline-related factors
IUI guideline is contradictory to other NVOG guidelines 3
Environmental-related factors
Cost price of urinary-based LH tests complicates IUI guideline adherence 29
Lack of facilities in practice setting complicates IUI guideline adherence 17
Inconvenient moment in time to deliver IUI care complicates IUI guideline adherence 15
Insufficient staff complicates IUI guideline adherence 13
Colleagues of the same profession complicate IUI guideline adherence 11
Other health care providers complicate IUI guideline adherence 10
FSH, Follicle stimulating hormone. LH, Luteinizing hormone.
a Physicians in agreement with a specific statement of all responding physicians.
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Results
Study population
Of the 860 distributed questionnaires, 11 were undeliverable. A total of 554 (65%) of the 
849 physicians completed and returned their questionnaire. Of these, we excluded 210 
physicians who reported that they never counseled subfertile couples about IUI and never 
performed IUI treatments. As a result, 344 questionnaires were available for analysis. Overall, 
257 (75%) of the 344 participating physicians were gynaecologists, 40 (12%) residents and 
47 (14%) fertility physicians. Among the gynaecologists, 85 (33%) specialized in the field 
of subfertility care. The demographic characteristics of the participating physicians are 
presented in Table 4.
Knowledge-related barriers
Physicians’ knowledge of the IUI guideline was adequate. Just 6% of the 344 physicians 
indicated that they lacked sufficient knowledge to perform according to the IUI guideline. 
Furthermore, the median level of unfamiliarity with each of the 31 key recommendations 
was 12% (range 2-49%). Only two guideline recommendations were exceptionally unfamiliar. 
Nearly half of the physicians (49%) were unaware that patients undergoing unstimulated 
IUI should be monitored using LH measurements twice daily. The other unfamiliar 
recommendation (41%) concerned the prescription of clomiphene citrate for controlled 
ovarian hyperstimulation in IUI treatment at a daily dose of 100 mg.
Characteristics
Median age (years) 44 (28-64)
Male/Female (%) 57/43
Median length of time in practice (years) 8 (< 1-31)
Median consultations for fertility problems per week 15 (< 1-150)
Median consultations for IUI treatments per week 4 (< 1-70)
Values in parentheses are ranges
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Attitude-related barriers
Physicians’ attitudes about the content of the IUI guideline were generally positive. The median 
level of disagreement with each of the 31 key recommendations was 7% (range 0-31%). We 
found that the two previously mentioned unfamiliar recommendations had high rates of 
disagreement among physicians: 31% mentioned lack of agreement with the recommendation 
to use LH measurements twice daily to monitor patients undergoing unstimulated IUI and 
26% disagreed with prescribing clomiphene citrate at a dose of 100 mg daily for controlled 
ovarian hyperstimulation in IUI treatment. Another key recommendation lacking agreement 
was related to the start of IUI treatment in couples with unexplained subfertility. Thirty-one 
per cent of the physicians disagreed with the guideline to start IUI treatment after 3 years of 
unexplained subfertility if female age is less than 36 years.
Statements of physicians about attitude-related barriers to IUI guideline adherence associated 
with agreement with the IUI guideline, self-efficacy, outcome expectancy and motivation to 
follow guideline recommendations are listed in Table 2. First, lack of agreement with the IUI 
guideline was limited. Just 0.3% of the 344 physicians felt that this subfertility guideline was 
not developed rigorously. No more than 3% reported that the IUI guideline is not sufficiently 
evidence-based. In addition, a minority (3%) indicated that the IUI guideline does not 
contribute to uniformity in IUI care.
However, disagreement with certain aspects of the IUI guideline was also reported. The 
majority of physicians (57%) mentioned disagreement in relation to lack of reimbursement 
and pointed out that working according to the IUI guideline requires financial compensation. 
Eighteen per cent of the physicians believed that this subfertility guideline could be abused 
easily in medical disciplinary law. Physicians also reported limitations with regard to their 
flexibility to consider patients’ requests (19%) and making personal considerations (12%). 
Moreover, 14% mentioned that the IUI guideline does not consider characteristics of 
individual patients adequately. Indeed, 86% of the physicians suggested at least one additional 
recommendation to the IUI guideline and most suggested recommendations were related to 
patients’ characteristics, for example, body mass index (60%), early follicular phase FSH levels 
(47%), female age (37%), successful IUI treatment in the past (22%) and endometriosis (18%).
Low self-efficacy could also affect guideline adherence. Several physicians described lack of 
confidence in their ability to convince patients about both low success rates (24%) and risks of 
multiple pregnancies in IUI treatment (20%). Furthermore, 18% of the physicians felt unable 
to deny patients’ requests.
We found poor outcome expectancy among 29% of the physicians. These physicians mentioned 
that working according to the IUI guideline will not lead to improved outcomes in the short 
term. 
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Although only a minority (3%) reported resistance to working according to guidelines in 
general, 11% of the physicians mentioned poor motivation to perform according to the 
IUI guideline, because this would be time-consuming. Additionally, 9% of the physicians 
indicated difficulty changing well-established routines as a motivation-related barrier to 
apply this subfertility guideline.
External barriers
External barriers may affect the ability of physicians to perform according to the IUI 
guideline (Table 3). Questioning physicians about patient-related external barriers revealed 
several specific characteristics of patients that complicate IUI guideline adherence, such 
as elevated early follicular phase FSH levels (43%), female age above 35 years (33%) and 
unexplained subfertility (22%). Important environment-related external barriers mentioned 
by physicians include the cost price of urinary-based LH tests (29%) and lack of facilities in 
the practice setting (17%).
Determinants of barriers to physician adherence to the IUI guideline
In multivariate linear regression analysis, several physician and practice setting characteristics 
were found to contribute independently to seven out of 12 factors of clustered attitude-
related and external barriers. However, for most determinants of these barriers the amount 
of variance explained in the final regression model was low. Determinants of barriers with 
more than 5% of the variance explained are presented in Table 5. Fewer consultations 
for fertility problems per week proved to be a determinant of attitude-related barriers 
regarding motivation. This determinant is also associated with patient-related external 
barriers. Furthermore, we observed that working in a non-teaching hospital is related to 
attitude-related barriers regarding motivation. Higher age of physicians is a determinant of 
patient-related external barriers.
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Discussion
This is the first study to identify barriers to physician adherence to a subfertility guideline 
and to explore determinants associated with these barriers. This survey revealed that a 
barrier with an important impact on adherence to subfertility guidelines is physicians’ 
lack of self-efficacy regarding communication with patients during the decision-making 
process about appropriate subfertility care. Physicians reported lack of confidence in their 
ability to convince patients about low success rates and risks of multiple pregnancies in IUI 
treatment and to deny patients’ requests. Physicians’ poor confidence in their convincing 
power may be attributable to inadequate knowledge of guideline recommendations, lack of 
communication skills or the persistence of external barriers.6,13,16
First, physicians may be unfamiliar with the specific content of a subfertility guideline.16 
A review of 31 surveys on physicians’ familiarity with guideline recommendations found a 
median unfamiliarity rate of 57%.13 However, in our study the median level of unfamiliarity 
was only 12%. Although this unfamiliarity rate is based on physician self-report, which might 
be inaccurate, others demonstrated that physicians’ self-reported familiarity adequately 
reflects actual familiarity with guideline recommendations.17 As a result, potential gaps 
in physicians’ knowledge about details of the IUI guideline are unlikely to contribute 
significantly to physicians’ lack of confidence in their convincing power.
Barriers Determinants B P R2 a Predictors of barriers
Attitude-related barriers 
regarding motivation
Number of consultations b -0.019 .024
.064
Less consultations b
Teaching hospital -1.239 .000
Non-teaching 
hospital
Patient-related external 
barriers
Age 0.032 .001
.065
Higher age
Number of consultations b -0.012 .002 Less consultations b
a Explained variance in final regression model.
b Average number of consultations for fertility problems per week.
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Second, physicians involved in subfertility care may lack good communication skills.6 
Despite the fact that only 2% of the physicians in our study indicated that they lacked skills 
to carry out IUI guideline recommendations, it is not imaginary that more physicians have 
insufficient communication techniques, because judgements regarding personal skills and 
performance are generally not very accurate.18 Education and training programmes that 
focus on development of communication skills of physicians may be useful for improving 
physicians’ low confidence in their convincing power due to insufficient communication 
techniques.19
Third, the persistence of patient-, guideline- or environment-related external barriers 
may eventually affect physicians’ confidence in their convincing power.13 Patient-related 
external barriers may play a role if patients are opposed to or perceive no need for guideline 
recommendations. The inability of physicians to reconcile preferences of these patients 
with guideline recommendations may in time compromise their confidence in their ability 
to communicate with patients with conflicting ideas.13 Interestingly, in our survey physicians 
mentioned several patient-related external barriers, especially regarding patients with 
specific physical and demographic features, such as elevated early follicular phase FSH 
levels, female age above 35 years or under 25 years, unexplained subfertility and non-Dutch 
ethnic background. In particular, older physicians and physicians with fewer consultations for 
fertility problems per week reported these external barriers. Additional studies into patients’ 
views about subfertility care are imperative to elucidate possible discrepancies between 
patients’ preferences and subfertility guideline recommendations. Subsequently, patients’ 
preferences about subfertility care that interfere with recommendations of subfertility 
guidelines could be addressed in a patient-directed intervention. For instance, targeted 
education programmes for patients could improve their understanding of subfertility care 
and tackle possible misconceptions and unrealistic expectations. Additionally, an intervention 
could also focus on educating physicians about patients’ views about subfertility care and 
shared decision-making. Both interventions could facilitate the medical decision-making 
process and improve physicians’ confidence in their convincing power.
No major guideline-related external barriers were identified in our study. However, the IUI 
guideline does not contain recommendations about information delivery and counseling, 
this contrasts with the NICE guideline, in which the importance of shared decision-making is 
clearly acknowledged. Adding such recommendations to the Dutch IUI guideline, especially 
recommendations regarding the counseling of patients with preferences about subfertility 
care that impede guideline adherence, could be valuable for physicians and effective in 
resolving lack of self-efficacy as a barrier to guideline adherence.
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Finally, we identified a number of environment-related external barriers that may compromise 
physicians’ confidence in their convincing power.13 In previous studies it was reported that 
environment-related external barriers associated with lack of counseling materials, lack 
of time and lack of support staff particularly affect physician-patient communication.20 
Interventions to address these external barriers could have a beneficial effect on physicians’ 
self-efficacy.
Lack of outcome expectancy was also an important barrier to adherence to subfertility 
guideline according to 29% of the physicians in our survey. Others reported similar rates 
of physicians’ lack of outcome expectancy regarding guideline adherence.13 Feedback and 
audit to demonstrate the positive outcomes of guideline adherence have previously been 
described as useful interventions to deal with low outcome expectancy of physicians.16
Besides barriers to physician adherence to subfertility guidelines, we documented multiple 
factors that facilitate the ability of physicians to perform according to subfertility guidelines. 
For example, lack of agreement among physicians regarding the developmental process 
and quality of the IUI guideline was low. A plausible explanation for these findings is that 
physicians are more likely to accept guidelines developed by their own specialty organization 
than by the government or insurance companies.17,21 Clearly, emphasizing physician 
participation in guideline development and increasing awareness of guideline approval by 
speciality societies remains important for the improvement and sustenance of physicians’ 
confidence in subfertility guidelines.
The strong point of our study is its systematic approach to obtaining information on barriers 
to physician adherence to a subfertility guideline, using both qualitative and quantitative 
research methods.11 We organized focus group discussions to identify potential obstacles to 
subfertility guideline adherence and performed an extensive questionnaire study among all 
Dutch physicians involved in subfertility care to quantify the prevalence and intensity of the 
different barriers.6
The results of our survey must be interpreted in the light of limitations regarding data 
collection from a self-selected sample. Physicians who lacked familiarity with the IUI 
guideline or who disagreed with the concept of guidelines in general or with this specific 
subfertility guideline may have been less likely to participate in our study. We investigated 
reasons for refusal to cooperate among 25% of non-respondents. Since none of these 
physicians indicated unfamiliarity or lack of agreement as a reason for non-response and 
because the overall response rate of 65% was adequate, we suspect that our results have 
considerable validity and therefore the issue of non-response was not further addressed.
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The generalizability of our findings may seem limited, because we focused on a specific 
subfertility guideline regarding IUI. Nevertheless, our results apply to other guidelines 
developed for comparable subfertility care settings, because these guidelines share rather 
similar developmental procedures, goals and content, target populations and target users.
Overall, our results have implications for initiatives to improve physician adherence to 
subfertility guidelines in order to optimize subfertility care. Whereas time and resources 
for quality improvement activities are generally limited, tailored interventions to address 
specific barriers to physician guideline adherence may be most effective and efficient.5,6,10 
This study provides an overview of the range of barriers that prevent physician adherence to 
subfertility guidelines. Important barriers include physicians’ lack of self-efficacy regarding 
physician-patient communication and low outcome expectancy. Communication skills 
training for physicians and targeted education programmes for patients and physicians 
to facilitate shared decision-making are suggested in order to overcome barriers related 
to poor self-efficacy. Feedback and audit about positive outcomes of physician guideline 
adherence could address the lack of outcome expectancy. Further research into patients’ 
preferences about subfertility care is needed. Clearly, both physicians and patients play an 
important role in future implementation interventions to optimize subfertility care.
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Subfertility affects millions of couples around the world.1 Treatments for subfertility have 
always attracted considerable public attention, often raising criticism and calls for greater 
transparency and accountability.2 Public claims for more information about the quality of 
subfertility care force health care professionals to react and release performance data. 
Intrauterine insemination (IUI) is a common treatment for subfertility.3 Nevertheless, 
assessment of the quality of IUI care, which implies more than just assessing the evident 
outcome measures clinical pregnancy and live birth rate, is rare. Therefore, the aim of this 
thesis was to study the quality of IUI care, focusing particularly on the extent, consequences 
and causes of variation in adherence to guidelines in IUI care and the implications for quality 
improvement.
The previous chapters of the thesis described the exploration of potential problems 
regarding guideline availability, quality and adherence in IUI care as well as the investigation 
of the motives to improve guideline adherence and the search for the determinants of 
guideline adherence in IUI care. In the first part of this chapter, the main findings of these 
studies are summarized. Then, the framework for a stepwise approach towards quality 
improvement in IUI care is brought to mind and taken as a starting point to discuss the 
results and methodology of the studies in detail. In the last part of this chapter, possible 
solutions to overcome problems regarding guideline availability, quality and adherence in 
IUI care, based on the main findings of the studies, are presented.
Main findings
The main findings of the studies described in this thesis can be summarized in the following 
statements:
•	 The number of IUI guidelines in Europe was surprisingly small. National guidelines on IUI 
were in 2005 only available in four of 25 European countries.
•	 The methodological quality of the four existing IUI guidelines in Europe was deficient 
in several domains of the internationally validated Appraisal of Guidelines for Research 
and Evaluation (AGREE) Instrument, mainly with regard to stakeholder involvement, 
rigour of development, applicability and editorial independence. Furthermore, the 
recommendations and references of these guidelines differed considerably.
•	 Guideline adherence regarding 20 process and five structure aspects of IUI care at 10 of 
the 91 Dutch hospitals providing IUI care was often substandard and varied considerably 
between hospitals.
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•	 Out of 10 possible associations investigated, optimal adherence to the guideline 
recommendations regarding sperm quality and the total number of IUI cycles was 
associated with improved ongoing pregnancy rates after IUI.
•	 Optimal adherence to the guideline recommendations regarding sperm quality, the 
total number of IUI cycles and the dose of human chorionic gonadotrophin (hCG) has 
substantial economic benefits compared to suboptimal guideline adherence.
•	 Many subfertile couples have had negative experiences with IUI care, particularly 
regarding the doctor’s attitude and coordination of care. Among several patient and 
hospital characteristics that significantly predicted these negative experiences, the main 
predictors were ‘no ongoing pregnancy’ and ‘high education level’.
•	 A number of patient and hospital characteristics were associated with variation in 
guideline adherence in IUI care, especially the patient characteristics ‘diagnosis’ and 
‘female age’. Couples with male factor or unexplained fertility problems as well as older 
women undergoing IUI treatment received less often recommended care than couples 
with cervical mucus hostility and younger women.
•	 Characteristics of individual physicians that hinder adherence to IUI guideline 
recommendations were mainly physicians’ lack of self-efficacy regarding communication 
with patients and low outcome expectancy.
Towards quality improvement in IUI care: a stepwise approach
In this thesis, the quality of IUI care was studied by means of a stepwise approach, which is 
displayed in diagrammatic form in Figure 1. The first step was to identify potential problems 
regarding guideline availability, quality and adherence in IUI care. The second step was to 
investigate the motives to improve guideline adherence in IUI care, including well-known 
motives, such as improved clinical effectiveness and safety, as well as frequently neglected 
motives, for example, increased cost-effectiveness and patient-centredness. The third step 
was to consider the determinants of guideline adherence in IUI care at the level of the 
patient, hospital and individual physician. The final step was to review possible solutions to 
overcome problems regarding guideline availability, quality and adherence in IUI care, which 
include strategies targeted at guideline development and strategies directed at guideline 
implementation. In the following paragraphs of this chapter, these various steps and the 
results plus methodological considerations are discussed in depth.
8147
Chapter 8
Problems
Guideline availability
Clinical practice guidelines are an important aid to bridge the gap between evidence 
and practice.4 Accordingly, guidelines can assist health care professionals and patients to 
make better decisions about clinically effective, safe and cost-effective care and reduce 
inappropriate practice variation. Research data confirmed that guidelines can substantially 
improve daily practice.5 Programmes have been set up in many European countries to 
develop clinical practice guidelines for various medical specialities, including subfertility 
care. However, whether or not IUI guidelines are available in different European countries 
was largely unknown.
Problems Determinants Solutions
Motives
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A comprehensive search for IUI guidelines in Europe, described in chapter 2 of this thesis, 
revealed that the number of IUI guidelines in Europe was surprisingly small. National 
guidelines on IUI were in 2005 only available in four of 25 European countries, which were 
Denmark, England and Wales, France, and the Netherlands.
In the meantime, the number of IUI guidelines in Europe has not changed. This small 
number of IUI guidelines in Europe is remarkable, because IUI has been a frequently used 
therapeutic modality in reproductive medicine across Europe for years.3,6 It is also in marked 
contrast to the large number of guidelines in other fields of medicine, such as oncology and 
diabetes care.7,8 Shortcomings in the methods used to identify IUI guidelines in Europe can 
be ruled out as a cause for the apparent lack of IUI guidelines in the majority of European 
countries. The systematic and rigorous search for IUI guidelines in electronic databases and 
on the Internet along with the 100% response rate in the survey among key experts on 
assisted reproduction guarantees the scientific validity of the results on the availability of 
IUI guidelines in 25 European countries. The true underlying reasons for the small number 
of IUI guidelines in Europe have not been systematically investigated yet. However, lack 
of a structured and coordinated guideline development programme, expertise, time and 
resources are well-known obstacles to guideline development and updating.9,10
The absence of IUI guidelines in most European countries points out the urgent need to 
improve the guideline availability in IUI care. This, in turn, will give individual health care 
professionals and patients better access to modern standards of clinical practice and 
thus contributes to improving IUI care. Promising solutions to deal with the problem of 
insufficient guideline availability in IUI care, such as striving for international co-operation 
on guidelines, will be reflected on in more detail later.
Guideline quality
Whether or not clinical practice guidelines can improve patient care depends on several factors, 
including the quality of the guideline itself. High-quality guidelines can lead to substantial 
changes in daily practice, but low-quality guidelines may harm patients.11 The Appraisal of 
Guidelines for Research and Evaluation (AGREE) Collaboration, an international consortium 
of researchers from several countries with extensive knowledge and experience regarding 
clinical practice guidelines, reflected on criteria to assess the quality of guidelines, particularly 
the process and reporting of guideline development. A multi-staged procedure of item 
generation, selection and scaling, international field testing and refinement measures resulted 
in a generic instrument to assess the methodological quality of clinical practice guidelines 
on 23 key items, grouped in six domains: scope and purpose, stakeholder involvement, 
rigour of development, clarity and presentation, applicability, and editorial independence.12 
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Appraisal of numerous guidelines with the AGREE Instrument revealed that many published 
guidelines do not meet the basic quality requirements.8,13-17 However, the quality of IUI 
guidelines had not been investigated previously.
A systematic assessment of the methodological quality of the four existing IUI guidelines in 
Europe with the AGREE Instrument, reported in chapter 2 of this thesis, established some 
striking flaws, particularly with regard to stakeholder involvement, rigour of development, 
applicability and editorial independence. Moreover, differences in the recommendations 
and references of the four IUI guidelines were considerable.
Flaws in the methodological quality of guidelines may result from lack of a structured 
and coordinated guideline development programme, expertise, time and resources.9,10 
Discrepancies in recommendations and references cited in guidelines on the same topic are 
common and mainly attributable to differences in the collection and interpretation of the 
evidence that supports the guideline recommendations.7,13 Previous research demonstrated 
that political and cultural factors, socioeconomic aspects and characteristics of health care 
systems have an important impact on the collection and interpretation of evidence in 
guideline development.7,15
The deficiencies in the quality of IUI guidelines in Europe highlight the imperative need 
for a transparent and explicit guideline development process that meets the specific 
quality criteria provided by the AGREE Collaboration.12 This allows individual health care 
professionals and patients to use high-quality guidelines and improve daily practice in IUI 
care. Potential solutions to overcome the problems of poor guideline quality in IUI care will 
be considered later on.
Guideline adherence
Health care delivery according to clinical practice guidelines is thought to be critical in 
achieving optimal outcomes. Yet, development and dissemination of guidelines does not 
ensure their implementation in daily practice.5,18,19 Previous studies in various fields of 
medicine established extensive variation in adherence to guidelines.20-22 Therefore, reliable 
assessment of the extent to which practice performance in health care is consistent with 
guideline recommendations is important and can not be done without a set of valid 
guideline-based performance indicators.23,24 However, performance indicators for IUI care 
were not available beforehand and published evidence about adherence to IUI guidelines 
was lacking.
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A thorough evaluation of the extent to which practice performance in IUI care is consistent 
with guideline recommendations was conducted at 10 of the 91 Dutch hospitals providing IUI 
care, using a systematically developed set of 25 guideline-based performance indicators for 
IUI care. This study, addressed in chapter 3 of this thesis, showed that guideline adherence 
regarding 20 process and five structure aspects of IUI care was often substandard and varied 
considerably between hospitals. For instance, adherence to guideline recommendations did 
not reach 50% in 12 of the 25 performance indicators assessed. In addition, the variation 
in guideline adherence between hospitals ranged up to a 100% for some performance 
indicators.
The entire development process of the performance indicators for IUI care was conducted 
with a specific goal in mind, that is, measuring practice performance regarding a broad 
range of relevant process and structure aspects of IUI care and comparing how it matches to 
the care proposed in clinical practice guidelines. Therefore, IUI guidelines based on the best 
scientific evidence available about a variety of process and structure aspects of care were 
a good departure point for the development of performance indicators for IUI care. It goes 
without saying that, if possible, performance indicators should be directly based on a firm 
body of research evidence. However, like in many areas of health care, scientific evidence 
for certain aspects of IUI care may be conflicting, methodologically weak or absent. For that 
reason, the performance indicators for IUI care were developed by a panel of experts in the 
field of IUI and quality-of-care research in a carefully planned consensus procedure that 
combined available evidence and expert opinion to assess additional aspects of IUI care 
for which evidence alone was contradictory, methodologically weak or non-existent.25,26 
Results from our expert consensus procedure demonstrated that non-evidence based 
recommendations may still be regarded as valuable by health care professionals. Using a 
technique that systematically combined available evidence and expert opinion enabled 
us to assess a broader range of aspects of IUI care than would have been possible if the 
performance indicators had been restricted to evidence only. When put to the test, the 
rigorously developed set of 25 guideline-based performance indicators for IUI care proved 
to be suitable to compare comprehensive IUI care actually provided to subfertile couples 
with recommended care in guidelines.
In addition, the set of 25 performance indicators for IUI care was primarily developed for 
internal quality measurement to enhance quality improvement. However, performance 
indicators can also be used for external quality measurement to support accountability, 
regulation and accreditation, or promote patient choice of providers.11,27 If the performance 
indicators for IUI care are used for external quality measurement, part of the whole set of 25 
performance indicators may be more suitable and desirable for use. In other words, what is 
to be measured and how the measurement will be conducted with performance indicators 
will depend, to a large extent, on the purpose of the measurement itself.
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The study demonstrated that IUI care was thus not consistently delivered according to 
guideline recommendations and varied substantially between hospitals. However, the 
implications of these results for current IUI care can be questioned since the results were 
based on data from the period April 2000 to August 2002. Given that the indications for IUI 
treatment, IUI procedures, and the number and content of IUI guidelines in Europe have not 
changed over the past few years and a more recent re-measurement with a subset of the 
original performance indicators for IUI care showed no improvement in guideline adherence in 
IUI care, it seems reasonable to assume that the presented results are not outdated.3,28
Without doubt, the impact of substandard IUI care on health and health care resources is 
considerable and shortcomings in practice performance in IUI care need to be dealt with 
sooner rather than later.2,29 For that reason, it is important to gain more insight into what 
motivates stakeholders to improve guideline adherence in IUI care and what determines that 
guideline recommendations are not adhered to in daily IUI care.
Motives to improve guideline adherence
Clinical effectiveness and safety
Although widely utilized, the clinical effectiveness and safety of IUI care remain controversial 
issues. On average, reported clinical pregnancy rates are only 5-13% per IUI cycle.3,6,30-36 In 
addition, IUI after ovarian stimulation with fertility drugs to increase the number of available 
oocytes may enhance the probability of conception to some extent, but also carries a risk of 
multiple pregnancy which, in turn, increases maternal and perinatal morbidity and mortality.37,38 
Multiple pregnancy rates up to 25% after IUI in combination with ovarian stimulation have been 
reported.31,38 Suboptimal guideline adherence and inappropriate practice variation in IUI care 
may contribute to the low clinical pregnancy rates and the high multiple pregnancy rates after 
IUI. Proof that better adherence to guideline recommendations in IUI care results in improved 
clinical effectiveness and safety could be an important driving force for all stakeholders to take 
measures to overcome the problems regarding guideline availability, quality and adherence in 
IUI care. Moreover, as time and resources for quality improvement in health care are usually 
limited, interventions to address shortcomings are probably most effective and efficient if the 
focus is specifically on aspects of care that are strongly associated with an improved clinical 
outcome.23 However, data about the link between guideline adherence and clinical outcome 
of IUI care, including clinical effectiveness and safety, were lacking.
A rigorous assessment of the association between guideline adherence and clinical outcome 
of IUI care using survival analysis, described in chapter 3 of this thesis, demonstrated that, out 
of 10 possible associations investigated, optimal adherence to the guideline recommendations 
regarding sperm quality and the total number of IUI cycles was associated with improved 
ongoing pregnancy rates after IUI.
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In this study, optimal guideline adherence was defined as adherence to a guideline 
recommendation in at least 90% of IUI cycles per couple. This cut-off point of 90% may 
seem arbitrary. However, as survival analysis was performed with other cut-off points, such 
as 75%, 80% and 85%, the survival model did not change, just the estimates of the effect to 
a limited extent.
The evidence is thus clear and compelling about the fact that better adherence to the 
guideline recommendations regarding sperm quality and the total number of IUI cycles 
improves ongoing pregnancy rates after IUI. So, in IUI care, efforts should be made to 
particularly promote implementation of the guideline recommendations regarding sperm 
quality and the total number of IUI cycles. It is presumed that the stakeholders will be 
motivated to take part in these implementation activities, because this could actually lead 
to a better clinical outcome of IUI care.
Remarkably, associations between guideline adherence and ongoing pregnancy after IUI 
were mainly non-significant. The few comparable studies evaluated the association between 
guideline adherence and patient mortality rate for acute myocardial infarction, heart 
failure, and pneumonia, and also found only small statistically significant or non-significant 
associations, despite large sample sizes.39-41 These findings raise fundamental questions: 
Why can adherence to guideline recommendations that are mostly based on solid research 
evidence not be successfully linked to improved clinical outcomes in actual practice? And, 
if better adherence to guideline recommendations is not strongly associated with improved 
clinical outcomes of care, what is then the value of these guideline recommendations and 
why should health care professional act on them?
For sure, only a few firm associations between guideline adherence and clinical 
outcomes of care have been found. Then again, it serves little purpose to make a case 
that guideline adherence is rather useless. Instead, patients, health care professionals 
and policy-makers will benefit more from efforts to evaluate and further understand the 
relationship between guideline adherence and clinical outcomes of care. In IUI care, for 
instance, an explanation might be that not all guideline recommendations are necessarily 
associated with ongoing pregnancy and other outcomes besides ongoing pregnancy, 
such as safety, cost-effectiveness and patient-centredness, may be more important. 
Unfortunately, it was not possible to establish statistically significant associations between 
guideline adherence and safety of IUI care, expressed as ongoing singleton pregnancies as 
outcome on the one hand and ongoing multiple pregnancies as outcome on the other hand, 
due to low multiple pregnancy rates after IUI in this study. The results of the evaluation of 
the cost-effectiveness and patient-centredness of IUI care, though, will be discussed in the 
following paragraphs.
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Cost-effectiveness
Health care professionals are challenged day after day to deliver appropriate, high-quality 
care to patients within resource constraints. This requires not just careful consideration 
of the clinical effectiveness and safety of different diagnostic and treatment options, but 
the cost-effectiveness should also be taken into account.42 IUI treatment is quite expensive 
and complications, such as ovarian hyperstimulation syndrome, as well as higher rates of 
adverse pregnancy outcomes, which are usually caused by multiple pregnancies, further 
increase the consumption of health care resources.3,6,37,38,43 As thousands of IUI cycles 
are initiated yearly throughout the world, the overall costs of IUI care should not be 
underestimated. Poor guideline adherence and inappropriate practice variation in IUI care 
may add needlessly to the health care expenditures. Evidence that optimal adherence to 
guideline recommendations in IUI care improves the cost-effectiveness could be a strong 
incentive for several stakeholders, in particular health care professionals, policy-makers 
and health insurance companies, to resolve the problems regarding guideline availability, 
quality and adherence in IUI care. In the context of limited time and resources for quality 
improvement in health care, strategies to solve shortcomings are probably most effective 
and efficient if they are targeted specifically at aspects of care that are strongly associated 
with improved cost-effectiveness.11 Yet, the association between guideline adherence and 
cost-effectiveness of IUI care had not been explored before.
A systematic evaluation of the cost-effectiveness of optimal versus suboptimal guideline 
adherence in IUI care was performed from a societal perspective. Costs included the medical 
and non-medical costs of IUI care, possible additional in vitro fertilisation (IVF) treatment and 
resulting pregnancies and deliveries up to 6 weeks after birth. Effectiveness was defined as 
an ongoing pregnancy. The results, reported in chapter 4 of this thesis, showed that optimal 
adherence to the guideline recommendations regarding sperm quality, the total number of 
IUI cycles and the dose of human chorionic gonadotrophin (hCG) was cost-effective with an 
incremental net monetary benefit between 645 and over 7500 euro per couple, depending 
on the recommendation and assuming a willingness to pay of 20 000 euro for a live birth.
This study is unique because of the societal perspective and the use of empirical data for 
the cost-effectiveness analyses. Although the data collection was an elaborate exercise, 
comprising a retrospective cohort study involving medical record analysis, a patient survey, 
interviews with staff members and a review of hospitals’ financial department reports and 
literature, the results provide a realistic economic picture which is not biased by potentially 
incorrect assumptions about effects and costs.
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Clearly, optimal adherence to the guideline recommendations regarding sperm quality, the 
total number of IUI cycles and the dose of hCG has substantial economic benefits compared 
to suboptimal guideline adherence. Therefore, in IUI care, it is particularly important to 
implement the guideline recommendations regarding sperm quality, the total number of IUI 
cycles and the dose of hCG. Stakeholders such as health care professionals, policy-makers 
and health insurance companies will almost certainly be encouraged to participate in these 
implementation activities, since this could contribute to the delivery of more cost-effective 
IUI care.
Whether or not these results can directly be translated to other countries is questionable, 
because all investigations were performed in Dutch fertility practice. Then again, most 
other countries do not have IUI guidelines and inappropriate practice variation is probably 
more extensive in countries without IUI guidelines. Therefore, our results may be especially 
interesting for countries lacking IUI guidelines, as potential cost saving could be even higher.
Patient-centredness
Patient-centredness is another important dimension of quality of care besides clinical 
effectiveness, safety and cost-effectiveness.42,44-46 Fundamental aspects of patient-centred 
care are information and education, respect for patients’ preferences, emotional support, 
physical comfort, coordination of care, involvement of family and friends, and continuity 
and transition.47 These days, the patient-centredness of care is considered equally important 
as the clinically effectiveness, safety and cost-effectiveness.46,48 That’s why, it is now more 
common than ever to explore whether or not delivered care meets the true needs and 
expectations of patients. It is increasingly recognized that the inclusion of evidence about 
patients’ perspectives of care in clinical practice guidelines may improve the patient-
centredness of care, but doing so has only recently become more customary. In fact, the 
four existing IUI guidelines in Europe generally lacked recommendations about aspects of 
patient-centred care. As a result, it was not possible to investigate the association between 
guideline adherence and patient-centredness of IUI care. Instead, it seemed more meaningful 
to verify subfertile couples’ perspectives of IUI care and assess the determinants of their 
perspectives. The information obtained can be used to direct the development and updating 
of IUI guidelines and steer quality improvement activities. Then, it will eventually become 
possible to evaluate if optimal adherence to IUI guidelines containing recommendations 
about aspects of patient-centred care improves the patient-centredness of IUI care.
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A comprehensive survey among subfertile couples about their experiences with 20 specific 
aspects of IUI care delivered at 10 of the 91 Dutch hospitals providing IUI care, addressed in 
chapter 5 of this thesis, revealed that many subfertile couples have had negative experiences 
with IUI care, particularly with regard to the doctor’s attitude and coordination of care, but 
also regarding information and explanation, and waiting times. Among a number of patient 
and hospital characteristics that significantly predicted these negative experiences, the 
major predictors were ‘no ongoing pregnancy’ and ‘high education level’.
Several others have also reported about patients’ perspectives of fertility care.49 The 
majority of studies investigated rather general aspects of fertility care. Consequently, 
more specific aspects of fertility care remained untouched. As a matter of fact, up till now, 
patients’ perspectives of IUI care had not been thoroughly sought. Furthermore, quite a few 
of these prior studies measured patient satisfaction and stated that patients with fertility 
problems were generally satisfied with the care received.49-53 However, measuring patient 
satisfaction usually provides a limited and overoptimistic picture of patients’ perspectives 
of care.54-56 Measuring patients’ experiences with concrete aspects of care appears to be a 
better approach, because the results are more specific and particularly useful to highlight 
problems in health care that are in need of improvement according to patients.47,57,58 While 
an appropriate instrument to assess subfertile couples’ experiences with specific aspects 
of IUI care was not available, a new questionnaire was developed for this purpose. This 
questionnaire was based on the existing patient experience questionnaires of the renowned 
Picker Institute47, but tailored to the particular needs and expectations of subfertile couples 
undergoing IUI treatment, which were derived from extensive qualitative research. This 
survey showed that, unlike the typically high satisfaction ratings of patients with fertility 
problems regarding the care received, many subfertile couples were indeed less positive 
when asked in detail about their experiences with concrete aspects of IUI care.
‘No ongoing pregnancy’ and ‘high education level’ emerged as the main predictors of 
subfertile couples’ negative experiences with IUI care. These findings enable health care 
professionals to further customize their care and quality improvement programmes to the 
needs and expectations of specific subgroups of patients. These results also emphasize the 
need to adjust for certain background factors when interpreting conclusions of research 
on patients’ experiences of care, because both patient and hospital characteristics can 
influence the way that health care delivery is experienced.
Thus, from the perspective of subfertile couples, IUI care needs to become much more patient-
centred. However, for a long time, the management of fertility problems has predominantly 
been assessed against the outcome measures clinical pregnancy and live birth rate. Even 
though health care professionals seem increasingly supportive of the concept that patients 
should have a key position in fertility care, it will require a paradigm shift in their sense 
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of quality of care to focus more on patient-centredness besides the traditional outcome 
measures.46,48 To promote this process of change, there is a strong argument for attempting 
to propagate important dimensions of patient-centred care to health care professionals in 
accessible formats, such as clinical practice guidelines. Integrating evidence about patients’ 
perspectives of care in clinical practice guidelines has not yet been widely adopted, but 
may, for instance, improve physicians’ knowledge and attitudes regarding the needs and 
expectations of patients and, in this way, stimulate action being taken to actually improve 
the patient-centredness of care. Though, more research is warranted to explore this matter 
further.
Determinants of guideline adherence
Prior research in other fields of medicine demonstrated that a broad variety of factors, 
including characteristics of patients, organizations and individual physicians, can act as 
barriers or facilitators for guideline adherence.23,59-65 Knowledge about factors that hamper 
or stimulate guideline adherence can guide the development of tailored interventions to 
improve adherence to guidelines.18,23 However, little was known about potential barriers 
and facilitators for guideline adherence in IUI care.
Barriers and facilitators at the level of the patient and hospital
A detailed exploration of the link between several patient and hospital characteristics and 
adherence to IUI guideline recommendations at 10 Dutch hospitals, described in chapter 6 
of this thesis, revealed that a number of characteristics, mostly patient characteristics, were 
associated with suboptimal guideline adherence and inappropriate practice variation in IUI 
care. Variation in guideline adherence in IUI care was predominantly associated with the 
patient characteristics ‘diagnosis’ and ‘female age’. For example, couples with male factor 
or unexplained fertility problems were significantly less often treated according to guideline 
recommendations than couples with cervical mucus hostility. Likewise, older women 
undergoing IUI treatment received less often recommended care than younger women.
Only adherence to the guideline recommendation regarding screening for tubal occlusion 
was associated with hospital characteristics, which were ‘hospital size’ and ‘IVF license’. 
Larger hospital size and an IVF license doubled the chance of suboptimal adherence to 
this guideline recommendation about performing screening for tubal occlusion before 
starting IUI. Other associations of hospital characteristics with adherence to IUI guideline 
recommendations could not be established, because variation between the different 
hospitals was sometimes too small, perhaps as a result of the limited sample size of 10 
hospitals.
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More than a few hypotheses can be developed to explain the determinants of guideline 
adherence in IUI care. A plausible explanation for variation in guideline adherence with 
different diagnoses and female ages may be that physicians deliberately decide to treat 
patients with particular diagnoses or of certain ages not according to IUI guideline 
recommendations, because pregnancy rates are known to vary by type of diagnosis and 
decline with increasing female age.66-68 Physicians may, for instance, choose to treat older 
couples with male factor fertility problems in an early stage with stimulated instead of 
unstimulated IUI, despite the increased risks of ovarian hyperstimulation syndrome and 
multiple pregnancy, because of the supposed increased pregnancy rates of stimulated IUI.
A possible reason why larger hospital size and an IVF license were associated with poor 
guideline adherence regarding screening for tubal occlusion could be that small, non-
IVF-licensed hospitals have to account to larger, IVF-licensed hospitals when couples are 
referred for tertiary care. So, smaller, non-IVF-licensed hospitals have an extra drive to treat 
their patients according to IUI guideline recommendations.
Regardless of explanations, the identification of different subgroups in the patient population 
and different types of hospitals with regard to the extent of guideline adherence in IUI 
care is important for the tailoring of interventions to improve adherence to IUI guidelines. 
Examples of interventions to resolve the problems regarding guideline adherence in IUI care 
will be presented and discussed later on.
Barriers and facilitators at the level of the individual physician
While the previously mentioned characteristics of patients and hospitals that impede 
guideline adherence can be regarded as external barriers, can characteristics of individual 
physicians that hinder guideline adherence be classified into two main categories: barriers 
relating to physicians’ knowledge, for example, lack of awareness and lack of familiarity, 
and barriers that affect physicians’ attitudes, for instance, lack of agreement, lack of self-
efficacy, lack of outcome expectancy and lack of motivation.64 An extensive survey among 
Dutch gynaecologists, residents and fertility physicians about barriers to adherence to IUI 
guideline recommendations, reported in chapter 7 of this thesis, confirmed, once more, that 
quite a few external barriers can hamper guideline adherence in IUI care, but also identified 
several barriers concerning physicians’ knowledge and attitudes.
External barriers to adherence to IUI guideline recommendations reported by physicians 
were mostly related to specific patient characteristics, for example, ‘diagnosis’ and ‘female 
age’, which is in line with the barriers described in chapter 6 of this thesis, but also ‘early 
follicular phase follicle stimulating hormone (FSH) levels’ and ‘ethnic background’. Important 
patient-related external barriers mentioned by physicians included unexplained fertility 
problems, female age above 35 years, elevated early follicular phase FSH levels and non-
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Dutch ethnic background. Interestingly, in particular older physicians and physicians with 
fewer consultations for fertility problems per week brought up these patient-related external 
barriers. Besides a few barriers regarding physicians’ knowledge, the survey revealed quite 
a lot of barriers regarding physicians’ attitudes, mainly physicians’ lack of self-efficacy 
regarding communication with patients and low outcome expectancy.
Without doubt, multiple barriers impair practice performance according to IUI guideline 
recommendations. Strategies designed to overcome poor adherence to IUI guidelines 
should at least tackle these barriers. If the budget available for quality improvement allows, 
it is valuable to take factors that enhance adherence to IUI guidelines into account as well. 
Possible strategies to solve the problems regarding guideline adherence in IUI care will be 
considered in the next paragraphs.
Solutions
Major problems regarding guideline availability, quality and adherence were established 
in IUI care. IUI guidelines were, for instance, not available in most European countries. 
In addition, deficiencies in the quality of the few existing IUI guidelines in Europe were 
considerable. Furthermore, guideline adherence in IUI care was far from optimal and 
varied substantially between hospitals. As a result, many subfertile couples did not receive 
appropriate IUI care, and received insufficient, unnecessary or even harmful care instead.
Several approaches claim to offer solutions to problems regarding guideline availability, 
quality and adherence in patient care, each based on different assumptions and theories 
about behavioural and organizational change.11 For many approaches, however, the 
empirical evidence behind these assumptions and theories is limited. Moreover, approaches 
that appear successful in one setting may fail in another.23 Therefore, it remains uncertain 
which strategy is most effective and efficient to achieve change in a given situation.5,69
Clearly, it is a complex and challenging task to come up with successful solutions to overcome 
the problems regarding guideline availability, quality and adherence in IUI care. However, 
the findings of the studies described in this thesis make it possible to solve some of these 
problems and, in that way, improve the quality of IUI care.
Guideline development
Research data on quality improvement confirmed that it is important to focus on the 
guideline itself.23 In other words, is it a good ‘product’? As mentioned before, the number 
of IUI guidelines in Europe was surprisingly small and shortcomings in the quality of IUI 
guidelines were substantial. Evidently, guidelines in IUI care need a change for the better. To 
make this happen, one should aim first and foremost at improving guideline development.
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Guideline development and updating require planning and specific expertise and are generally 
time-consuming and costly.11 Lack of a structured and coordinated guideline development 
programme, expertise, time and resources definitely impede guideline development and 
updating.9,10 As all countries in Europe face common challenges with regard to guideline 
development and updating, there is an argument for more international collaboration.70 
Contrary to common opinion, cultural, legal and organizational differences across Europe do 
not necessarily hinder a shared guideline development process. While diversity in different 
countries may justify a certain extent of variability in guideline recommendations, the 
evidence on which the guideline recommendations are based should be the same and could 
thus be exchanged.
This concept was the starting point of a framework for shared guideline development in 
Europe. In this framework, a central body with expertise in up-to-date guideline development 
methodology and sufficient resources selects the best scientific evidence available to support 
guideline recommendations. Then, the centrally selected evidence is shared internationally 
in the form of evidence tables, summarizing the content of the selected studies and indicating 
the level of evidence according to validated evidence-level structures. After that, the 
formulation of recommendations, external review, and dissemination and publication of the 
guideline should preferably be a national responsibility to ensure relevance for local practice 
and maximum acceptance by guideline users.10 To be credible, a transparent and explicit 
guideline development process that meets the internationally accepted quality criteria 
provided by the AGREE Collaboration is important.12 Also, to guarantee local acceptance 
and use, clinical practice guidelines should, if possible, be developed with the input and 
approval of well-regarded professional societies.71,72 This strategy may very well increase the 
number and quality of guidelines, giving individual health care professionals and patients 
better access to the latest standards of clinical practice and, in this way, improve care. 
The proposed strategy could also promote international consensus on the clinical content 
of guidelines, reduce unnecessary duplication of effort and bring down inefficient use of 
resources across Europe.9,10
In the field of reproductive medicine, the European Society of Human Reproduction and 
Embryology (ESHRE) has adopted this framework, initiating European collaboration in 
guideline development by selecting and sharing the evidence for the development of 
guideline recommendations.73 Topics addressed so far include ‘counseling in infertility’, 
‘clinical pre-implantation genetic diagnosis (PGD) and pre-implantation genetic screening 
(PGS)’, ‘the diagnosis and treatment of endometriosis’ and ‘the investigation and medical 
treatment of recurrent miscarriage’.73-75 The intention of ESHRE to continue to act as a 
central body to select the evidence for the development of guideline recommendations 
shows off from recent activities, such as allocating part of the ESHRE website to guidelines, 
publishing a manual for ESHRE guideline development and organizing courses for ESHRE 
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members about guideline development. The fact that ESHRE is a respected professional 
society will almost certainly have a positive influence on the adoption of the evidence 
tables by the target groups.11 Moreover, ESHRE has enough budget to sustain the initiative 
of shared guideline development in Europe in the future.
At this point, proposals for the development or updating of guidelines on other clinical 
subjects in reproductive medicine, including IUI, should be brought forward and set in 
motion. To meet the anticipated surge in requests for the development or updating of 
guidelines on various topics, the assistance of trained guideline development experts and 
use of modern information and communication technologies should be considered to 
facilitate and expedite the guideline development process.
Integrating guideline development and guideline implementation
Then again, development and dissemination of guidelines does not guarantee their 
implementation in daily practice.5,18,19 In the past, major efforts have been put into single 
or multifaceted interventions to improve guideline implementation in different health 
care settings. Commonly attempted single interventions were reminders, dissemination 
of educational materials, and audit and feedback. Multifaceted interventions generally 
also involved educational outreach. However, systematic reviews of the effectiveness and 
efficiency of different interventions to enhance guideline implementation showed that 
these efforts were not extremely successful.5,69,76 The majority of interventions resulted only 
in small to moderate improvements in care.77
These days, it is increasingly recognized that it is imperative to consider potential aids and 
obstacles to guideline implementation at an earlier stage, preferably when developing a 
guideline.11 Thus, at the same time as the evidence for the development of guideline 
recommendations is collected, motives to improve guideline adherence, such as increased 
clinical effectiveness, safety, cost-effectiveness and patient-centredness, and possible 
determinants of guideline adherence should be taken into account. Ideally, guidelines 
should be developed in a way that they, as you might say, implement themselves later on.
In IUI care, guideline implementation could thus be promoted by including a clear description 
of the advantages of guideline adherence in the guideline itself. For example, the fact that 
optimal adherence to the guideline recommendations regarding sperm quality and the total 
number of IUI cycles is associated with improved ongoing pregnancy rates after IUI should 
be emphasized in IUI guidelines. Similarly, it should be more noticeable in IUI guidelines that 
optimal adherence to the guideline recommendations regarding sperm quality, the total 
number of IUI cycles and the dose of hCG is cost-effective. Moreover, patients’ perspectives 
of IUI care should be incorporated in IUI guidelines, assuming that this will improve the 
patient-centredness of IUI care. The guideline development group may therefore draw on 
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the results of the survey among subfertile couples about their experiences with specific 
aspects of IUI care, particularly with regard to the doctor’s attitude and coordination of care, 
but may also involve patients’ representatives in the guideline development process.
Guideline implementation in IUI care could also be enhanced by addressing any possible 
barriers to guideline adherence in the guideline itself. For instance, several external 
barriers impede adherence to IUI guideline recommendations, particularly the patient 
characteristics ‘diagnosis’ and ‘female age’. IUI guidelines should therefore contain explicit 
recommendations about the best care for certain subgroups in the patient population, 
that is, for each type of diagnosis, higher female age, elevated early follicular phase FSH 
levels, non-Dutch ethnic background, and so on. Likewise, as physicians’ lack of self-
efficacy regarding communication with patients during the decision-making process about 
appropriate IUI care appeared an important barrier to guideline adherence, IUI guidelines 
should include recommendations about information delivery and counseling, especially of 
patients with conflicting preferences or ideas about IUI treatment.
Guideline implementation
Besides the adaptations of guidelines to stimulate that they, so to speak, implement 
themselves, it is also possible to employ specific interventions focussed on physicians 
or patients to improve guideline implementation in health care.11 Literature on quality 
improvement suggests that change may be more likely if strategies to enhance guideline 
implementation are specifically chosen to address identified barriers to guideline 
adherence.23,78
In IUI care, an example of a strategy to improve guideline implementation involving physicians 
is communication skills training. Prior studies have demonstrated that communication skills 
training could be helpful to tackle physicians’ lack of self-efficacy regarding communication 
with patients.79 
Another approach targeted at physicians is giving feedback about the benefits of adherence 
to IUI guideline recommendations, particularly about the improved clinical effectiveness 
and cost-effectiveness. Feedback about the positive outcomes of guideline adherence has 
previously been described as a useful method to deal with low outcome expectancy of 
physicians.80
Valuable interventions directed at patients are, for instance, education programmes to 
improve their knowledge and address possible misconceptions and unrealistic expectations 
with regard to health care.5 In fact, in a recently published patient-directed strategy to 
improve guideline implementation in subfertility care using information leaflets, the 
majority of patients reported an increased understanding of causes of subfertility, treatment 
162
General discussion
procedures, guideline recommendations, and their doctor’s treatment policy, and also felt 
more empowered to ask questions about their treatment.81 An alternative way to promote 
care delivery according to IUI guideline recommendations is by giving patients a decision aid 
and counseling by a specialized nurse to improve their knowledge and support the decision-
making process. Lately, research showed that these interventions increase the knowledge 
and feeling of empowerment regarding the decision-making process of subfertile couples 
undergoing IVF treatment.82
Although the suggested strategies to enhance guideline implementation seem promising, 
future research is necessary to show that they actually are effective and efficient in IUI care.
Final considerations
Currently, IUI is a common treatment for all categories of subfertility other than ovulatory 
disorders, bilateral tubal obstruction and severe male factor fertility problems.3 However, 
when the success rates of IUI are compared with the three to seven-fold higher success 
rates of IVF, questions arise about the future of IUI. Some even claim that IUI is no more 
than a stopgap treatment while waiting for IVF or just a poor substitute when IVF is not 
affordable.3 Then again, before deciding on a treatment, there is more to consider than 
just success rates. For example, the availability of the methods, the invasiveness of the 
techniques, adverse effects, patients’ preferences, the likelihood of patient compliance, and 
the costs need to be weighed as well. Access to IVF at affordable levels is often limited and 
IVF treatment is, in relation to IUI, usually more demanding for patients. In other words, 
IVF may not be affordable, or a premature choice, particularly when subfertile couples have 
a relatively good prognosis. Consequently, IUI will almost certainly remain a widely used 
treatment for subfertility in the future.
It is hard to keep up with the constantly increasing body of relevant research data. The 
development and publication of high-quality clinical practice guidelines by appropriate 
regulating authorities could substantially aid health care professionals and patients to decide 
on the best treatment strategy. This thesis demonstrated that, with regard to guidelines, 
IUI care is on the right track, but several problems regarding guideline availability, quality 
and adherence in IUI care need to be dealt with. The findings of the studies described in 
this thesis make it possible to solve some of these problems and, in that way, improve the 
quality of IUI care.
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Summary
Chapter 1 - General introduction
Chapter 1 describes the background, aim, research questions and outline of the thesis. In 
short, subfertility concerns millions of couples around the world. Treatments for subfertility 
have always drawn the attention of the public, often instigating heated discussions and claims 
for greater transparency and accountability. The desire of the public to be better informed 
about the quality of subfertility care forces health care professionals to respond and disclose 
performance data. Intrauterine insemination (IUI), which involves artificial insemination 
of prepared sperm directly into the uterus at the expected time of ovulation, is a widely 
used treatment for a broad range of fertility problems. Though, assessment of the quality 
of IUI care, which entails more than just assessing the obvious outcome measures clinical 
pregnancy and live birth rate, is uncommon. Therefore, the aim of this thesis is to study the 
quality of IUI care, focusing particularly on the extent, consequences and causes of variation 
in adherence to guidelines in IUI care and the implications for quality improvement. And so, 
the thesis addresses the following research questions:
•	 What is the availability and quality of IUI guidelines in Europe? (chapter 2)
•	 What is the quality of IUI care? Is guideline adherence in IUI care clinically effective? 
Which improvements are needed in IUI care? (chapter 3)
•	 What are the economic consequences of guideline adherence in IUI care? (chapter 4)
•	 What are patients’ perspectives of IUI care? (chapter 5)
•	 What are the determinants of guideline adherence in IUI care? (chapter 6 and 7)
Chapter 2 - Guideline availability and quality in IUI care
Clinical practice guidelines are an important aid to bridge the gap between evidence 
and practice. Accordingly, guidelines can assist health care professionals and patients to 
make better decisions about clinically effective, safe and cost-effective care and reduce 
inappropriate practice variation. Prior research established that guidelines can improve 
health care, as long as specific quality criteria are met. Programmes have been set up in many 
European countries to develop clinical practice guidelines for various medical specialities, 
including subfertility care. However, little was known about IUI guidelines in Europe. Chapter 
2 presents the exploration of the availability and quality of IUI guidelines in Europe. To 
identify IUI guidelines in Europe, electronic databases and the Internet were systematically 
searched and key experts on assisted reproduction in 25 European countries were 
questioned. The quality of IUI guidelines was systematically assessed with the internationally 
validated Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument. 
Qualitative methods were used to appraise IUI guideline recommendations and references. 
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National guidelines on IUI were in 2005 only available in four of 25 European countries, 
which were Denmark, England and Wales, France, and the Netherlands. The methodological 
quality of the IUI guidelines was deficient in several domains of the AGREE Instrument, mainly 
with regard to stakeholder involvement, rigour of development, applicability and editorial 
independence. Furthermore, the recommendations and references of the IUI guidelines 
differed considerably. The problems regarding the availability and quality of IUI guidelines 
in Europe may result from lack of a structured and coordinated guideline development 
programme, expertise, time and resources. To overcome these problems, a central body 
with expertise in up-to-date guideline development methodology and sufficient resources 
could be established in Europe for central selection and international exchange of evidence 
to support guideline recommendations.
Chapter 3 - Guideline adherence and clinical effectiveness in IUI care
Health care delivery according to clinical practice guidelines is thought to be imperative in 
achieving optimal outcomes. However, development and dissemination of guidelines does 
not guarantee their implementation in daily practice. Previous studies in various health care 
settings revealed large variation in adherence to guidelines. Yet, there has been limited 
published evidence about guideline adherence in IUI care and the link between guideline 
adherence and clinical outcome of IUI care. Chapter 3 describes the assessment of the extent 
to which practice performance in IUI care is consistent with guideline recommendations 
and the evaluation of the association between guideline adherence and clinical outcome 
of IUI care. In a retrospective cohort study, 1100 subfertile couples from 10 Dutch hospitals 
were asked to grant access to their medical record if they had undergone IUI treatment 
for assessment of guideline adherence using 25 systematically developed guideline-based 
performance indicators. A total of 558 couples who started 2334 IUI cycles participated. 
Guideline adherence regarding 20 process and five structure aspects of IUI care was often 
substandard and varied considerably between hospitals. Out of 10 possible associations 
investigated, optimal adherence to the guideline recommendations regarding sperm quality 
and the total number of IUI cycles was associated with improved ongoing pregnancy rates 
after IUI. Shortcomings in practice performance in IUI care need to be dealt with sooner 
rather than later. Preferably, the focus should be on promoting implementation of the 
guideline recommendations regarding sperm quality and the total number of IUI cycles. As 
associations between guideline adherence and ongoing pregnancy after IUI were mainly 
non-significant, further research is needed to evaluate associations between guideline 
adherence and other outcomes of IUI care besides ongoing pregnancy, such as safety, cost-
effectiveness and patient-centredness.
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Chapter 4 - Guideline adherence and cost-effectiveness in IUI care
Health care professionals are challenged day after day to deliver appropriate, high-quality 
care to patients within resource constraints. This requires not just careful consideration of 
the clinical effectiveness and safety of different diagnostic and treatment options, but the 
cost-effectiveness should be taken into account as well. Clinical practice guidelines can help 
health care professionals and patients in the decision-making process about cost-effective 
care and promote the efficient use of the scarce health care resources. In spite of this, the 
association between guideline adherence and cost-effectiveness of IUI care had not been 
explored before. Chapter 4 presents the investigation of the cost-effectiveness of optimal 
versus suboptimal guideline adherence in IUI care from a societal perspective. Costs included 
the medical and non-medical costs of IUI care, possible additional in vitro fertilisation (IVF) 
treatment and resulting pregnancies and deliveries up to 6 weeks after birth. Effectiveness 
was defined as an ongoing pregnancy. Data were obtained from medical records and 
questionnaires of 415 subfertile couples from 10 Dutch hospitals who participated in a 
retrospective cohort study and a patient survey, interviews with staff members involved in 
IUI care, hospitals’ financial department reports and literature. Optimal adherence to the 
guideline recommendations about sperm quality, the total number of IUI cycles and dose of 
human chorionic gonadotrophin (hCG) was cost-effective with an incremental net monetary 
benefit between 645 and over 7500 euro per couple, depending on the recommendation 
and assuming a willingness to pay for a live birth of 20 000 euro.These results provide an 
excellent opportunity to increase awareness among health care professionals, patients and 
authorities about the importance of development and implementation of clinical practice 
guidelines.
Chapter 5 - Subfertile couples’ experiences with IUI care
Patient-centredness is another important dimension of quality of care besides clinical 
effectiveness, safety and cost-effectiveness. So, it is very common these days to explore 
whether or not delivered care meets the true needs and expectations of patients. 
Measuring patients’ perspectives of care seems simple, but the best approach is subject 
of debate. Assessing patients’ experiences with concrete aspects of care appears to be 
the most useful method, because the results provide a clear view of specific problems 
in practice performance that are in need of improvement according to patients. 
However, subfertile couples’ experiences with IUI care had not yet been thoroughly 
sought. Chapter 5 describes the measurement of subfertile couples’ experiences with 
specific aspects of IUI care and the assessment of the determinants of their experiences. 
In a cross-sectional survey, 1100 subfertile couples from 10 Dutch hospitals were 
sent a questionnaire about their experiences with 20 concrete aspects of IUI care. 
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The questionnaire was based on the existing patient experience questionnaires of the 
renowned Picker Institute, but tailored to the particular needs and expectations of subfertile 
couples undergoing IUI treatment, which were derived from extensive qualitative research. 
The response rate was 71% and 581 couples were eligible to participate. Many subfertile 
couples have had negative experiences with IUI care, particularly with regard to the doctor’s 
attitude and coordination of care, but also regarding information and explanation, and 
waiting times. Among several patient and hospital characteristics that significantly predicted 
these negative experiences, the main predictors were ‘no ongoing pregnancy’ and ‘high 
education level’. These findings can be regarded as a strong incentive to develop tailored 
interventions that address the reported deficits and to further customize IUI care to meet 
subfertile couples’ needs better.
Chapter 6 - Barriers and facilitators at the level of the patient and hospital in IUI care
A broad variety of factors at the level of the patient and hospital can act as barriers or 
facilitators for guideline adherence in health care. Knowledge about barriers and facilitators 
is important in every approach to improve adherence to guidelines, because improvement 
strategies are more likely to be effective if they focus directly on barriers. For IUI care, 
evidence was scarce about the potential barriers and facilitators involved. Chapter 6 presents 
the assessment of the association of patient and hospital characteristics with guideline 
adherence in IUI care. Studied characteristics at patient level were female age, type and 
duration of subfertility, diagnosis and number of started IUI cycles. At hospital level, the 
studied characteristics were hospital size, teaching hospital, IVF license and number of 
physicians involved in the IUI programme. Data were obtained from medical records of 558 
subfertile couples from 10 Dutch hospitals who participated in a retrospective cohort study 
and questionnaires for gynaecologists. Several patient characteristics were associated with 
variation in guideline adherence in IUI care, especially ‘diagnosis’ and ‘female age’. Only 
adherence to the guideline recommendation regarding screening for tubal occlusion was 
associated with hospital characteristics, which were ‘hospital size’ and ‘IVF license’. Large 
explained variances up to 39% were found for the different multilevel regression models. 
The identification of different subgroups in the patient population and different types of 
hospitals with regard to the extent of guideline adherence in IUI care is important for the 
tailoring of interventions to improve adherence to IUI guidelines.
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Chapter 7 - Barriers and facilitators at the level of the individual physician in IUI care
A wide range of factors at the level of the individual physician have been identified as barriers 
or facilitators for guideline adherence in health care. Insight into barriers and facilitators 
is crucial in every attempt to improve adherence to guidelines, because improvement 
strategies are more likely to succeed if they are targeted specifically at barriers. For IUI care, 
research data were lacking about the possible barriers and facilitators involved. Chapter 7 
describes the search for barriers to physician adherence to IUI guideline recommendations. 
In a cross-sectional survey among all 860 Dutch gynaecologists, residents and fertility 
physicians, using written questionnaires that were based on information obtained in 
focus group discussions, barriers relating to physicians’ knowledge, for example, lack of 
awareness and lack of familiarity, barriers that affect physicians’ attitudes, for instance, 
lack of agreement, lack of self-efficacy, lack of outcome expectancy and lack of motivation, 
and external barriers, including patient- guideline- and environment-related factors, were 
investigated. The response rate was 65% and 344 questionnaires were used for analysis. 
Physicians’ knowledge was adequate and attitudes generally positive, especially regarding 
guideline development and quality. Important attitude-related barriers included physicians’ 
lack of self-efficacy regarding communication with patients and low outcome expectancy. 
External barriers to adherence to IUI guideline recommendations reported by physicians 
were mostly related to specific patient characteristics. Without doubt, multiple barriers 
impair practice performance according to IUI guideline recommendations. Strategies 
designed to overcome poor adherence to IUI guidelines should at least tackle these barriers.
Chapter 8 - General discussion
Chapter 8 starts with a summary of the main findings of the studies described in the thesis. 
After that, the results and methodology of these studies are discussed in detail. In brief, 
major problems regarding guideline availability, quality and adherence were established 
in IUI care. IUI guidelines were, for example, not available in most European countries. 
In addition, deficiencies in the quality of the few existing IUI guidelines in Europe were 
considerable. Furthermore, guideline adherence in IUI care was far from optimal and varied 
substantially between hospitals. Convincing the target group that guideline adherence leads 
to desired goals, such as better clinical effectiveness, safety, cost-effectiveness and patient-
centredness, can improve guideline adherence. Therefore, these motives to improve 
guideline adherence were investigated. Interestingly, optimal adherence to a number of IUI 
guideline recommendations was associated with improved ongoing pregnancy rates after 
IUI and had substantial economic benefits compared to suboptimal guideline adherence. 
Unfortunately, it was not possible to establish statistically significant associations 
between guideline adherence and either safety or patient-centredness of IUI care. 
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However, we did demonstrate that many subfertile couples have had negative experiences 
with IUI care, particularly regarding the doctor’s attitude and coordination of care, which 
is valuable information to steer the development, updating and implementation of IUI 
guidelines. A good understanding of determinants of guideline adherence in IUI care at the 
level of the patient, hospital and individual physician is also important in every approach to 
improve guideline adherence. Several patient and hospital characteristics were associated 
with variation in guideline adherence in IUI care, especially the patient characteristics 
‘diagnosis’ and ‘female age’. Characteristics of individual physicians that hinder adherence 
to IUI guideline recommendations were mainly physicians’ lack of self-efficacy regarding 
communication with patients and low outcome expectancy.
Subsequently, this chapter presents possible solutions to overcome the problems regarding 
guideline availability, quality and adherence in IUI care. Solutions include strategies targeted 
at guideline development and strategies directed at guideline implementation. Promising 
interventions focusing on guideline development are striving for international co-operation 
in guideline development and updating as well as describing the advantages of guideline 
adherence, incorporating patients’ perspectives of care and addressing any possible barriers 
to guideline adherence in the guideline itself. Strategies that aim to improve guideline 
implementation include communication skills training for physicians, feedback to physicians 
about the benefits of guideline adherence, patient education programmes, decision aids 
and counseling of patients by specialized nurses.
To conclude, this thesis demonstrated that, with regard to guidelines, IUI care is on the right 
track, but several problems regarding guideline availability, quality and adherence in IUI care 
need to be dealt with. The findings of the studies described in this thesis make it possible to 
solve some of these problems and, in that way, improve the quality of IUI care.
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Samenvatting
Hoofdstuk 1 - Algemene inleiding
Hoofdstuk 1 beschrijft de achtergronden, doelstelling, onderzoeksvragen en opbouw 
van het proefschrift. Onvruchtbaarheid is een veel voorkomend probleem. Maar liefst 
een op de zes paren krijgt ermee te maken. De meeste paren zoeken hiervoor medische 
hulp. De afgelopen decennia zijn de mogelijkheden voor diagnostiek en behandeling van 
vruchtbaarheidsproblemen enorm toegenomen. Daarnaast zijn de toegepaste technieken 
steeds geavanceerder geworden. Dit heeft echter ook aanzienlijk meer gezondheidsrisico’s, 
kosten en ethische, juridische en maatschappelijke dilemma’s met zich mee gebracht. Het 
is dan ook niet verwonderlijk dat de voortplantingsgeneeskunde nauwlettend in de gaten 
wordt gehouden en kritische vragen worden gesteld over de kwaliteit en de grenzen van de 
verleende zorg. Zorgverleners zullen daarop moeten inspelen en de maatschappij moeten 
informeren over hun handelen. Intra-uteriene inseminatie (IUI), het kunstmatig inbrengen 
van bewerkt zaad in de baarmoeder rondom het tijdstip van de eisprong, is een veel 
toegepaste behandeling voor een scala aan vruchtbaarheidsproblemen. Onderzoek naar de 
kwaliteit van IUI-behandelingen, dat meer omvat dan het simpelweg meten van voor de 
hand liggende uitkomstmaten als het percentage zwangerschappen en levendgeborenen, 
wordt toch maar weinig gedaan. De doelstelling van dit proefschrift is dan ook het in kaart 
brengen van de kwaliteit van IUI-behandelingen, waarbij de nadruk ligt op het onderzoeken 
van de mate van variatie in het naleven van IUI-richtlijnen, de gevolgen en oorzaken hiervan 
en de implicaties voor kwaliteitsverbetering. Het proefschrift behandelt de volgende 
onderzoeksvragen:
• Hoeveel IUI-richtlijnen zijn er in Europa en wat is de kwaliteit van deze richtlijnen? 
(hoofdstuk 2)
• Wat is de kwaliteit van IUI-behandelingen? Is het naleven van IUI-richtlijnen klinisch 
effectief? Wat kan beter in IUI-behandelingen? (hoofdstuk 3)
• Wat zijn de economische consequenties van het naleven van IUI-richtlijnen? 
(hoofdstuk 4)
• Wat zijn de ervaringen van patiënten die IUI-behandelingen hebben ondergaan? 
(hoofdstuk 5)
• Welke factoren beïnvloeden het naleven van IUI-richtlijnen? (hoofdstuk 6 en 7)
Samenvatting
Hoofdstuk 2 - Aantal en kwaliteit IUI-richtlijnen
Richtlijnen zijn een belangrijk hulpmiddel om de kloof te overbruggen tussen de beschikbare 
kennis en de klinische praktijk. Richtlijnen kunnen zorgverleners en patiënten helpen bij de 
besluitvorming over effectieve, veilige en kosteneffectieve zorg en ongewenste variatie in de 
zorg verminderen. Uit eerder onderzoek is gebleken dat richtlijnen de gezondheidszorg kunnen 
verbeteren, mits aan bepaalde kwaliteitscriteria wordt voldaan. In een aantal Europese landen 
zijn initiatieven ontplooid om richtlijnen te ontwikkelen voor diverse medische vakgebieden, 
waaronder de voortplantingsgeneeskunde. Er is echter weinig bekend over IUI-richtlijnen in 
Europa. Hoofdstuk 2 beschrijft de inventarisatie van het aantal IUI-richtlijnen in Europa en de 
kwaliteit van deze richtlijnen. Om het aantal IUI-richtlijnen in Europa vast te stellen, werden 
elektronische databases en het Internet op systematische wijze doorzocht en experts op het 
gebied van voortplantingsgeneeskunde uit 25 Europese landen ondervraagd. De kwaliteit 
van de getraceerde IUI-richtlijnen werd systematisch beoordeeld met het internationaal 
gevalideerde Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument. 
Kwalitatieve methoden werden gebruikt om de aanbevelingen en literatuurverwijzingen van de 
IUI-richtlijnen te beoordelen. In 2005 bleken in slechts vier van de 25 Europese landen nationale 
IUI-richtlijnen te bestaan, namelijk in Denemarken, Engeland en Wales, Frankrijk en Nederland. 
Qua methodologische kwaliteit scoorden de IUI-richtlijnen in meerdere domeinen van het 
AGREE Instrument onvoldoende, vooral wat betreft betrokkenheid van belanghebbenden, 
methodologie, toepasbaarheid en onafhankelijkheid van de opstellers. De aanbevelingen en 
literatuurverwijzingen van de verschillende IUI-richtlijnen liepen ook sterk uiteen. Het kleine 
aantal IUI-richtlijnen in Europa en de suboptimale kwaliteit van deze richtlijnen komt mogelijk 
door het ontbreken van een gestructureerd en gecoördineerd richtlijnprogramma, expertise, 
tijd en middelen. Een oplossing voor deze problemen is wellicht het oprichten van een 
centraal orgaan in Europa met expertise op het gebied van richtlijnontwikkeling en voldoende 
middelen voor centrale selectie en internationale uitwisseling van onderzoeksresultaten ter 
onderbouwing van aanbevelingen.
Hoofdstuk 3 - Naleving IUI-richtlijnen en klinische effectiviteit
Het verlenen van klinische zorg volgens door de beroepsgroep geaccepteerde richtlijnen 
kan een belangrijke bijdrage leveren aan de verbetering van de uitkomsten bij patiënten. 
Ontwikkeling en verspreiding van richtlijnen staat echter niet garant voor daadwerkelijke 
naleving van deze richtlijnen in de dagelijkse praktijk. Eerdere studies in diverse settings 
binnen de gezondheidszorg hebben aangetoond dat de variatie in het naleven van richtlijnen 
groot is. Er is echter nauwelijks onderzoek gepubliceerd over de naleving van IUI-richtlijnen 
en de invloed hiervan op de uitkomsten van IUI-behandelingen. Hoofdstuk 3 beschrijft het 
onderzoek naar de mate waarin de zorgverlening in IUI-behandelingen overeenkomt met 
de aanbevelingen uit IUI-richtlijnen en het verband tussen de naleving van IUI-richtlijnen en 
de uitkomsten van IUI-behandelingen. In een retrospectief cohortonderzoek werd aan 1100 
paren met vruchtbaarheidsproblemen uit 10 Nederlandse ziekenhuizen gevraagd inzage in hun 
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medisch dossier toe te staan als zij een IUI-behandeling hadden ondergaan om de naleving van 
IUI-richtlijnen te inventariseren met behulp van 25 systematisch ontwikkelde en op richtlijnen 
gebaseerde kwaliteitsindicatoren. In totaal werden 558 paren geïncludeerd. Gezamenlijk 
hadden zij 2334 IUI-cycli ondergaan. In 10 van de 91 ziekenhuizen waar IUI-behandelingen 
plaatsvinden werden aanbevelingen over 20 proces- en vijf structuuraspecten van IUI-
behandelingen over het algemeen slecht nageleefd. Bovendien was de variatie in de naleving 
van deze aanbevelingen tussen de ziekenhuizen groot. Van de 10 mogelijke associaties die 
onderzocht zijn, bleek optimale naleving van de aanbevelingen over zaadkwaliteit en het totaal 
aantal IUI-cycli samen te hangen met een grotere kans op een doorgaande zwangerschap na 
IUI. Er is veel voor verbetering vatbaar in IUI-behandelingen, maar de aandacht zou vooral uit 
moeten gaan naar het bevorderen van de naleving van de aanbevelingen over zaadkwaliteit 
en het totaal aantal IUI-cycli. Aangezien de associaties tussen naleving van IUI-richtlijnen en 
doorgaande zwangerschappen na IUI voornamelijk niet-significant waren, is meer onderzoek 
nodig naar de relatie tussen naleving van IUI-richtlijnen en andere uitkomstmaten dan 
doorgaande zwangerschappen, zoals veiligheid, kosteneffectiviteit en patiëntgerichtheid.
Hoofdstuk 4 - Naleving IUI-richtlijnen en kosteneffectiviteit
Zorgverleners worden elke dag uitgedaagd zorg te leveren die van optimale kwaliteit is, maar 
ook betaalbaar moet zijn. Naast de klinische effectiviteit en veiligheid van de verschillende 
mogelijkheden betreffende diagnostiek en behandeling dient ook de kosteneffectiviteit in 
de besluitvorming te worden meegenomen. Richtlijnen kunnen zorgverleners en patiënten 
helpen bij het maken van keuzes over kosteneffectieve zorg en stimuleren dat efficiënt gebruik 
wordt gemaakt van de relatief schaarse collectieve middelen. Desondanks is de relatie tussen 
de naleving van IUI-richtlijnen en de kosteneffectiviteit van IUI-behandelingen niet eerder 
onderzocht. Hoofdstuk 4 beschrijft de studie naar de kosteneffectiviteit van optimale versus 
suboptimale naleving van IUI-richtlijnen vanuit maatschappelijk perspectief. Qua kosten werd 
gekeken naar de medische en niet-medische kosten van IUI-behandelingen, eventuele in vitro 
fertilisatie (IVF) behandelingen, zwangerschap, bevalling en periode van de geboorte tot 6 
weken erna voor zowel moeder als kind. Effectiviteit werd gedefinieerd als een doorgaande 
zwangerschap. Gegevens werden verkregen uit medische dossiers en vragenlijsten van 415 
paren met vruchtbaarheidsproblemen uit 10 Nederlandse ziekenhuizen die participeerden 
in een retrospectief cohort- en vragenlijstonderzoek, interviews met zorgverleners betrokken 
bij IUI-behandelingen, financiële rapportages van ziekenhuizen en wetenschappelijke 
publicaties. Optimale naleving van de aanbevelingen over zaadkwaliteit, het totaal aantal 
IUI-cycli en dosering van humaan choriongonadotrofine (hCG) was kosteneffectief met 
een ‘incremental net monetary benefit’ (INB) tussen 645 en meer dan 7500 euro per paar, 
afhankelijk van de aanbeveling en uitgaande van een ‘willingness to pay’ van 20 000 euro voor 
een levendgeborene. Deze resultaten bieden volop kansen om het besef onder zorgverleners, 
patiënten en autoriteiten te vergroten over het belang van het ontwikkelen en naleven van 
richtlijnen in de dagelijkse praktijk.
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Hoofdstuk 5 - Ervaringen van paren met vruchtbaarheidsproblemen met IUI-behandelingen
Naast klinische effectiviteit, veiligheid en kosteneffectiviteit is patiëntgerichtheid een 
belangrijke dimensie van kwaliteit van zorg. Het is tegenwoordig dan ook een goed 
gebruik om na te gaan of de verleende zorg voldoet aan de behoeften en verwachtingen 
van patiënten. Het achterhalen van het perspectief van de patiënt lijkt eenvoudig, maar 
de manier waarop is onderwerp van discussie. Het inventariseren van de ervaringen van 
patiënten met concrete aspecten van zorg lijkt veelbelovend. Hiermee kunnen specifieke 
problemen die volgens patiënten verbeterd moeten worden aan het licht worden gebracht. 
De ervaringen van paren met vruchtbaarheidsproblemen ten aanzien van IUI-behandelingen 
zijn onvoldoende geïnventariseerd. Hoofdstuk 5 beschrijft hoe de ervaringen van paren 
met vruchtbaarheidsproblemen met specifieke aspecten van IUI-behandelingen en de 
determinanten hiervan in kaart zijn gebracht. In een vragenlijstonderzoek kregen 1100 paren 
met vruchtbaarheidsproblemen uit 10 Nederlandse ziekenhuizen een enquête toegestuurd 
over hun ervaringen met 20 concrete aspecten van IUI-behandelingen. Deze enquête was 
gebaseerd op een bestaande vragenlijst over patiëntervaringen van het gerenommeerde Picker 
Instituut die, na uitgebreid kwalitatief onderzoek onder paren met vruchtbaarheidsproblemen 
die IUI-behandelingen hadden ondergaan, kon worden toegespitst op hun specifieke 
behoeften en verwachtingen. De respons bedroeg 71% en 581 paren konden worden 
geïncludeerd. Veel paren met vruchtbaarheidsproblemen hadden negatieve ervaringen met 
IUI-behandelingen, vooral ten aanzien van de houding van de arts en coördinatie van zorg, maar 
ook wat betreft informatievoorziening en uitleg, en de wachttijden. Verschillende patiënt- en 
ziekenhuiskenmerken bleken voorspellend voor deze negatieve patiëntervaringen, waarvan 
‘geen doorgaande zwangerschap’ en ‘hoog opleidingsniveau’ de belangrijkste waren. Deze 
resultaten kunnen een belangrijke drijfveer vormen om gerichte interventies te ontwikkelen 
om de tekortkomingen aan te pakken en IUI-behandelingen meer patiëntgericht te maken.
Hoofdstuk 6 - Patiënt- en ziekenhuis-gerelateerde belemmerende en bevorderende factoren 
in IUI-behandelingen
Een groot aantal patiënt- en ziekenhuis-gerelateerde factoren kunnen het naleven van 
richtlijnen in de dagelijkse praktijk belemmeren of bevorderen. Kennis over deze factoren is 
belangrijk, omdat strategieën ter verbetering van het naleven van richtlijnen grotere kans van 
slagen hebben als die gericht zijn op belemmeringen. Er was weinig bekend over de mogelijke 
belemmerende en bevorderende factoren die het naleven van IUI-richtlijnen beïnvloeden. 
Hoofdstuk 6 beschrijft het onderzoek naar het verband tussen patiënt- en ziekenhuis-
gerelateerde belemmerende en bevorderende factoren en het naleven van IUI-richtlijnen. 
Onderzochte patiëntkenmerken waren leeftijd van de vrouw, type, duur en oorzaak van het 
vruchtbaarheidsprobleem en het aantal gestarte IUI-cycli. Onderzochte ziekenhuiskenmerken 
waren grootte van het ziekenhuis, opleidingskliniek, IVF-vergunning en het aantal artsen 
betrokken bij IUI-behandelingen. De gegevens werden verkregen uit de medische dossiers 
van 558 paren met vruchtbaarheidsproblemen uit 10 Nederlandse ziekenhuizen die hebben 
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deelgenomen aan een retrospectief cohortonderzoek en uit vragenlijsten ingevuld door 
gynaecologen. Meerdere patiëntkenmerken bleken samen te hangen met variatie in de 
naleving van IUI-richtlijnen, in het bijzonder ‘oorzaak van het vruchtbaarheidsprobleem’ en 
‘leeftijd van de vrouw’. Paren met een vruchtbaarheidsprobleem ten gevolge van verminderde 
zaadkwaliteit of onverklaarde vruchtbaarheidsproblemen alsmede andere vrouwen die een 
IUI-behandeling ondergingen werden minder vaak behandeld volgens de richtlijn dan paren 
met vruchtbaarheidsproblemen ten gevolge van cervix factor en jonge vrouwen. Alleen 
naleving van de aanbeveling over het screenen op aandoeningen van de eileiders hing 
samen met ziekenhuiskenmerken, namelijk ‘grootte van het ziekenhuis’ en ‘IVF-vergunning’. 
Met deze factoren kan tot 39% van het naleven van IUI-richtlijnen voorspeld worden. Het 
identificeren van verschillen in de naleving van IUI-richtlijnen bij bepaalde subgroepen in de 
patiëntenpopulatie en in bepaalde typen ziekenhuizen is belangrijk om gerichte interventies 
te kunnen ontwikkelen ter verbetering van de naleving van IUI-richtlijnen.
Hoofdstuk 7 - Behandelaar-gerelateerde belemmerende en bevorderende factoren in IUI-
behandelingen
Uiteenlopende behandelaar-gerelateerde factoren blijken het naleven van richtlijnen in de 
dagelijkse praktijk te kunnen belemmeren of bevorderen. Inzicht in deze factoren is van belang, 
omdat strategieën ter verbetering van het naleven van richtlijnen effectiever zijn als die direct 
aansluiten bij factoren die een verandering daadwerkelijk belemmeren. Onderzoeksgegevens 
over mogelijke belemmerende en bevorderende factoren in IUI-behandelingen 
ontbreken. Hoofdstuk 7 beschrijft de inventarisatie van het verband tussen behandelaar-
gerelateerde belemmerende en bevorderende factoren en het naleven van IUI-richtlijnen. 
In een vragenlijstonderzoek onder alle 860 Nederlandse gynaecologen, arts-assistenten en 
fertiliteitsartsen werd met een enquête, die gebaseerd was op gegevens uit focusgroepen, 
informatie verkregen over belemmeringen bij behandelaren op drie verschillende terreinen: 
kennis, bijvoorbeeld niet bewust zijn van de richtlijn of niet precies op de hoogte zijn van de 
inhoud van de richtlijn; houding, zoals oneens zijn met de richtlijn, geen vertrouwen hebben in 
eigen kunnen, geen positieve verwachting hebben van het resultaat of gebrek aan motivatie om 
te veranderen; externe belemmeringen, waaronder patiënt-, richtlijn- en omgevingsgebonden 
factoren. De respons bedroeg 65% en 344 vragenlijsten waren bruikbaar voor analyse. Het 
kennisniveau van behandelaren was adequaat en hun houding over het algemeen positief, 
vooral wat betreft richtlijnontwikkeling en -kwaliteit. Belangrijke belemmeringen gerelateerd 
aan de houding van behandelaren waren onvoldoende vertrouwen hebben in het kunnen 
communiceren met patiënten en geen positieve verwachting hebben van het resultaat van 
het naleven van IUI-richtlijnen. Externe belemmeringen voor het naleven van IUI-richtlijnen 
betroffen vooral specifieke kenmerken van patiënten. Het is onomstotelijk vast komen te 
staan dat meerdere behandelaar-gerelateerde factoren het naleven van IUI-richtlijnen in de 
dagelijkse praktijk belemmeren. Strategieën om de naleving van IUI-richtlijnen te verbeteren, 
dienen in ieder geval gericht te zijn op de geïdentificeerde belemmeringen.
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Samenvatting
Hoofdstuk 8 - Algemene discussie
In hoofdstuk 8 worden eerst de belangrijkste bevindingen van de verschillende studies 
samengevat. Vervolgens worden de resultaten en methodologie van deze studies in meer 
detail besproken. Samenvattend kan gesteld worden dat er problemen zijn met het aantal, 
de kwaliteit en het naleven van IUI-richtlijnen. Zo ontbrak het bijvoorbeeld in de meeste 
Europese landen aan IUI-richtlijnen. Daarnaast bleek de kwaliteit van de paar bestaande IUI-
richtlijnen in Europa suboptimaal. Verder bleek bij onderzoek in 10 van de 91 ziekenhuizen 
waar IUI-behandelingen plaatsvinden dat IUI-richtlijnen over het algemeen slecht nageleefd 
werden en waren de verschillen in de naleving van IUI-richtlijnen tussen ziekenhuizen 
groot. Door de doelgroep ervan te overtuigen dat het naleven van richtlijnen tot gewenste 
uitkomsten leidt, zoals toegenomen klinische effectiviteit, veiligheid, kosteneffectiviteit en 
patiëntgerichtheid, kan de naleving van richtlijnen verbeterd worden. Daarom werden deze 
motieven onderzocht. Optimale naleving van een aantal aanbevelingen uit IUI-richtlijnen 
hing samen met meer doorgaande zwangerschappen na IUI en had aanzienlijke economische 
voordelen vergeleken met suboptimale naleving van deze aanbevelingen. Helaas was 
het niet mogelijk een statistisch significant verband aan te tonen tussen de naleving van 
IUI-richtlijnen enerzijds en veiligheid of patiëntgerichtheid anderzijds. Wel hebben we 
geconstateerd dat veel paren met vruchtbaarheidsproblemen negatieve ervaringen hadden 
met IUI-behandelingen, vooral ten aanzien van de houding van de arts en coördinatie van 
zorg. Deze informatie kan waardevol zijn bij het ontwikkelen, updaten en invoeren van 
IUI-richtlijnen in de praktijk. Een goed beeld van de patiënt-, ziekenhuis- en behandelaar-
gerelateerde factoren die het naleven van IUI-richtlijnen beïnvloeden, is hierbij ook van 
belang. Diverse patiënt- en ziekenhuis-gerelateerde factoren bleken samen te hangen met 
variatie in de naleving van IUI-richtlijnen, in het bijzonder de patiëntkenmerken ‘oorzaak van 
het vruchtbaarheidsprobleem’ en ‘leeftijd van de vrouw’. Kenmerken van behandelaren die 
de naleving van IUI-richtlijnen belemmeren, waren vooral onvoldoende vertrouwen hebben 
in het kunnen communiceren met patiënten en geen positieve verwachting hebben van het 
resultaat van het naleven van IUI-richtlijnen.
Verder worden in dit hoofdstuk mogelijke oplossingen voor de problemen met het aantal, 
de kwaliteit en het naleven van IUI-richtlijnen besproken. De oplossingen betreffen 
strategieën gericht op de ontwikkeling van richtlijnen en strategieën gericht op de 
invoering van richtlijnen in de praktijk. Veelbelovende interventies die zich concentreren 
op de ontwikkeling van richtlijnen zijn het stimuleren van internationale samenwerking in 
richtlijnontwikkeling en -updating en het benoemen van de voordelen van het naleven van 
richtlijnen, patiëntervaringen en mogelijke belemmeringen voor het naleven van richtlijnen 
in de richtlijn zelf. Strategieën gericht op het invoeren van richtlijnen in de praktijk lopen 
uiteen van communicatietraining voor behandelaren, feedback aan behandelaren over de 
voordelen van het naleven van richtlijnen, educatieprogramma’s voor patiënten, gebruik 
van een keuzehulp en counseling van patiënten door gespecialiseerde verpleegkundigen.
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Concluderend kan gesteld worden dat dit proefschrift heeft aangetoond dat er problemen 
zijn met het aantal, de kwaliteit en het naleven van IUI-richtlijnen. De resultaten van de 
studies beschreven in dit proefschrift maken het mogelijk tot oplossingen voor deze 
problemen te komen en op die manier bij te dragen aan verbetering van de kwaliteit van 
IUI-behandelingen.
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Dankwoord
Graag wil ik iedereen bedanken die heeft bijgedragen aan het tot stand komen van dit 
proefschrift. Een aantal mensen wil ik in het bijzonder bedanken.
Allereerst gaat mijn dank uit naar mijn promotores en copromotores:
Prof. dr. Kremer, beste Jan, bij jou is het allemaal begonnen. Een wetenschappelijke stage, 
baan als fertiliteitsarts en promotieonderzoek. Jij had vertrouwen in mij en dat vertrouwen 
heb jij altijd gehouden. Ik ben trots op het eindresultaat, maar ook minstens zo trots op onze 
samenwerking. Ik heb hier goede herinneringen aan en wil jou vooral bedanken voor jouw 
innovatieve ideeën, razendsnelle feedback en geduld.
Prof. dr. Grol, beste Richard, het was een voorrecht om onder jouw hoede de vele facetten 
van het vakgebied ‘kwaliteit van zorg’ te verkennen. Als ik dreigde te verzanden in details, 
lukte het jou als geen ander de grote lijnen te bewaken. Bedankt ook dat jij, ondanks jouw 
overvolle agenda, altijd bereid was tijd vrij te maken.
Dr. Nelen, beste Willianne, aanvankelijk was jij als arts-onderzoeker aangesteld om in dit 
onderzoek de kar te trekken, maar al snel werd duidelijk dat jouw ruime onderzoekservaring 
in een andere functie waarschijnlijk beter tot zijn recht kon komen. Achteraf bleek niets 
minder waar. In jouw nieuwe rol als onderzoekscoördinator leerde jij mij alles wat een 
junioronderzoeker moet weten en kunnen. Jouw aandeel in de begeleiding werd eens te 
meer duidelijk toen jij 9 maanden lang aan een ander project werkte, want wat heb ik jou 
toen gemist. Ik heb het al velen malen eerder gezegd, maar misschien toch nog niet vaak 
genoeg? Bedankt!
Dr. Hermens, beste Rosella, ik keek altijd uit naar jouw revisies, want jij wist artikelen een 
zet in de goede richting te geven. Bovendien werkte jouw enthousiasme en positiviteit 
aanstekelijk om met nieuw elan door te gaan. Jij was ook altijd oprecht geïnteresseerd in 
wat er speelde in en buiten het onderzoek en ik kon rekenen op jouw steun en advies. Daar 
ben ik jou zeer dankbaar voor.
De overige leden van de projectgroep verdienen aparte vermelding:
Dr. Adang, beste Eddy, Health Technology Assessment is een vak apart! Jij hebt mij hier wegwijs 
in gemaakt. Bedankt voor de prettige samenwerking bij de kosteneffectiviteitsanalyses.
Prof. dr. Braat, beste Didi, hoewel jouw rol in de projectgroep gaandeweg naar de achtergrond 
is verschoven, heb ik steeds jouw steun ervaren. Met jouw hulp als opleider vond ik een 
manier om mijn promotieonderzoek te combineren met mijn opleiding tot gynaecoloog.
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Uiteraard ben ik veel dank verschuldigd aan de paren die hebben deelgenomen aan het 
onderzoek. Ik ben dankbaar voor het feit dat zij in of vlak na een periode van intensieve 
behandeling bereid waren zich te laten interviewen, in focusgroepen te participeren, inzage 
in hun medisch dossier toe te staan en vragenlijsten in te vullen.
Veel dank gaat ook uit naar de betrokken gynaecologen, fertiliteitsartsen, verpleegkundigen, 
embryologen, analisten en secretaresses van de 10 deelnemende ziekenhuizen: Ziekenhuis 
Bernhoven - Oss, Ziekenhuis Bernhoven - Veghel, Canisius-Wilhelmina Ziekenhuis - Nijmegen, 
Catharina Ziekenhuis - Eindhoven, Ziekenhuis Gelderse Vallei - Ede, Gelre Ziekenhuis - 
Apeldoorn, Ziekenhuis Rijnstate - Arnhem, Slingeland Ziekenhuis - Doetinchem, St Antonius 
Ziekenhuis - Nieuwegein en UMC St Radboud - Nijmegen. Bedankt voor het mogelijk maken 
van het onderzoek en de prettige samenwerking.
Ik dank ook alle gynaecologen, gynaecologen in opleiding en fertiliteitsartsen die naast 
hun drukke werkzaamheden de tijd en de moeite hebben genomen om te helpen met het 
ontwikkelen van indicatoren, deel te nemen aan focusgroepen of de uitgebreide vragenlijst 
in te vullen. 
Dr. Willemsen, beste Wim, hartelijk dank voor jouw optreden als moderator in de 
focusgroepen.
Sabine van den Akker en Annelies Pellegrino, jullie hebben bergen werk verzet bij het 
verzamelen van de data. Niets dan lof voor jullie inzet.
Reinier Akkermans, multilevelanalyse behoort tot de categorie ‘statistiek voor gevorderden’. 
Wat fijn dat ik gebruik mocht maken van jouw expertise op dat gebied.
Jan van Doremalen, uren zaten wij achter jouw computer in SAS analyses uit te voeren en te 
checken of wij hierbij geen fouten hadden gemaakt. Uiteindelijk was het alle inspanningen 
meer dan waard, want alle berekeningen klopten als een bus. Hartelijk dank voor jouw 
precisie en eindeloos geduld met deze arts-onderzoeker die steeds maar weer nog iets 
anders wilde berekenen.
Graag wil ik mijn collega’s bedanken van de afdeling Verloskunde en Gynaecologie - UMC 
St Radboud, IQ healthcare - UMC St Radboud en afdeling Verloskunde en Gynaecologie - 
Jeroen Bosch Ziekenhuis. Teveel om bij naam te noemen. Daarom, beste gynaecologen,
A(N)IOS, fertiliteitsartsen, klinisch verloskundigen, nurse-practitioners, verpleegkundigen, 
embryologen, analisten, senior- en junioronderzoekers en secretaresses, bedankt voor de 
leerzame tijd, fijne samenwerking en gezellige nevenactiviteiten.
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Zonder anderen te kort te doen, wil ik wel specifiek stilstaan bij mijn roomies van kamer 
1.04 bij IQ healthcare: Marije Bosch, liefkozend Bosschie genoemd, en Selma Mourad, 
alias Selmi. Op onze kamer werd hard gewerkt, maar ook werden er publicaties gevierd, 
tegenslagen verwerkt, reisverhalen uitgewisseld en toekomstplannen gesmeed. Jullie 
hebben de 1.04-wisseltrofee al in ontvangst mogen nemen, waarvoor hulde. Nu krijg ik 
deze dubieuze eer. Lieve Selma, dank dat jij mijn paranimf wil zijn!
Lieve familie en vrienden, wat ben ik blij met de bijzondere band die wij hebben. Bedankt 
voor jullie belangstelling, begrip en steun de afgelopen jaren. Ik kijk uit naar de periode na 
20 januari 2012 waarin er meer tijd voor elkaar zal zijn.
Lieve Jos, veel kwam de laatste tijd vooral op jou neer. Hoewel jij dat als vanzelfsprekend 
beschouwde, was het dat zeker niet. Jij bent het beste dat mij ooit is overkomen. Luv U!
Lieve Sebastiaan, jij bent er nog maar net, maar een leven zonder jou is niet meer voor 
te stellen. Onbewust help jij mij mij te relativeren met jouw glimoogjes en schaterlach. 
Wat ben jij toch een heerlijk ventje!
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